<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31824347</article-id>
<article-id pub-id-type="pmc">6881463</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2019.00835</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bygrave</surname>
<given-names>Alexei M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/651807" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kilonzo</surname>
<given-names>Kasyoka</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/808122" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kullmann</surname>
<given-names>Dimitri M.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/8734" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bannerman</surname>
<given-names>David M.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/314835" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kätzel</surname>
<given-names>Dennis</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/257304" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neuroscience, Johns Hopkins University</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Institute of Applied Physiology, Ulm University</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
<aff id="aff3"><sup>3</sup><institution>UCL Queen Square Institute of Neurology, University College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Experimental Psychology, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country>United Kingdom</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Bernat Kocsis, Harvard Medical School, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Margarita Behrens, Salk Institute for Biological Studies, United States; Vasileios Kafetzopoulos, Harvard Medical School, United States</p>
</fn>
<corresp id="fn001">*Correspondence: Dennis Kätzel, <email xlink:href="mailto:dennis.kaetzel@uni-ulm.de" xlink:type="simple">dennis.kaetzel@uni-ulm.de</email></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Schizophrenia, a section of the journal Frontiers in Psychiatry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>835</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Bygrave, Kilonzo, Kullmann, Bannerman and Kätzel</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Bygrave, Kilonzo, Kullmann, Bannerman and Kätzel</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Hypofunction of N-methyl-D-aspartate glutamate receptors (NMDARs), whether caused by endogenous factors like auto-antibodies or mutations, or by pharmacological or genetic manipulations, produces a wide variety of deficits which overlap with—but do not precisely match—the symptom spectrum of schizophrenia. In order to understand how NMDAR hypofunction leads to different components of the syndrome, it is necessary to take into account which neuronal subtypes are particularly affected by it in terms of detrimental functional alterations. We provide a comprehensive overview detailing findings in rodent models with cell type–specific knockout of NMDARs. Regarding inhibitory cortical cells, an emerging model suggests that NMDAR hypofunction in parvalbumin (PV) positive interneurons is a potential <italic>risk factor</italic> for this disease. PV interneurons display a selective vulnerability resulting from a combination of genetic, cellular, and environmental factors that produce pathological multi-level positive feedback loops. Central to this are two antioxidant mechanisms—NMDAR activity and perineuronal nets—which are themselves impaired by oxidative stress, amplifying disinhibition. However, NMDAR hypofunction in excitatory pyramidal cells also produces a range of schizophrenia-related deficits, in particular maladaptive learning and memory recall. Furthermore, NMDAR blockade in the thalamus disturbs thalamocortical communication, and NMDAR ablation in dopaminergic neurons may provoke over-generalization in associative learning, which could relate to the positive symptom domain. Therefore, NMDAR hypofunction can produce schizophrenia-related effects through an action on various different circuits and cell types.</p>
</abstract>
<kwd-group>
<kwd>schizophrenia</kwd>
<kwd>psychosis</kwd>
<kwd>N-methyl-D-aspartate receptor</kwd>
<kwd>N-methyl-D-aspartate receptor hypofunction</kwd>
<kwd>parvalbumin</kwd>
<kwd>ketamine</kwd>
<kwd>MK-801</kwd>
<kwd>catatonic schizophrenia</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Wellcome Trust<named-content content-type="fundref-id">10.13039/100004440</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn002">Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg<named-content content-type="fundref-id">10.13039/501100003542</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn003">Medical Research Council<named-content content-type="fundref-id">10.13039/501100000265</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn004">John Fell Fund, University of Oxford<named-content content-type="fundref-id">10.13039/501100004789</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn005">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content></funding-source>
<award-id rid="cn005">KA/4594/2-1</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="253"></ref-count>
<page-count count="23"></page-count>
<word-count count="10914"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction: The Glutamate Hypothesis of Schizophrenia</title>
<p>Schizophrenia is characterized by a wide range of symptoms, classically grouped into positive (hallucinations, delusions, disordered thought), negative (social withdrawal, anhedonia, apathy), and cognitive (deficits of attention, working memory, cognitive flexibility) domains (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Despite decades of research, the circuit basis of schizophrenia remains elusive, hampering progress in diagnosis and treatment.</p>
<p>No major breakthrough has been made in drug discovery for schizophrenia treatments since the introduction of the most effective atypical antipsychotic clozapine in 1971 (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). All antipsychotic drugs currently approved for schizophrenia therapy have in common that they decrease signaling through dopamine D2 receptors (D2Rs), and are most effective on positive symptoms. However, negative and cognitive symptoms are largely resistant to currently available medication, and even positive symptoms respond only partially to the usual antipsychotic drugs, which in turn have significant side effects (<xref ref-type="bibr" rid="B1">1</xref>). Therefore, different treatment targets—not relying on dopamine receptor antagonism—are urgently required.</p>
<p>In that context, the so-called “glutamate hypothesis”—the assumption that aberrant glutamatergic signaling is at the core of schizophrenia pathology—has sparked the most hope. The only two new specific targets tested in phase III clinical trials in the last two decades in schizophrenia patients—the metabotropic glutamate receptor type 2/3 (mGluR2/3) (<xref ref-type="bibr" rid="B5">5</xref>–<xref ref-type="bibr" rid="B8">8</xref>) and the glycine transporter 1 (GlyT1) (<xref ref-type="bibr" rid="B9">9</xref>), which affects levels of the N-methyl-D-aspartate (NMDA) receptor (NMDAR) co-agonist glycine—result from work pointing to abnormal glutamatergic transmission in schizophrenia. A third target currently under investigation, D-amino acid oxidase (DAAO) (<xref ref-type="bibr" rid="B10">10</xref>), which also indirectly affects occupancy of the NMDAR co-agonist site, is also based on the “glutamate hypothesis.” A central pillar of this hypothesis is that hypofunction of NMDARs causes some or all of the symptoms of schizophrenia (<xref ref-type="bibr" rid="B11">11</xref>–<xref ref-type="bibr" rid="B13">13</xref>). NMDAR hypofunction may be a precursor to deficits in synaptic plasticity which have also been strongly linked to the disorder (<xref ref-type="bibr" rid="B14">14</xref>). The core question for preclinical research in this context is whether the NMDAR itself, or molecules that affect its activity, are appropriate drug targets in established schizophrenia. In turn, this can only be evaluated when the molecular phenomenon of NMDAR hypofunction is spelled out mechanistically in the context of neural circuits—i.e. when it is clarified which cell types in different brain structures are affected by NMDAR hypofunction and how such altered signaling could cause different aspects of the complex symptoms characterizing the disease.</p>
</sec>
<sec id="s2">
<title>Linking NMDAR Hypofunction to Schizophrenia: Genetic Evidence</title>
<p>The glutamatergic synapse, and in particular the NMDAR, is one of the most prominent points of convergence of genetic risk factors for schizophrenia (<xref ref-type="bibr" rid="B15">15</xref>–<xref ref-type="bibr" rid="B17">17</xref>). Reduced expression of the obligatory NMDAR subunit GluN1 (also known as NR1; encoded by <italic>GRIN1</italic>) and also of GluN2C (NR2C, encoded by <italic>GRIN2C</italic>) has been reported in post-mortem prefrontal cortex tissue of schizophrenia patients (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). In addition, the <italic>GRIN2A</italic> and <italic>GRIN2B</italic> genes, encoding the GluN2A (NR2A) and GluN2B (NR2B) subunit of the NMDAR respectively, are identified schizophrenia risk genes (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>Risk genes and molecules producing N-methyl-D-aspartate receptor (NMDAR) hypofunction and their effects on different cell types. Overview of three different categories of risk genes or NMDAR-antagonistic molecules which may produce NMDAR hypofunction (yellow boxes). The expression of different GluN2-subunits by different cell types may be a key driver of differential vulnerability of specific types of neurons in schizophrenia. The extent of GluN2B expression in interneurons and GluN2A expression in pyramidal cells is uncertain, as conflicting results exist in the literature and public databases, but they are likely to be small, at least in prefrontal cortex (see main text).</p>
</caption>
<graphic xlink:href="fpsyt-10-00835-g001"></graphic>
</fig>
<p>At least one <italic>GRIN2B</italic> risk allele (rs1805502) is associated with decreased expression of GluN1 in patients (<xref ref-type="bibr" rid="B18">18</xref>). Moreover, exome-sequencing studies revealed that rare damaging mutations in <italic>GRIN1</italic>, <italic>GRIN2A</italic>, and <italic>GRIN2B</italic>, which are expected to cause NMDAR hypofunction directly, are found in samples from schizophrenia patients, but not controls (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>Experiments in mice provide further support for a link between schizophrenia and hypofunction of GluN2A and GluN2B: Global ablation of <italic>Grin2A</italic> causes spatial working/short-term memory deficits (without impairing basic spatial processing) (<xref ref-type="bibr" rid="B22">22</xref>). Further, pharmacological blockade of GluN2B alone is sufficient to cause behavioral abnormalities in rodents, in particular increased locomotor activity, which has been likened to psychosis (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>), as well as reduced cognitive flexibility (<xref ref-type="bibr" rid="B25">25</xref>), but does not recapitulate the entire profile of schizophrenia, at least as far as the disease can be modeled in rodents. For instance, pharmacological GluN2B blockade does not affect pre-pulse inhibition and may increase motivation, working memory, processing speed, sustained attention, and also motor impulsivity (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>–<xref ref-type="bibr" rid="B29">29</xref>)—note, however, that these pharmacological results can contrast strongly with the schizophrenia-related deficits seen with cell type–specific <italic>Grin2B</italic>-ablation in mice (see below).</p>
<p>Risk genes other than those encoding NMDAR subunits may affect the production or degradation of D-amino acids that act as obligatory co-agonists at the NMDAR, especially of D-serine (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). This includes the genes encoding the D-serine producing enzyme <italic>serine racemase (SR)</italic>, the D-serine degrading enzyme <italic>D-amino acid oxidase</italic> (DAAO, encoded by <italic>DAO</italic>), and its activator DAOA, also termed G72 (<xref ref-type="bibr" rid="B30">30</xref>). Four other risk genes—dysbindin (<italic>DTNP1</italic>), neuregulin 1 (<italic>NRG1</italic>), neuregulin 2 (<italic>NRG2</italic>), and the NRG1/2-receptor ErbB4 (<italic>ERBB4</italic>)—are implicated in regulating NMDAR function and synaptic plasticity, and their expression is altered in post-mortem tissue in schizophrenia: downregulation of <italic>DTNP1</italic> in hippocampal and cortical tissue has been reported in schizophrenia patients, and <italic>Dtnp1</italic> knockout in mice leads to reduced expression of NMDARs and correlates with working memory impairments (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Increased neuregulin 1–ErbB4 signaling has been reported in the frontal cortex in patients and suppresses NMDAR activation (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>), modulating GluN2B subunits in particular (<xref ref-type="bibr" rid="B35">35</xref>). Two studies also found increased neuregulin 1 expression in post-mortem tissue from prefrontal cortex (<xref ref-type="bibr" rid="B36">36</xref>) and hippocampus (<xref ref-type="bibr" rid="B37">37</xref>) of schizophrenia patients, although a third did not detect this pattern (<xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>Similarly, neuregulin 2 expression leads to internalization of GluN2B-containing NMDARs in cortical interneurons, but is also itself decreased by NMDAR activation (<xref ref-type="bibr" rid="B38">38</xref>). Neuregulin 2 expression is, however, <italic>reduced</italic> in schizophrenia patients (<xref ref-type="bibr" rid="B36">36</xref>), and <italic>Nrg2</italic> knockout in mice leads to a wide range of schizophrenia-related and partly clozapine-responsive deficits (reduced prefrontal dopamine, novelty- and amphetamine-induced hyperlocomotion, and impairments of T-maze working memory, sociability, and pre-pulse inhibition) (<xref ref-type="bibr" rid="B39">39</xref>). Finally, exome sequencing has revealed rare schizophrenia-related damaging mutations in the gene encoding the tyrosine-kinase <italic>FYN</italic>, which regulates NMDAR-trafficking (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>).</p>
</sec>
<sec id="s3">
<title>Linking NMDAR Hypofunction to Schizophrenia: Pharmacological Evidence</title>
<p>Support for the NMDAR hypofunction hypothesis of schizophrenia also comes from the observation that ketamine and phencyclidine (PCP), which are use-dependent non-competitive blockers of the NMDAR-channel, induce cognitive, negative, and positive symptoms of the disease (and increased dopamine signaling) in humans and rodents (<xref ref-type="bibr" rid="B13">13</xref>). The finding that dopaminergic agonists, in contrast, may only reproduce <italic>positive</italic> symptoms is central to the proposal that NMDAR hypofunction is causally upstream of dopaminergic aberrations in schizophrenia (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Importantly though, both PCP and ketamine have also been reported to act as agonists on D2Rs as well, they display a similar affinity for D2Rs as for NMDARs and a considerably higher affinity for the high dopamine-affinity functional state D2R<sup>High</sup> (<xref ref-type="bibr" rid="B42">42</xref>–<xref ref-type="bibr" rid="B45">45</xref>). Such D2R-agonism could contribute synergistically to the psychotomimetic effects of PCP and ketamine. Also, low-affinity binding of both drugs to 5-HT2 receptors has been suggested (<xref ref-type="bibr" rid="B42">42</xref>) but has not been confirmed by others (<xref ref-type="bibr" rid="B46">46</xref>). Low-affinity binding of PCP to the serotonin transporter (SERT) has also been found (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>), but the contribution to its psychotomimetic effects are unclear. Finally, ketamine—through its main metabolite hydroxynorketamine—also increases expression of prefrontal and hippocampal AMPA glutamate receptor subunits, alters striatal BDNF signaling, and—just like ketamine itself—increases G<sub>s</sub>-protein mediated signaling, including cAMP response element binding (CREB) protein levels, independently from NMDARs (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>).</p>
<p>The similarity between the psychological effects of NMDAR blockers in humans and symptoms of schizophrenia was described in a large review of over two dozen studies, which report the effects of PCP when used as an anesthetic or recreationally, or when administered experimentally in schizophrenia patients (<xref ref-type="bibr" rid="B51">51</xref>). This evidence was complemented with several subsequent controlled studies using ketamine (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B52">52</xref>–<xref ref-type="bibr" rid="B54">54</xref>). Some studies showed that ketamine (<xref ref-type="bibr" rid="B55">55</xref>) or PCP (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B56">56</xref>–<xref ref-type="bibr" rid="B58">58</xref>) may re-institute psychotic symptoms in therapeutically stabilized patients with schizophrenia. Notably, in healthy humans, ketamine induces a resting state connectivity pattern (especially involving the prefrontal cortex) that resembles the brain state of the prodrome and early-stage schizophrenia, rather than the chronic brain state in schizophrenia (<xref ref-type="bibr" rid="B59">59</xref>).</p>
<p>Furthermore, there is evidence that maternal PCP abuse during pregnancy (putatively causing NMDAR hypofunction in the developing brain) increases the risk for developing schizophrenia later in life (<xref ref-type="bibr" rid="B60">60</xref>). Complementary rodent studies show that NMDARs have a crucial role in virtually <italic>all</italic> processes of cellular neuronal development (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>), leading to alterations of neuronal circuits (<xref ref-type="bibr" rid="B63">63</xref>) and behavior later in life (<xref ref-type="bibr" rid="B64">64</xref>).</p>
</sec>
<sec id="s4">
<title>Schizophrenia Does Not Equal NMDAR Blockade: a Need to Refine the Framework</title>
<p>While the evidence summarized above supports an association between NMDAR hypofunction and schizophrenia, several recent studies call for qualification of some earlier conclusions.</p>
<p><italic>Firstly</italic>, the <italic>specific</italic> deficits seen with PCP and ketamine do not <italic>precisely</italic> recapitulate the specific symptoms seen in patients with schizophrenia. The apparent discrepancy might, at least in part, result from over-generalization during symptom classification, for instance when referring too airily to “symptom domains.” One recent study evaluated the experiences reliably induced by ketamine—as reported by recreational drug users; the experience items of the questionnaire used in this study had previously been matched to distinct psychiatric disorders by professional psychiatrists. Notably, ketamine was not reported to reliably induce experiences that cluster specifically within any of the cognitive, positive, or negative domains of schizophrenia as opposed to other psychiatric disorders (e.g. depression) (<xref ref-type="bibr" rid="B65">65</xref>). In fact, non-glutamatergic drugs such as psilocybin and amphetamine provided a better match (<xref ref-type="bibr" rid="B65">65</xref>).</p>
<p>Another study demonstrated that the psychotic experiences induced by ketamine, especially body image disturbances and “out-of-body” experiences—also described in previous PCP-studies (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B66">66</xref>)—do not correspond to psychotic symptoms seen in schizophrenia (<xref ref-type="bibr" rid="B66">66</xref>). The effects seen after higher doses of PCP (e.g. 10 mg PCP i.v.) may be better categorized as “delirium” as defined by <italic>DSM-V</italic> (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>). There is also evidence that the use of ketamine as an anaesthetic seems to be tolerated by schizophrenic patients at least as well as, if not better than, depressed subjects (<xref ref-type="bibr" rid="B68">68</xref>). The <italic>specificity</italic> of symptom-matching required to evaluate the suitability of this pharmacological model also raises a note of caution for <italic>preclinical</italic> research, which does not even come close to the level of precision in measuring psychological deficits achieved in humans.</p>
<p><italic>Secondly</italic>, there are questions surrounding data from mouse models designed to exhibit reduced NMDAR function. So-called NMDAR hypomorph mice which have a 90–95% reduction of NMDAR levels exhibit a very wide range of behavioral and physiological abnormalities not restricted to those related to schizophrenia (<xref ref-type="bibr" rid="B69">69</xref>–<xref ref-type="bibr" rid="B74">74</xref>). Indeed, there were no behavioral assays on which these mice performed normally. Thus, these mice exhibit a global behavioral impairment, and it is impossible to determine what psychological processes are disrupted in these mice. For instance, they also show altered ultrasonic vocalizations and increased repetitive behavior which are more suggestive of autism (<xref ref-type="bibr" rid="B75">75</xref>). Likewise, electrophysiological biomarkers of both schizophrenia and autism are found (<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B75">75</xref>). In essence, these mice may not show a <italic>specific</italic> schizophrenia-related endophenotypic profile.</p>
<p><italic>Thirdly</italic>, although the identification of <italic>anti-NMDAR encephalitis</italic> as an important neurological disease with marked psychotic features (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>) at first sight provides a direct link to schizophrenia (<xref ref-type="bibr" rid="B78">78</xref>), the syndromes exhibit important differences. These patients develop an autoimmune disorder associated with antibodies targeting the extracellular domain of the obligatory NR1 (GluN1) subunit present in all NMDARs, leading to receptor clustering and internalization (<xref ref-type="bibr" rid="B79">79</xref>). In primary neuronal cultures, patient antibodies can reduce the surface expression of NR1 in both excitatory and inhibitory neurons (<xref ref-type="bibr" rid="B80">80</xref>). Some patients experience symptom patterns that are remarkably similar to schizophrenia—including positive symptoms such as hallucinations, delusions, and agitation; deficits in attention, executive functioning, working, and short-term memory present in around 50% of patients (<xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B81">81</xref>–<xref ref-type="bibr" rid="B83">83</xref>). A further common endophenotype of both diseases is increased delta oscillations (<xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B85">85</xref>). However, these schizophrenia-like symptoms do not occur in <italic>all</italic> patients with anti-NMDAR encephalitis, and negative symptoms are rather rare (<xref ref-type="bibr" rid="B86">86</xref>). Furthermore, deficits unrelated to schizophrenia such as hyper-religiosity, strong speech reduction and disintegration, high anxiety and impulsivity, epileptic seizures, breathing problems, and autonomic instability are common. Given the frequent occurrence of rigidity, mutism, or dystonia (<xref ref-type="bibr" rid="B83">83</xref>), there might be parallels to catatonic schizophrenia (a sub-category, which has, however, been separated from schizophrenia in <italic>DSM-V</italic>), but, overall, NMDAR encephalitis appears to extend beyond and is not a perfect match for schizophrenia (<xref ref-type="bibr" rid="B86">86</xref>). This conclusion is supported by the very different temporal trajectories of pathologies in the two disorders with a rapid onset of symptoms in NMDAR encephalitis (<xref ref-type="bibr" rid="B86">86</xref>) but a more prolonged (likely neurodevelopmental) disease course over multiple years in schizophrenia (<xref ref-type="bibr" rid="B87">87</xref>).</p>
<p>A <italic>final</italic> note of caution derives from the limited clinical success of pharmacological enhancement of NMDAR function. Several phase III clinical trials evaluating the GlyT1 inhibitor bitopertin, which elevates extrasynaptic levels of the NMDAR co-agonist glycine, have failed to show significant symptom improvements (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B88">88</xref>). Moreover, a meta-analysis of the therapeutic efficacy of glycine, D-serine, and other NMDAR co-agonists or positive modulators revealed that—while these drugs had small-to-medium significant beneficial effects when given to non-clozapine-treated schizophrenia patients (with glycine having qualitatively a larger effect-size than D-serine)—none of the approaches was superior to therapy with clozapine (<xref ref-type="bibr" rid="B89">89</xref>); for a review, see (<xref ref-type="bibr" rid="B90">90</xref>). In line with these results, knockout mice lacking serine racemase failed to show key deficits expected for a mouse model of schizophrenia, including no impairment of social interaction or various forms of short-term memory (<xref ref-type="bibr" rid="B91">91</xref>). Furthermore, the evidence that the glycine-binding site can be activated by these drugs is actually quite weak. Indeed, the lack of strong effects might be due to the fact that this binding site is already largely saturated (<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>). On the other hand, the DAAO inhibitor sodium benzoate, which blocks degradation of D-serine, has shown promising effects on positive and negative symptoms (<xref ref-type="bibr" rid="B10">10</xref>). Several clinical trials with DAAO inhibitors are underway. Providing a potential proof of concept for DAAO inhibitors, genetic ablation of DAAO in mice results in enhancement of multiple forms of short-term memory—but not long-term memory (<xref ref-type="bibr" rid="B94">94</xref>, <xref ref-type="bibr" rid="B95">95</xref>).</p>
<p>In summary, numerous studies link NMDAR hypofunction to schizophrenia-related deficits in humans and animal models, but the actual nature and extent of its contribution to the causation of human schizophrenia remains uncertain. The effects of global NMDAR antagonism <italic>exceed</italic> the symptom spectrum of schizophrenia. This discrepancy might be explained if NMDAR hypofunction in human schizophrenia is only partial (i.e. weaker than, for example, in anti-NMDAR encephalitis), and potentially causes aberrations across many years of learning and brain development, reflective of the neurodevelopmental nature of schizophrenia (<xref ref-type="bibr" rid="B87">87</xref>). Another possibility explored in the remainder of this review is that schizophrenia might be associated with NMDAR hypofunction in <italic>only some</italic> cell types of the brain, but not others. These alternative explanations are, of course, not mutually exclusive.</p>
</sec>
<sec id="s5">
<title>Does NMDAR Blockade Exert Its Effects Primarily Through Interneurons?</title>
<p>Pharmacological blockade of NMDARs by ketamine or PCP leads to an increase in extracellular glutamate levels (<xref ref-type="bibr" rid="B96">96</xref>). Elevated glutamate in the hippocampus and prefrontal cortex has also been suggested to occur in patients with schizophrenia, measured using magnetic resonance spectroscopy (MRS) (<xref ref-type="bibr" rid="B97">97</xref>), although the relationship between glutamate detected using MRS and extracellular (synaptic or extrasynaptic) levels of glutamate remains uncertain. In rodents, NMDAR blockade has been reported to lead to increased activity of excitatory neurons and release of glutamate (<xref ref-type="bibr" rid="B98">98</xref>–<xref ref-type="bibr" rid="B101">101</xref>). This counterintuitive finding, that the blockade of a major excitatory ionotropic receptor leads to an <italic>elevated</italic> activity of cortical excitatory cells releasing glutamate, has been explained by a preferential decrease of NMDAR-mediated excitatory drive on to <italic>inhibitory</italic> cells within the circuit, leading to a net disinhibition of excitatory cells (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B99">99</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>).</p>
<fig id="f2" position="float">
<label>Figure 2</label>
<caption>
<p>Effects of acute and chronic blockade of NMDARs. <bold>(A)</bold> Baseline state with GluN2 NMDA receptor subunit types most prevalent in each of the three cortical neuron classes (somatostatin-positive interneuron, SST; glutamatergic pyramidal cells, PCs; parvalbumin-positive interneuron, PV) color-coded. SST and PV interneurons provide inhibition to pyramidal cells. <bold>(B)</bold> PCs express mainly GluN2B-containing NMDARs that are less sensitive to ketamine and strongly blocked by magnesium ions at normal (hyperpolarized) resting membrane potential; in some areas they might also express GluN2A subunits, which are similar in terms of sensitivity to magnesium and ketamine. NMDARs containing GluN2C (on PV cells) and GluN2D (on PV and SST cells) (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B102">102</xref>–<xref ref-type="bibr" rid="B106">106</xref>), in contrast, may be more sensitive to ketamine (<xref ref-type="bibr" rid="B107">107</xref>), and are hardly blocked by magnesium (<xref ref-type="bibr" rid="B107">107</xref>–<xref ref-type="bibr" rid="B109">109</xref>), therefore contributing to the glutamate-mediated excitation of these cells even at non-depolarized resting potential. [Although note that a recent RNAseq study questions the notion that GluN2C/D are strongly expressed in neocortical PV cells (<xref ref-type="bibr" rid="B110">110</xref>, <xref ref-type="bibr" rid="B111">111</xref>)]. Consequently, when ketamine is applied, glutamatergic excitation of SST and PV cells could be strongly reduced, while excitation of PCs is not altered much, and the activity in the circuit increases due to disinhibition. Note, that—as an important qualification of this model—NMDARs are only weakly expressed by the somata of PV cells, but they occur in their presynaptic terminals, and their blockade reduces release of their inhibitory neurotransmitter GABA (see main text). Also, this model is complicated by the fact that the affinities of different GluN2-subunits differ for the two NMDAR blockers frequently used to model schizophrenia, ketamine and MK-801, and, furthermore, that the relevant literature is inconsistent. While one study reported nearly equal efficacies of MK-801 for all GluN2-subunits (<xref ref-type="bibr" rid="B112">112</xref>), another study reported nearly equal efficacies for ketamine but a 10-fold higher efficacy of MK-801 on GluN2A/B relative to GluN2C/D (<xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B113">113</xref>). A more recent study demonstrated a high selectivity of ketamine for GluN2C/D over GluN2A/B, and additionally reported that the discrepancy with the earlier study might have been due to lack of Mg<sup>2+</sup> (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B107">107</xref>). Also note that a further blocker applied frequently in both humans and animals, phencyclidine (PCP), seems to cause schizophrenia-related abnormalities preferentially by blockade of GluN2D-NMDARs (<xref ref-type="bibr" rid="B115">115</xref>), similarly to ketamine (<xref ref-type="bibr" rid="B116">116</xref>). <bold>(C</bold>, <bold>D)</bold> Repeated blockade of NMDARs on pyramidal cells and PV interneurons <bold>(C)</bold> results in an adaptive <italic>increase</italic> of NMDAR expression in PCs, but a <italic>reduction</italic> of NMDAR expression in PV cells <bold>(D)</bold> (<xref ref-type="bibr" rid="B117">117</xref>). This means that the contribution that NMDARs make to the excitation of these two neuron classes shifts, which could be responsible for the observed overactivity of the hippocampus produced by chronic ketamine, and could make the circuit prone to different responses (e.g. leading to catatonic states of schizophrenia) when global blockade of NMDARs occurs again (see main text). Note, however, that the adaptation shown in <bold>(C</bold>, <bold>D)</bold> has been shown in prefrontal cortex using MK-801, while the mechanisms in acute blockade <bold>(A</bold>, <bold>B)</bold> largely reflect data collected in the hippocampus and usage of ketamine or PCP.</p>
</caption>
<graphic xlink:href="fpsyt-10-00835-g002"></graphic>
</fig>
<p>So far, however, this <italic>local</italic> disinhibitory mechanism has only been demonstrated in the CA1-network of the hippocampus (<xref ref-type="bibr" rid="B101">101</xref>). The observed increase of excitatory activity in prefrontal cortex (mPFC) (<xref ref-type="bibr" rid="B99">99</xref>) appears to be a consequence of NMDAR blockade in the hippocampus or/and thalamus, rather than local disinhibition in the mPFC (<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B118">118</xref>–<xref ref-type="bibr" rid="B121">121</xref>).</p>
<p>Both acute and chronic application of ketamine in mice increases glutamate release in the ventral hippocampus, corresponding to hyperactivity of the anterior hippocampus in patients (<xref ref-type="bibr" rid="B98">98</xref>). However, while <italic>acute</italic> blockade of NMDARs leads to elevated dopamine release in the prefrontal cortex (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>), <italic>repeated</italic> treatment blunts prefrontal dopamine release and—in contrast to <italic>acute</italic> application—also decreases mismatch-negativity and both the power and coherence of gamma oscillations (<xref ref-type="bibr" rid="B124">124</xref>). Given that schizophrenia patients also show <italic>reduced</italic> prefrontal dopamine release (<xref ref-type="bibr" rid="B125">125</xref>), the <italic>adaptation to</italic> NMDAR hypofunction, rather than—or in addition to—NMDAR hypofunction itself, could be important to the pathophysiology of the disease.</p>
</sec>
<sec id="s6">
<title>Localizing Schizophrenia-Related NMDAR Hypofunction to Parvalbumin-Positive Interneurons</title>
<p>To date the most influential version of the NMDAR hypofunction hypothesis of schizophrenia localizes this defect to interneurons that express the calcium-buffer protein parvalbumin (PV, encoded by <italic>PVALB</italic>), which are typically fast-spiking and implicated in gamma oscillations (<xref ref-type="bibr" rid="B41">41</xref>). PV interneurons appear to react uniquely when NMDAR hypofunction is induced globally: For example, in rodents PV expression is reduced following MK-801 (<xref ref-type="bibr" rid="B126">126</xref>–<xref ref-type="bibr" rid="B128">128</xref>), PCP (<xref ref-type="bibr" rid="B129">129</xref>), or ketamine treatment (<xref ref-type="bibr" rid="B130">130</xref>, <xref ref-type="bibr" rid="B131">131</xref>) [although see (<xref ref-type="bibr" rid="B132">132</xref>)], potentially due to hypermethylation of the <italic>Pvalb</italic> promoter (<xref ref-type="bibr" rid="B133">133</xref>). This recapitulates the reduced expression of PV found <italic>post-mortem</italic> in cortical tissue from schizophrenia patients (<xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B135">135</xref>), which is expected to alter GABAergic output from PV interneurons given that PV buffers calcium during the high-frequency firing of these interneurons (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B136">136</xref>, <xref ref-type="bibr" rid="B137">137</xref>). Also, acute NMDAR antagonism by MK-801 leads to a chronic reduction of NMDAR expression in PV interneurons but not in the vast majority of other neurons (<xref ref-type="bibr" rid="B117">117</xref>). Furthermore, increased expression of NRG1 in transgenic mice, reproducing an endophenotype in patients (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>), leads to reduced NMDAR expression in PV-positive basket cells of the hippocampus, although CCK-positive cells also show this pattern (<xref ref-type="bibr" rid="B138">138</xref>). Interestingly, the NRG1-receptor ErbB4, encoded by a schizophrenia risk gene (<xref ref-type="bibr" rid="B16">16</xref>), is preferentially expressed in PV and other hippocampal interneurons, but not pyramidal cells (<xref ref-type="bibr" rid="B139">139</xref>), and may regulate NMDAR expression also in response to the NRG1-homolog NRG2, which is expressed by those interneurons themselves (<xref ref-type="bibr" rid="B38">38</xref>).</p>
</sec>
<sec id="s7">
<title>From NMDAR Hypofunction to PV Interneuron Hypofunction</title>
<p>The PV cell population itself includes several subtypes, and there is continuing uncertainty regarding which population and which brain region (the hippocampus, the prefrontal cortex, the neocortex as a whole, or other brain areas such as the thalamus) is the most relevant. The most prominent account (<xref ref-type="bibr" rid="B41">41</xref>), which has become known as the “Lisman/Grace model,” assumes that NMDAR hypofunction in PV interneurons of the CA1-subfield of the human anterior hippocampus (corresponding to the rodent <italic>ventral</italic> hippocampus) is the key starting point of schizophrenia pathology (<xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>).</p>
<fig id="f3" position="float">
<label>Figure 3</label>
<caption>
<p>Circuit model of NMDAR hypofunction induced deficit of PV neurons. The original model by Lisman et al. (<xref ref-type="bibr" rid="B41">41</xref>) proposed that parvalbumin-positive (PV) interneurons of the CA1 region of the human anterior (rodent ventral) hippocampus is the primary location of NMDAR hypofunction in schizophrenia. Reduced NMDAR activity in these PV cells is supposed to lead to a downregulation of PV and Gad67 expression and thereby of the GABAergic output of PV cells and resulting disinhibition of surrounding excitatory glutamatergic (Glu) cells. The resulting disinhibition of CA1 excitatory glutamatergic projection neurons would lead to overactivation of the output stage of the hippocampus (subiculum) as seen in patients (<xref ref-type="bibr" rid="B98">98</xref>), and through a disynaptic loop through the basal ganglia cause a hyperactivity of ventral tegmental area (VTA) dopamine (DA) neurons innervating the nucleus accumbens (potentially causing psychosis) and also the hippocampus (positive feedback loop).</p>
</caption>
<graphic xlink:href="fpsyt-10-00835-g003"></graphic>
</fig>
<p>From the outset, this seems to be an unlikely scenario, since PV cells have very low expression of NMDA receptors compared to other neuron types in this region (<xref ref-type="bibr" rid="B140">140</xref>). In fact, PV interneurons across the brain (in common with other medial ganglionic eminence–derived interneurons) have relatively small NMDAR-mediated currents and, conversely, a high synaptic calcium current through inward-rectifying calcium-permeable AMPA-receptors (<xref ref-type="bibr" rid="B141">141</xref>). This implies that a reduction of NMDAR expression might not be expected to reduce the excitation or calcium influx in PV cells appreciably. However, it is important to note that there are input-specific differences in the magnitude of NMDAR currents recorded in CA1 PV interneurons (<xref ref-type="bibr" rid="B142">142</xref>). More specifically, Schaffer collateral feed-forward inputs onto PV-basket cells—as recorded in (<xref ref-type="bibr" rid="B141">141</xref>)—have vastly lower NMDAR currents compared to feedback inputs from within CA1 (<xref ref-type="bibr" rid="B142">142</xref>, <xref ref-type="bibr" rid="B143">143</xref>). This likely has consequences for dendritic computations in PV interneurons, as has been shown with NMDAR-dependent supra-linear summation of local CA1 inputs (<xref ref-type="bibr" rid="B143">143</xref>).</p>
<p>However, a key twist in this model (which posits a deficit of NMDAR signaling in PV cells as a core pathological mechanism, <xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>) is the assumption that NMDARs in such PV interneurons serve primarily as <italic>sensors</italic> of the overall glutamatergic activity present in a local circuit—thereby obviating the need for a receptor to be present in large quantities in order to have strong effects (<xref ref-type="bibr" rid="B41">41</xref>). Lower activation of NMDARs and a resulting decrease in calcium entry could signal reduced overall <italic>excitatory</italic> network activity and lead to a homeostatic downregulation of <italic>inhibitory</italic> output from PV cells in order to maintain the excitation/inhibition balance. Reduced expression of the primary GABA-producing enzyme GAD67 (encoded by <italic>GAD1</italic>) and PV could then reflect adaptive reductions of inhibitory output, and are indeed seen in <italic>post-mortem</italic> cortical tissue from schizophrenia patients (<xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B144">144</xref>, <xref ref-type="bibr" rid="B145">145</xref>). While the number of neocortical PV interneurons does not seem to decrease in schizophrenia, about half of them lack GAD67 (at least in prefrontal and anterior cingulate cortex) (<xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B146">146</xref>, <xref ref-type="bibr" rid="B147">147</xref>), and may thereby lose their ability to exert an inhibitory influence on the network (<xref ref-type="bibr" rid="B148">148</xref>, <xref ref-type="bibr" rid="B149">149</xref>). Notably, the expression of GAD67 and PV seems to be constantly changing even under physiological conditions, depending on sensory experience and memory formation (<xref ref-type="bibr" rid="B150">150</xref>). This implies that a pathological situation that decouples NMDAR activity in PV cells from actual glutamate release in the circuit could lead to a maladaptive reduction of GABA release from PV interneurons (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>The nature of this decoupling is unclear. Post-mortem findings in schizophrenia have reported reduced NMDAR expression in multiple cell types, including interneurons, but notably PV cells were not disproportionately affected (<xref ref-type="bibr" rid="B146">146</xref>, <xref ref-type="bibr" rid="B151">151</xref>, <xref ref-type="bibr" rid="B152">152</xref>). However, the GluN2C subunit, which is much more prominently expressed in cortical PV interneurons than pyramidal cells according to some studies (<xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B117">117</xref>)—but not others (<xref ref-type="bibr" rid="B110">110</xref>, <xref ref-type="bibr" rid="B111">111</xref>)—is indeed downregulated in the prefrontal cortex (<xref ref-type="bibr" rid="B18">18</xref>). Alternatively, a decrease in levels of NMDAR co-agonists (D-serine, glycine; for example due to genetic changes in the schizophrenia risk genes <italic>SR</italic>, <italic>DAO</italic>, or <italic>DAOA/G72</italic>) or increased levels of endogenous NMDAR blockers such as zinc or kynurenic acid, could play a role (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). The tryptophan-degradation metabolite kynurenic acid, which is also an endogenous non-specific antagonist of the NMDAR glycine site, exhibits elevated levels in the cortex (<xref ref-type="bibr" rid="B153">153</xref>) and cerebrospinal fluid (<xref ref-type="bibr" rid="B154">154</xref>) in patients with schizophrenia. Application of kynurenic acid induces spatial working memory deficits in rodents (<xref ref-type="bibr" rid="B155">155</xref>), while blockade of its production enhances cognition (<xref ref-type="bibr" rid="B156">156</xref>) and reduces firing activity of ventral tegmental area (VTA) dopamine neurons, as would be predicted from a specific augmenting action on inhibitory neurons of the ventral hippocampus (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B157">157</xref>). However, it is unclear why such global NMDAR hypofunction should affect PV cells with relative specificity.</p>
<p>In the Lisman/Grace model (<xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>), at the circuit level the proposed key downstream consequences of the resulting disinhibition of CA1 pyramidal cells are hyperactivity of the anterior hippocampal output stage, the subiculum, and excess activation of dopamine neurons in the VTA resulting from a disinhibitory loop through the nucleus accumbens and the ventral pallidum (<xref ref-type="bibr" rid="B41">41</xref>). Virtually all of those physiological aberrations have been documented in patients with schizophrenia, and the control of VTA dopamine neurons by the subiculum has been established in rodents (<xref ref-type="bibr" rid="B158">158</xref>, <xref ref-type="bibr" rid="B159">159</xref>). However, it is as yet unclear if such a hyperactivity of the hippocampal output actually results from a decrease of inhibitory output from CA1 PV interneurons. While direct chemogenetic silencing of hippocampal PV interneurons failed to evoke behavioral correlates of elevated VTA-dopamine activity—elevated locomotion and amplification of amphetamine-induced locomotion—inhibition of <italic>other</italic> hippocampal interneurons (specified by <italic>GAD2</italic>-expression) was able to do so (<xref ref-type="bibr" rid="B160">160</xref>). Also, putative blockade of GluN2A-containing NMDARs, which are particularly prominent in PV interneurons (<xref ref-type="bibr" rid="B117">117</xref>, <xref ref-type="bibr" rid="B161">161</xref>), does not appear to cause hyperlocomotion at all (<xref ref-type="bibr" rid="B23">23</xref>). On the other hand, mouse models in which hippocampal PV interneurons are permanently reduced in numbers <italic>did</italic> recapitulate core deficits of schizophrenia, including hippocampal hyperactivity and increased novelty-induced hyperlocomotion which was partially resistant to anti-dopaminergic treatment (<xref ref-type="bibr" rid="B162">162</xref>, <xref ref-type="bibr" rid="B163">163</xref>). It should be noted that although the characteristic increase of locomotion (a rodent correlate of positive symptoms) seen with stimulation of the ventral subiculum is usually attributed to increased VTA dopaminergic activity (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B159">159</xref>), the locomotion-inducing effect of NMDAR blockers may not entirely require intact dopamine release given that it is also apparent in dopamine-depleted rodents (<xref ref-type="bibr" rid="B164">164</xref>–<xref ref-type="bibr" rid="B167">167</xref>).</p>
<p>Other versions of this hypothesis propose that NMDAR hypofunction is instead localized to <italic>prefrontal</italic> PV interneurons (<xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B145">145</xref>, <xref ref-type="bibr" rid="B168">168</xref>–<xref ref-type="bibr" rid="B170">170</xref>). Decreased PV expression has so far been documented in <italic>neocortical</italic> tissue from schizophrenia patients rather than in the hippocampus (<xref ref-type="bibr" rid="B146">146</xref>–<xref ref-type="bibr" rid="B148">148</xref>). It has been suggested that weakening of the output of prefrontal PV interneurons would lead to less synchronized output from prefrontal projection neurons targeting a specific subset of dopamine and GABAergic neurons in the VTA (<xref ref-type="bibr" rid="B168">168</xref>). Given their known target specificity, this would be expected to result in reduced activation of prefrontal-projecting (mesocortical) dopaminergic neurons and concomitant disinhibitory activation of (mesolimbic) dopamine cells projecting to the nucleus accumbens, thereby giving rise to the well-documented co-existence of hypofrontality and striatal hyperdopaminergia in schizophrenia (<xref ref-type="bibr" rid="B168">168</xref>). However, a direct demonstration of this mechanism is so far lacking. Related accounts focused rather on the link between NMDARs in PV interneurons and gamma oscillations, which are relevant to various cognitive functions and are disrupted in schizophrenia (<xref ref-type="bibr" rid="B145">145</xref>, <xref ref-type="bibr" rid="B169">169</xref>–<xref ref-type="bibr" rid="B171">171</xref>).</p>
<p>Finally, a recent study showed that NMDARs are expressed <italic>presynaptically</italic> by prefrontal PV interneurons innervating pyramidal cells, and that their activation can enhance evoked GABA release (i.e. PV cell–mediated inhibition), and their blockade by MK-801 reduced inhibitory currents in pyramidal cells, if (and only if) glutamate was released by surrounding neurons (<xref ref-type="bibr" rid="B172">172</xref>). This finding could resolve the long-standing puzzle as to how <italic>acute</italic> application of NMDAR antagonists could lead to an effective PV disinhibition of pyramidal cells, despite the fact that NMDARs might not contribute significantly to the somatodendritic excitation of PV interneurons.</p>
</sec>
<sec id="s8">
<title>Genetic Modeling of NMDAR Hypofunction in Cortical Interneurons</title>
<p>In order to assess whether NMDAR hypofunction in PV-positive interneurons—during both postnatal development and adulthood—can indeed cause core aberrations of schizophrenia, several laboratories have now deleted the obligatory NMDAR subunit GluN1 (and thereby all NMDARs) selectively from PV-positive interneurons in mice. The principal method to achieve this is to cross a mouse line in which an exon of the GluN1-encoding gene <italic>Grin1</italic> is floxed, to a mouse line that expresses <italic>Cre</italic>-recombinase selectively in PV-positive interneurons. In the resulting double-transgenic mice, NMDARs are ablated only in neurons where <italic>Cre</italic> is expressed. The time at which this occurs depends on when the promoter that drives <italic>Cre</italic> is activated and on the location of the lox-sites within the <italic>Grin1</italic> gene because recombination is a stochastic event whose probability increases the closer the lox-sites are to each other (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B173">173</xref>). Because the average lifetime of an individual NMDAR-molecule in the post-synaptic membrane is not known, it is difficult to estimate precisely the actual time course of the removal of those NMDARs that had been produced before the gene disruption. In practice, strategies to delete NMDARs from PV interneurons have placed <italic>Cre</italic> under the control of the promoter of either the <italic>Ppp1r2</italic> gene, with expression onset at postnatal day (P) 7, or the PV gene (<italic>Pvalb</italic>) with an estimated onset between P10 and P14 in neocortex (<xref ref-type="bibr" rid="B174">174</xref>), generating <italic>Grin1<sup>ΔPpp1r2</sup></italic> or <italic>Grin1<sup>ΔPV</sup></italic> mice, respectively. In our experiments using the <italic>Pvalb</italic> promoter, a significantly reduced NMDAR-mediated current in PV cells could be measured at 2 months of age, although some PV interneurons did still show NMDAR-mediated currents, despite the comprehensive coverage of the PV cell population by the genetic driver line that was used (<xref ref-type="bibr" rid="B175">175</xref>).</p>
</sec>
<sec id="s9">
<title>PV-Specific NMDAR Ablation Alone Does Not Reliably Induce a Schizophrenia-Related Spectrum of Deficits</title>
<p>Surprisingly, selective genetic deletion of NMDARs in PV interneurons in mice has, by and large, <italic>not</italic> supported the model that NMDAR hypofunction in these cells is <italic>sufficient</italic> to mimic schizophrenia. <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref> summarizes the results of the behavioral assessment of these mouse lines published to date. In our hands, using either the <italic>Ppp1r2</italic>-Cre (<xref ref-type="bibr" rid="B176">176</xref>) or the more commonly used <italic>Pvalb</italic>-Cre (<xref ref-type="bibr" rid="B175">175</xref>) line to drive GluN1 ablation, there were hardly any behavioral deficits across a wide spectrum of rodent correlates of positive, negative, and cognitive symptoms when the mice were raised in enriched environments (that is, involving a shelter, such as a house and/or tube, and nesting material). This is largely supported by the results from three other labs that have used the same <italic>Pvalb</italic>-Cre mouse line, albeit in combination with a floxed-GluN1 line that featured a larger distance between lox-sites (<xref ref-type="bibr" rid="B171">171</xref>, <xref ref-type="bibr" rid="B177">177</xref>–<xref ref-type="bibr" rid="B179">179</xref>); see <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>. A possible exception is a deficit in alternation-based spatial working memory assays, which has been seen in either strong (<xref ref-type="bibr" rid="B180">180</xref>) or very subtle (<xref ref-type="bibr" rid="B171">171</xref>, <xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B176">176</xref>) forms by some labs but not by others (<xref ref-type="bibr" rid="B177">177</xref>, <xref ref-type="bibr" rid="B178">178</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Deficits induced by putative genetic N-methyl-D-aspartate receptor (NMDAR) ablation in parvalbumin interneurons. Results of behavioral tests conducted in the indicated studies (top row) measuring rodent correlates of schizophrenia in the positive, cognitive, and negative domain as well as anxiety (see left two columns) in distinct double-transgenic conditional knockout lines (stated in rows 2–4). Green →, no change; magenta, schizophrenia-related deficit; orange, deficit provoked or exacerbated by environmental stress; blue, apparent improvement of function or opposite of the expected. ↑, increase of behavioral measure; ↓, decrease of behavioral measure. <italic>Studies</italic>: Belforte 2010 (<xref ref-type="bibr" rid="B173">173</xref>), Billingslea 2014 (<xref ref-type="bibr" rid="B178">178</xref>), Bygrave 2016 (<xref ref-type="bibr" rid="B175">175</xref>), Bygrave 2019 (<xref ref-type="bibr" rid="B176">176</xref>), Carlen 2012 (<xref ref-type="bibr" rid="B171">171</xref>), Jiang 2013 (<xref ref-type="bibr" rid="B181">181</xref>), Korotkova 2010 (<xref ref-type="bibr" rid="B180">180</xref>), Saunders 2013 (<xref ref-type="bibr" rid="B177">177</xref>), Pozzi 2014 (<xref ref-type="bibr" rid="B179">179</xref>). <italic>Cre-Driver lines</italic>: Ppp1r2 (Jax# 012686) (<xref ref-type="bibr" rid="B173">173</xref>), PV (Monyer) (<xref ref-type="bibr" rid="B182">182</xref>, <xref ref-type="bibr" rid="B183">183</xref>), PV (Arber, Jax# 008069) (<xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B184">184</xref>, <xref ref-type="bibr" rid="B185">185</xref>). <italic>Floxed-Grin1 responder lines</italic>: Seeburg (<xref ref-type="bibr" rid="B186">186</xref>), Li (<xref ref-type="bibr" rid="B187">187</xref>), Tonegawa (Jax# 005246) (<xref ref-type="bibr" rid="B188">188</xref>).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1" valign="top"></th>
<th colspan="1" rowspan="1" valign="top">Publication</th>
<th colspan="1" rowspan="1" valign="top">Belforte 2010<break></break>Jiang 2013</th>
<th colspan="1" rowspan="1" valign="top">Belforte 2010</th>
<th colspan="1" rowspan="1" valign="top">Bygrave 2019</th>
<th colspan="1" rowspan="1" valign="top">Korotkova 2010</th>
<th colspan="1" rowspan="1" valign="top">Carlen 2012</th>
<th colspan="1" rowspan="1" valign="top">Saunders 2013</th>
<th colspan="1" rowspan="1" valign="top">Billingslea 2014</th>
<th colspan="1" rowspan="1" valign="top">Pozzi 2014</th>
<th colspan="1" rowspan="1" valign="top">Bygrave 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="3" valign="top">Line</td>
<td colspan="1" rowspan="1" valign="top">Driver</td>
<td colspan="1" rowspan="1" valign="top">Ppp1r2</td>
<td colspan="1" rowspan="1" valign="top">Ppp1r2</td>
<td colspan="1" rowspan="1" valign="top">Ppp1r2</td>
<td colspan="1" rowspan="1" valign="top">PV (Monyer)</td>
<td colspan="1" rowspan="1" valign="top">PV (Arber)</td>
<td colspan="1" rowspan="1" valign="top">PV (Arber)</td>
<td colspan="1" rowspan="1" valign="top">PV (Arber)</td>
<td colspan="1" rowspan="1" valign="top">PV (Arber)</td>
<td colspan="1" rowspan="1" valign="top">PV (Arber)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Responder</td>
<td colspan="1" rowspan="1" valign="top">Li</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Seeburg</td>
<td colspan="1" rowspan="1" valign="top">Seeburg</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Seeburg</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">loxP-to-loxP distance</td>
<td colspan="1" rowspan="1" valign="top">2.1 kb</td>
<td colspan="1" rowspan="1" valign="top">12 kb</td>
<td colspan="1" rowspan="1" valign="top">3.3 kb</td>
<td colspan="1" rowspan="1" valign="top">3.3 kb</td>
<td colspan="1" rowspan="1" valign="top">12 kb</td>
<td colspan="1" rowspan="1" valign="top">12 kb</td>
<td colspan="1" rowspan="1" valign="top">12 kb</td>
<td colspan="1" rowspan="1" valign="top">12 kb</td>
<td colspan="1" rowspan="1" valign="top">3.3 kb</td>
</tr>
<tr>
<td colspan="1" rowspan="3" valign="top">Positive</td>
<td colspan="1" rowspan="1" valign="top">Novelty-induced LMA</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">↑ periphery; ↓center*</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (young)</td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">→ (young)<break></break>↑ (old)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">MK801-induced LMA</td>
<td colspan="1" rowspan="1" style="background-color: #d4ebf1" valign="top">↓ (0.2)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #d4ebf1" valign="top">↓ (0.2)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #d4ebf1" valign="top">↓ (0.3)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #d4ebf1" valign="top">↓ (0.2, 0.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Pre-pulse inhibition</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→*</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="12" valign="top">Cognitive</td>
<td colspan="1" rowspan="1" valign="top">SWM: T-maze rewarded alternation</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">(↓) <sup>$</sup></td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (↓ 1s)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (↓ 1s)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">SWM: spontaneous alternation; Y-maze/T-maze)</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">↓** (Y)</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ * (Y)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (discrete)</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (discrete)<break></break>↑ (contin.)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Spatial novelty-preference</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">→ ; ↓***</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Novel-object recognition, short-term</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">→ ; ↓***</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Object displacement, short-term</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Object displacement, long-term</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Spatial ref. learning</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (+)</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (Y)</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (water)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (+)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Cue fear-conditioning</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (1 shock)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Context fear-conditioning</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (1 shock)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Reversal learning</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (water)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (+)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Attention (5CSRTT)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Social memory</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">(→)*</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">(→)*</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">(→)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="5" valign="top">Negative</td>
<td colspan="1" rowspan="1" valign="top">Reciprocal sociability</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓*</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→*</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Non-reciprocal sociability</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">(→)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Nest building</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓**</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→*</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Anhedonia (sweet preference)</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">→/↓** (Sacch)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (Sucr)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (2% Sucr)</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (10% Sucr)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Motivation</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (FST)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="5" valign="top">Anxiety</td>
<td colspan="1" rowspan="1" valign="top">EPM (young age)</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">↑**</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #d4ebf1" valign="top">↓</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">EPM (medium/old age)</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↑</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→*</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Open field</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↑</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Light/dark-box</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Hyponeophagia</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #d4ebf1" valign="top">↓</td>
</tr>
<tr>
<td colspan="1" rowspan="2" valign="top">m.</td>
<td colspan="1" rowspan="1" valign="top">Impulsivity (5CSRTT)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Perseverance (5CSRTT)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Qualifications of results: * phenotype only tested after many days of social isolation/if deficit present, potentially or reportedly dependent on social isolation; ** not present or present in a mild form in group-housed animals but provoked/exacerbated by social isolation; *** phenotype only evoked by decreased environmental enrichment (genotype–environment interaction); () indicative or partially unclear result. <sup>$</sup> Deficit very mild, only seen across multiple test (repeated-measures), not within any individual test or protocol. +, plus-maze used for spatial reference testing.</p>
<p>5CSRTT, 5-choice-serial-reaction-time task; contin, continuous; FST, forced swim test of behavioral despair; LMA, locomotor-activity; m., miscellaneous behavioral assessments; PV, parvalbumin (Pvalb); Sacch, saccharine-based sweet preference; Sucr, sucrose-based assessment of sweet preference; Y, Y-maze used for testing of spatial alternation, spatial habituation (novelty-preference), or spatial associative learning; 0.2, 0.5 dose of MK-801 used.</p>
</table-wrap-foot>
</table-wrap>
<p>However, there are some technical differences among the published studies using mouse models with NMDAR knockout in PV interneurons (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). <italic>Firstly</italic>, they differ partly with respect to the deployed Cre-driver lines. While most recent studies (<xref ref-type="bibr" rid="B171">171</xref>, <xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B177">177</xref>–<xref ref-type="bibr" rid="B179">179</xref>) used a widely adopted targeted PV-Cre 3’UTR knock-in line (<xref ref-type="bibr" rid="B184">184</xref>) that covers the vast majority of PV neurons in neocortex and hippocampus with high specificity (<xref ref-type="bibr" rid="B175">175</xref>, <xref ref-type="bibr" rid="B185">185</xref>), the Ppp1r2-Cre line (<xref ref-type="bibr" rid="B173">173</xref>) as well as the PV-Cre line (<xref ref-type="bibr" rid="B180">180</xref>, <xref ref-type="bibr" rid="B182">182</xref>, <xref ref-type="bibr" rid="B183">183</xref>) used in earlier studies are BAC-transgenic lines that did not target the PV cell population comprehensively. The Ppp1r2-Cre line had originally been reported to express in roughly 70% of the cortical PV cell population, while—conversely—around 75% of the targeted cells were PV-positive (<xref ref-type="bibr" rid="B173">173</xref>). A recent re-evaluation in neocortex, however, reported that fewer than 40% of neurons targeted by Ppp1r2-Cre are PV-positive, 10–16% are reelin-positive and 8–12% are somatostatin (SST)-positive (<xref ref-type="bibr" rid="B40">40</xref>). In addition, a small fraction of neurons in the hippocampus were also Gad67-negative, and expression in such putative pyramidal cells was reported to expand strongly, especially in CA1, by the ∼20<sup>th</sup> week of age (<xref ref-type="bibr" rid="B173">173</xref>). In general, therefore, the <italic>Ppp1r2</italic>-Cre line cannot be considered a strictly PV-specific driver.</p>
</sec>
<sec id="s10">
<title>NMDAR Hypofunction on PV Interneurons and Environmental Stressors Interact to Produce Behavioral Deficits</title>
<p>Another important reason for the potential differences between previous results in different labs, even with the same line, is that NMDAR hypofunction in PV interneurons may interact with environmental risk factors in order to be pathophysiologically harmful. Environmental stressors such as drug abuse, social stress, or even urbanicity can influence both symptoms and treatment success in patients with schizophrenia (<xref ref-type="bibr" rid="B189">189</xref>–<xref ref-type="bibr" rid="B194">194</xref>). There are now two studies showing that both post-weaning long-term social isolation (<xref ref-type="bibr" rid="B181">181</xref>) and a long-term reduction of environmental enrichment starting in early adulthood (<xref ref-type="bibr" rid="B176">176</xref>) may provoke or exacerbate various schizophrenia-related deficits in <italic>Grin1<sup>ΔPpp1r2</sup></italic> mice. A further study demonstrated elevated novelty-induced locomotion in <italic>Grin1<sup>ΔPV</sup></italic> mice with increasing age (<xref ref-type="bibr" rid="B175">175</xref>). Jiang et al. demonstrated that genetic deletion of NMDARs renders PV interneurons more susceptible to oxidative stress which may, in turn, be evoked by environmental stressors such as social isolation (<xref ref-type="bibr" rid="B181">181</xref>). It is therefore possible that the susceptibility to stress that NMDAR deletion confers to PV interneurons interacts with differences in housing conditions or other stress-inducing manipulations and thereby causes the differences observed at the behavioral level across studies. Notably, as marked in <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>, the vast majority of testing in the first study in <italic>Grin1<sup>ΔPpp1r2</sup></italic> mice was conducted in mice that had been socially isolated for at least a week, and sometimes for many weeks, before testing (<xref ref-type="bibr" rid="B173">173</xref>). Indeed, for two of these deficits—anhedonia and decreased alternation-based working memory—their dependence on social isolation was subsequently demonstrated explicitly (<xref ref-type="bibr" rid="B181">181</xref>, <xref ref-type="bibr" rid="B195">195</xref>). Bygrave et al. demonstrated that even seemingly minor changes in animal housing conditions—as likely exist between different laboratories (reflecting e.g. different regulatory conditions in different parts of the world)—are sufficient to provoke deficits in <italic>Grin1<sup>ΔPpp1r2</sup></italic> mice, which are otherwise absent in highly enriched conditions (<xref ref-type="bibr" rid="B176">176</xref>).</p>
</sec>
<sec id="s11">
<title>Oxidative Stress and Zinc Release Constitute Positive Feedback Loops Amplifying NMDAR Hypofunction and Disinhibition</title>
<p>There is evidence that increased oxidative stress in the brain is involved in the pathophysiology of schizophrenia (<xref ref-type="bibr" rid="B196">196</xref>, <xref ref-type="bibr" rid="B197">197</xref>) and, due to their high metabolic demands, fast-spiking PV interneurons are thought to be particularly sensitive to oxidative stress (<xref ref-type="bibr" rid="B198">198</xref>) (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>). In patients with schizophrenia, levels of the antioxidant glutathione (GSH) have been shown to be reduced (<xref ref-type="bibr" rid="B199">199</xref>), whereby GSH levels correlated with the severity of negative symptoms of the disease (<xref ref-type="bibr" rid="B200">200</xref>). In the rodent <italic>neonatal ventral hippocampus lesion model</italic> of schizophrenia, early administration of <italic>N</italic>-acetylcysteine (NAC), a precursor to GSH, is able to prevent oxidative stress and rescue associated electrophysiological and behavioral abnormalities (<xref ref-type="bibr" rid="B201">201</xref>).</p>
<fig id="f4" position="float">
<label>Figure 4</label>
<caption>
<p>Potential positive feedback loops provoking PV interneuron dysfunction and oxidative stress. <bold>(A)</bold> Healthy baseline state; parvalbumin-positive (PV) interneurons are prone to higher oxidative stress due to their fast-spiking activity and resulting higher metabolism, but perineuronal nets (PNNs) around them and signaling triggered by NMDARs provide antioxidant defenses. They express high levels of PV and Gad67 (producing the inhibitory neurotransmitter GABA) and therefore provide intact inhibition to the neurons in the surrounding circuit. <bold>(B)</bold> Once oxidative stress prevails, e.g. evoked by additional environmental stressors or hypofunction (downregulation/decreased activation) of PV-NMDARs, multiple positive feedback loops are triggered that further amplify oxidative stress and decrease PV interneuron function: the prior protection mechanisms are themselves reduced by oxidative stress—perineuronal nets are degraded by oxidative stress, and specifically, GluN2A-containing NMDARs (that are prominent in PV cells) become oxidized and thereby hypofunctional. Also, the resulting reduction of Gad67 and GABAergic inhibitory output leads to disinhibition of excitatory neurons of the circuit, and <italic>via</italic> IL6/NOX2 and calcium influx through voltage-gated calcium channels increases oxidative stress further. Disinhibition also provokes more glutamate release entailing co-release of zinc ions (Zn<sup>2+</sup>), which block preferentially GluN2A-NMDARs. See (<xref ref-type="bibr" rid="B195">195</xref>, <xref ref-type="bibr" rid="B198">198</xref>, <xref ref-type="bibr" rid="B202">202</xref>) for details. Lines with arrows indicate enhancement; lines with vertical line-endings indicate suppression or degradation.</p>
</caption>
<graphic xlink:href="fpsyt-10-00835-g004"></graphic>
</fig>
<p>Intriguingly, there appear to be <italic>reciprocal</italic> interactions between NMDAR hypofunction and oxidative stress (<xref ref-type="bibr" rid="B198">198</xref>) (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>). NMDARs are themselves sensitive to oxidative stress because GluN1 and GluN2A<italic>-</italic>NMDAR subunits contain redox-sensitive cysteine residues that can form disulfide bonds resulting in reduced receptor currents (<xref ref-type="bibr" rid="B203">203</xref>). Conversely, the activation of NMDARs can promote the transcription of antioxidant genes (<xref ref-type="bibr" rid="B204">204</xref>, <xref ref-type="bibr" rid="B205">205</xref>). This coupling of NMDAR activation and regulation of the antioxidant system is thought to equip metabolically active neurons with sufficient antioxidant defenses (<xref ref-type="bibr" rid="B198">198</xref>). Therefore, NMDAR hypofunction could reduce such antioxidant mechanisms, and the ensuing oxidative stress then further reduces the conductance of GluN1/GluN2A-containing NMDARs, effectively creating a positive feedback loop. PV interneurons would be particularly vulnerable to this vicious cycle because of their relatively high content of GluN2A-containing NMDARs (<xref ref-type="bibr" rid="B117">117</xref>) and their high metabolic activity (<xref ref-type="bibr" rid="B206">206</xref>).</p>
<p>A second pathological positive feedback loop involves perineuronal nets (PNNs), which provide an antioxidant defense system, particularly around PV interneurons, but are themselves damaged by oxidative stress. PNNs are reduced in post-mortem tissue from schizophrenia patients, as well as in a variety of related rodent models (<xref ref-type="bibr" rid="B206">206</xref>–<xref ref-type="bibr" rid="B208">208</xref>).</p>
<p>Beyond cellular mechanisms, NMDAR hypofunction may also induce oxidative stress through circuit-wide effects. Through initiating disinhibition of cortical circuits, NMDAR antagonists can boost levels of the pro-inflammatory cytokine IL-6, with subsequent activation of NADPH oxidase (Nox2) and the production of H<sub>2</sub>O<sub>2</sub> [reviewed in (<xref ref-type="bibr" rid="B209">209</xref>, <xref ref-type="bibr" rid="B210">210</xref>)]. Therefore, repeated or chronic global NMDAR hypofunction—as induced by multiple applications of ketamine, but not by a single injection—leads to an IL-6/Nox2–mediated reduction of GABAergic inhibition from PV interneurons specifically (<xref ref-type="bibr" rid="B202">202</xref>, <xref ref-type="bibr" rid="B211">211</xref>). Complementing this finding, interneuron-specific deletion of NMDARs increases reactive oxygen species (ROS), albeit in both inhibitory and excitatory cortical neurons (<xref ref-type="bibr" rid="B181">181</xref>). Notably, IL-6 is also increased by immune challenges (<xref ref-type="bibr" rid="B212">212</xref>) which in this way—and particularly during development—may contribute to disinhibition independently from (but synergistically with) an NMDAR-dependent mechanism (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>).</p>
<p>Environmental stressors, in turn, may lead to oxidative stress if NMDARs on PV interneurons are hypofunctional, thereby provoking damage to cortical circuits that lead to schizophrenia-related deficits. Interestingly, chronic treatment with the antioxidant apocynin was reported to improve many social isolation–induced behavioral deficits in <italic>Grin1<sup>ΔPpp1r2</sup></italic> mice, including nest building, spontaneous alternation, and pre-pulse inhibition, while also normalizing the production of ROS (<xref ref-type="bibr" rid="B181">181</xref>).</p>
<p>A similar circuit-level pathological positive feedback loop may revolve around zinc: zinc is co-released with glutamate by glutamatergic synapses and reduces the open probability (at low concentrations) and blocks (at high concentrations) preferentially GluN2A-containing NMDARs (<xref ref-type="bibr" rid="B213">213</xref>–<xref ref-type="bibr" rid="B215">215</xref>). In this way, disinhibition in the circuit leads to more zinc release, causing GluN2A-NMDAR hypofunction in PV interneurons, and thereby more disinhibition (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>).</p>
</sec>
<sec id="s12">
<title>NMDAR Hypofunction in PV Cells as a Risk Factor for Schizophrenia</title>
<p>A model that emerges from this work is that NMDAR hypofunction in PV interneurons is likely to be a <italic>risk factor</italic> for developing schizophrenia, but may not be sufficient on its own. Other (risk) factors, such as environmental stress (potentially causing oxidative stress at the cellular level), or acutely occurring NMDAR hypofunction in other cell types of the circuit [see below and (<xref ref-type="bibr" rid="B175">175</xref>)] need to be present and to interact with the cellular consequences of reduced NMDAR expression in PV interneurons to provoke symptoms of schizophrenia (<xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>). Moreover, it is interesting to note that NMDAR knockout in PV interneurons provokes molecular and electrophysiological endophenotypes of schizophrenia potentially <italic>predisposing</italic> the circuit to future insults. For example, <italic>Grin1<sup>ΔPpp1r2</sup></italic> mice show reduced expression of GAD67 (as also seen in patients with schizophrenia (<xref ref-type="bibr" rid="B173">173</xref>) and excess amphetamine-induced accumbal dopamine release aside blunted prefrontal dopamine release (<xref ref-type="bibr" rid="B40">40</xref>). The same dopaminergic phenotype was seen in <italic>Grin1<sup>ΔPV</sup></italic> mice (<xref ref-type="bibr" rid="B40">40</xref>).</p>
</sec>
<sec id="s13">
<title>Does NMDAR Hypofunction in PV Interneurons Induce Schizophrenia Only When Occurring During Development?</title>
<p>Against this backdrop of discrepancies between studies (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>), it has also been proposed that NMDAR hypofunction in PV cells may cause schizophrenia-related deficits only if it occurs at a young age but not if it begins after adolescence (<xref ref-type="bibr" rid="B173">173</xref>). For example, NMDAR blockade by ketamine leads to reduced PV expression (as also seen in neocortical and hippocampal post-mortem tissue from schizophrenia patients) if the drug is administered during adolescence but not in adulthood (<xref ref-type="bibr" rid="B126">126</xref>). It has also been reported that juvenile NMDAR ablation in PV interneurons in mice leads to schizophrenia-related deficits, while ablation later in life does not (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B216">216</xref>). According to this view, the P7-onset of the Ppp1r2-promoter activation, potentially in combination with the 2.1-kB-short distance between lox-P sites used in the Belforte et al. study (<xref ref-type="bibr" rid="B173">173</xref>), which reported a wide range of deficits, might result in NMDAR hypofunction in a critical juvenile developmental window, while the ∼P14-onset of the PV-Cre promoter (<xref ref-type="bibr" rid="B174">174</xref>), potentially in combination with a slightly (3.3 kB) (<xref ref-type="bibr" rid="B175">175</xref>) or even a much larger distance between loxP sites (12 kB) (<xref ref-type="bibr" rid="B177">177</xref>, <xref ref-type="bibr" rid="B178">178</xref>) achieves significant NMDAR hypofunction only in adulthood and is therefore less effective in causing deficits (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Indeed, some evidence aligns directly with this view. Most importantly, two studies from the Nakazawa lab have shown directly that NMDAR ablation which is stochastically delayed by using the 12-kB-long inter-loxP distance responder line does not lead to a schizophrenia-related phenotype even when combined with long-term social isolation (see <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>), while ablation of GluN1 at an earlier time point using the 2.1 kB inter-loxP distance responder line <italic>does</italic> (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B173">173</xref>).</p>
<p>However, when looking across the large body of studies as a whole (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>), the argument is not always empirically supported. For example, when using the same early-onset Ppp1r2-Cre driver line and only a slightly larger distance between loxP sites, we (<xref ref-type="bibr" rid="B176">176</xref>) obtained a rather different phenotype from the originally published one (<xref ref-type="bibr" rid="B173">173</xref>).</p>
</sec>
<sec id="s14">
<title>Acute Global NMDAR Hypofunction in Mice With Chronic PV-Specific NMDAR Hypofunction as a Model of Catatonic Schizophrenia</title>
<p>A single exposure to the NMDAR blocker MK-801 reduces NMDAR expression in PV interneurons but increases expression of NMDARs in all neocortical neurons combined (i.e. presumably in excitatory cells, <xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>) (<xref ref-type="bibr" rid="B117">117</xref>). This means that a brain that has previously been exposed to an NMDAR blocker resembles a mouse line with NMDAR hypofunction in PV cells. In such a brain, the balance of NMDAR-mediated contribution to excitation is shifted between the excitatory and PV inhibitory populations of neurons, and when a NMDAR blocker is applied to such a brain—i.e. when <italic>global</italic> NMDAR hypofunction occurs—the consequences are expected to be different. In line with these considerations, we found that MK-801 may induce cognitive and negative deficits of schizophrenia in <italic>Grin1<sup>ΔPV</sup></italic> mice at concentrations lower than those required in wild type animals to produce similar effects (<xref ref-type="bibr" rid="B175">175</xref>). Again, this argues that NMDAR hypofunction in PV interneurons is a <italic>risk factor</italic>—rather than a direct cause—of schizophrenia.</p>
<p>However, the most pronounced phenotype observed with MK-801 application at moderate doses in <italic>Grin1<sup>ΔPV</sup></italic> mice was the induction of catalepsy, with mice often remaining in the same posture for several minutes. Such cataleptic episodes alternated abruptly with phases of increased locomotion and various forms of stereotypic movement, including circling and repetitive head-shaking (<xref ref-type="bibr" rid="B175">175</xref>). Those symptoms are most akin to <italic>catatonia</italic>—a condition that can occur in, but is not specific for, schizophrenia. Catatonic episodes can last for days or even weeks and can be resistant to antipsychotic drugs (<xref ref-type="bibr" rid="B217">217</xref>). We also observed pronounced prefrontal delta-frequency (4 Hz) oscillations induced by MK-801 application in these mice (<xref ref-type="bibr" rid="B175">175</xref>). An abnormal enhancement of delta oscillations in the awake state has also been described in patients with schizophrenia (<xref ref-type="bibr" rid="B85">85</xref>), and it would be intriguing to investigate their presence in patients with catatonic schizophrenia, specifically. These considerations suggest that PV-specific NMDAR hypofunction may be a necessary pre-condition particularly for catatonic schizophrenia patients. This predicts that repeated episodes of pronounced NMDAR antagonism may produce first the <italic>pre-condition</italic> (downregulation of NMDARs specifically in PV cells) and subsequently the <italic>trigger</italic> (global NMDAR hypofunction) of catatonic episodes.</p>
</sec>
<sec id="s15">
<title>The Role of NMDAR Hypofunction in Cortical Excitatory Cells</title>
<p>Most studies relevant to the potential consequences of NMDAR hypofunction in <italic>excitatory</italic> cortical cells have not been designed to study the relevance to schizophrenia, but rather to investigate the role of NMDAR-dependent synaptic plasticity in various forms of learning and memory. Despite early demonstrations that associative spatial learning in the Morris water maze (MWM)—but not non-spatial, visual discrimination learning—was impaired by pharmacological blockade of NMDARs (<xref ref-type="bibr" rid="B218">218</xref>), it was subsequently shown that rats treated with NMDAR antagonists were in fact perfectly capable of acquiring the MWM task if they were given drug-free pre-training prior to subsequent spatial testing (<xref ref-type="bibr" rid="B219">219</xref>–<xref ref-type="bibr" rid="B221">221</xref>).</p>
<p>Likewise, the evidence from genetically modified mouse studies that NMDARs on hippocampal principal cells are required for associative memory formation is equivocal at best. Initially, genetically targeted NMDAR ablation (<xref ref-type="table" rid="T2"><bold>Table 2</bold></xref>) focused on subsets of cell types such as the principal cells of CA1 (<xref ref-type="bibr" rid="B188">188</xref>) and CA3 (<xref ref-type="bibr" rid="B222">222</xref>, <xref ref-type="bibr" rid="B223">223</xref>). It was reported that ablation of NMDARs specifically from the CA1 hippocampal subfield impaired associative spatial memory in the water maze (<xref ref-type="bibr" rid="B188">188</xref>). However, the first Cre-Driver line (T29-1, CamKIIα-Cre) used in this study to target CA1 excitatory cells was later found to express across the vast majority of excitatory cells of the hippocampus, neocortex, and peri- and enthorhinal cortex (<xref ref-type="bibr" rid="B224">224</xref>, <xref ref-type="bibr" rid="B225">225</xref>). It was subsequently demonstrated that NMDARs in CA1 and/or dentate gyrus are necessary for making correct choices related to <italic>ambiguous</italic> cues associated with overlapping or competing memories, rather than mediating associative spatial memory formation or recall as such (<xref ref-type="bibr" rid="B226">226</xref>). NMDARs in CA3 are likewise not essential for associative spatial memory formation, but have been claimed to support memory recall with incomplete cues as well as performance on a delayed match-to-place (serial reversal) memory task (<xref ref-type="bibr" rid="B222">222</xref>, <xref ref-type="bibr" rid="B223">223</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Deficits induced by putative genetic NMDAR ablation in excitatory cells of the cortex, including hippocampus. Results of behavioral tests conducted in the indicated studies (top row) measuring rodent correlates of schizophrenia in the positive, cognitive, and negative domain as well as anxiety (see left two columns) in distinct double-transgenic conditional knockout lines (stated in rows 2–4). Green →, no change; magenta, schizophrenia-related deficit; orange, deficit seen in specific test phases or with specific test conditions but not others; blue, apparent improvement of function or opposite of the expected. ↑, increase of behavioral measure; ↓, decrease of behavioral measure. <italic>Studies</italic>: Tsien 1996 (<xref ref-type="bibr" rid="B188">188</xref>), McHugh 1996 (<xref ref-type="bibr" rid="B227">227</xref>), Tatard-Leitman 2015 (<xref ref-type="bibr" rid="B228">228</xref>), Nakazawa 2002, 2003 (<xref ref-type="bibr" rid="B222">222</xref>, <xref ref-type="bibr" rid="B223">223</xref>), Finlay 2015 (<xref ref-type="bibr" rid="B229">229</xref>), Bannerman 2012 (<xref ref-type="bibr" rid="B226">226</xref>), Rompala 2013 (<xref ref-type="bibr" rid="B230">230</xref>), Vieira 2015 (<xref ref-type="bibr" rid="B231">231</xref>), Brigman 2010, 2013 (<xref ref-type="bibr" rid="B224">224</xref>, <xref ref-type="bibr" rid="B232">232</xref>). <italic>Cre-Driver lines</italic>: T29-1/CamK-Cre (<xref ref-type="bibr" rid="B225">225</xref>) [originally assumed to target CA1 pyramidal cells, but later shown to target excitatory cells across neocortex and hippocampus, e.g. (<xref ref-type="bibr" rid="B224">224</xref>); Tg<italic><sup>Cre4</sup></italic>/CamK-Cre (<xref ref-type="bibr" rid="B233">233</xref>); KA1/G32-4-Cre expresses in CA3 pyramidal cells (<xref ref-type="bibr" rid="B222">222</xref>); <italic>Tg</italic>CN12<italic>;Tg</italic>LC1 expresses in excitatory cells of CA1 and dentate gyrus (<xref ref-type="bibr" rid="B226">226</xref>); G35-3-Cre expresses in excitatory neurons of the hippocampus and the frontal, parahippocampal, and sensory cortex, esp. in layers 2/3 (<xref ref-type="bibr" rid="B230">230</xref>). AAV-CamK, Cre is expressed from a locally injected AAV-vector and driven by the CamKIIα-promoter (<xref ref-type="bibr" rid="B229">229</xref>). <italic>Floxed-Grin1 and -Grin2B responder lines</italic>: Tonegawa (Jax# 005246) (<xref ref-type="bibr" rid="B188">188</xref>), Seeburg (<xref ref-type="bibr" rid="B186">186</xref>), Holmes (<xref ref-type="bibr" rid="B224">224</xref>), Monyer (<xref ref-type="bibr" rid="B234">234</xref>).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1" valign="top"></th>
<th colspan="1" rowspan="1" valign="top">Publication</th>
<th colspan="1" rowspan="1" valign="top">Tsien 1996<break></break>McHugh 1996</th>
<th colspan="1" rowspan="1" valign="top">Tatard-Leitman 2015*</th>
<th colspan="1" rowspan="1" valign="top">Nakazawa 2002, 2003;<break></break>Finlay 2015</th>
<th colspan="1" rowspan="1" valign="top">Bannerman 2012</th>
<th colspan="1" rowspan="1" valign="top">Rompala 2013</th>
<th colspan="1" rowspan="1" valign="top">Finlay 2015;<break></break>Vieira 2015</th>
<th colspan="1" rowspan="1" valign="top">Brigman 2010, 2013<break></break>v. Engelhardt 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="9" rowspan="1" valign="top"></td>
</tr>
<tr>
<td colspan="1" rowspan="4" valign="top">Line</td>
<td colspan="1" rowspan="1" valign="top">Driver</td>
<td colspan="1" rowspan="1" valign="top">CamK: T29-1</td>
<td colspan="1" rowspan="1" valign="top">CamK: T29-1</td>
<td colspan="1" rowspan="1" valign="top">KA1/G32-4; AAV-CamK</td>
<td colspan="1" rowspan="1" valign="top">
<italic>TgCN12;TgLC1</italic>
</td>
<td colspan="1" rowspan="1" valign="top">KA-1/G35-3</td>
<td colspan="1" rowspan="1" valign="top">AAV-CamK</td>
<td colspan="1" rowspan="1" valign="top">CamK: T29-1; Tg<italic><sup>Cre4</sup></italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Responder</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Seeburg</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Tonegawa</td>
<td colspan="1" rowspan="1" valign="top">Holmes; Monyer</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Gene, loxP–loxP distance</td>
<td colspan="1" rowspan="1" valign="top">Grin1, 12 kb</td>
<td colspan="1" rowspan="1" valign="top">Grin1, 12 kb</td>
<td colspan="1" rowspan="1" valign="top">Grin1, 12 kb</td>
<td colspan="1" rowspan="1" valign="top">Grin1, 3.3 kb</td>
<td colspan="1" rowspan="1" valign="top">Grin1, 12 kb</td>
<td colspan="1" rowspan="1" valign="top">Grin1, 12 kb</td>
<td colspan="1" rowspan="1" valign="top">Grin2B, 1 kb; 2 kb</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Targeted region</td>
<td colspan="1" rowspan="1" valign="top">CA1 (&amp; cortex)</td>
<td colspan="1" rowspan="1" valign="top">Cortex/HC</td>
<td colspan="1" rowspan="1" valign="top">CA3</td>
<td colspan="1" rowspan="1" valign="top">CA1, DG</td>
<td colspan="1" rowspan="1" valign="top">Cortex, HC</td>
<td colspan="1" rowspan="1" valign="top">mPFC</td>
<td colspan="1" rowspan="1" valign="top">Cortex, HC</td>
</tr>
<tr>
<td colspan="1" rowspan="4" valign="top">Positive</td>
<td colspan="1" rowspan="1" valign="top">Novelty-induced LMA</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↑</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↑</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">MK801-induced LMA</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Amphetamine –induced LMA</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Pre-pulse inhibition</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="17" valign="top">Cognitive</td>
<td colspan="1" rowspan="1" valign="top">SWM: spontaneous alternation</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (T) <sup>&amp;#</sup></td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (Y)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (T, Y) <sup>#</sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Spatial novelty-preference</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (Y, 3h delay)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Novel-object recognition, short-term</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">→, ↓ <sup>£</sup></td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Spatial reference learning</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (MWM)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (MWM)</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">↓ (MWM<sup>&amp;</sup>, RM, Y)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (MWM)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Spatial ref. learning w. partial cue</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Spatial reference learning—beacon</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">↓ MWM) <sup>&amp;</sup></td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Spatial reversal learning</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (MWM)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Visual discrimination assoc. learning</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (MWM)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (MWM, T)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">→ (T.Sc.), ↓ (T)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Visual discrimination reversal</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (MWM, T)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓ (T.Sc.)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Context/cue fear-conditioning (FC)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (context FC)</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→ (cue FC)</td>
<td colspan="1" rowspan="1" style="background-color: #fdc58b" valign="top">→ (delay); ↓ (trace)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Cue-discrimination FC</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Fear-memory extinction</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Operant learning</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Social memory</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">(→)</td>
<td colspan="1" rowspan="1" style="background-color: #d4ebf1" valign="top">↑</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Sustained attention, 5CSSRT</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Inattentiveness, 5CSSRT</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Response latency, 5CSSRT</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td colspan="1" rowspan="5" valign="top">Negative</td>
<td colspan="1" rowspan="1" valign="top">Reciprocal sociability</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Non-reciprocal sociability</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Nest building</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↓</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Anhedonia (sweet preference)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">→ (Sacch.)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Motivation (reward latency)</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
</tr>
<tr>
<td colspan="1" rowspan="3" valign="top">misc.</td>
<td colspan="1" rowspan="1" valign="top">Open field: anxiety</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Motor impulsivity, 5CSSRT</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↑</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Perseveration, 5CSSRT</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #eec7de" valign="top">↑</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" valign="top">–</td>
<td colspan="1" rowspan="1" style="background-color: #cbe5bd" valign="top">→</td>
<td colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top">Electrophysiology</td>
<td colspan="1" rowspan="1" valign="top">Larger &amp; less specif. CA1 place fields</td>
<td colspan="1" rowspan="1" valign="top">↓ evoked power<break></break>↑ baseline power</td>
<td colspan="1" rowspan="1" valign="top">Smaller/absent CA1 place fields w. partial cue</td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top">↓ cellular LTP</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Qualifications of results: () indicative result, not properly measured or nor clear result. <sup>$</sup> Deficit very mild, only seen across multiple test (repeated-measures), not within any individual test or protocol. <sup>&amp;</sup> A deficit occurs in spatial reference memory in the MWM if the starting point is further away from the correct goal (platform) than from the incorrect goal (distracting beacon in beacon-version or opposing quadrant in standard version), there are also deficits in the Y-maze and radial-maze; i.e. deficits are seen in all cases were multiple and partially undefined spatial cues are used, rendering the reference-frame ambiguous. <sup>#</sup> Note that this result may be confounded by more fundamental aberrations in spatial processing. <sup>£</sup> Impairment only seen with longer delays or large memory load (five objects instead of two). * This mouse line also shows increased baseline power and decreased evoked power in the theta, beta, and gamma range, and also reduced expression of CCK (in neocortex), 5HT-2A (in hippocampus), dopamine D2 receptor (D2R) (in neocortex), and GRIK2 (both), while cortical expression of GAD67, PV, somatostatin (SST), D1R, GluA1/2/3/4, and 5HT-1A/2B/2C is unchanged (<xref ref-type="bibr" rid="B228">228</xref>).</p>
<p>5CSRTT, 5-choice-serial-reaction-time task; assoc., associative; FC, fear-conditioning; LMA, locomotor-activity; MWM, Morris water maze, ref., reference; RM, radial-arm maze; Sacch., saccharine-based assessment of sweet preference; T, T-maze; Y, Y-maze; T.Sc. touch-screen–based operant assay used for testing.</p>
</table-wrap-foot>
</table-wrap>
<p>A later re-assessment of a mouse line with NMDAR ablation in cortical excitatory cells (<italic>Grin1<sup>ΔCamKIIα</sup></italic> mice) across a wide range of schizophrenia-related behaviors and endophenotypes demonstrated that this line shows impairments across the major symptom domains related to schizophrenia (see <xref ref-type="table" rid="T2"><bold>Table 2</bold></xref>), including robust deficits in alternation-based spatial working memory, nest building, social interaction, and novelty-induced hyperlocomotion (<xref ref-type="bibr" rid="B228">228</xref>). <italic>Grin1<sup>ΔCamKIIα</sup></italic> mice also displayed electrophysiological endophenotypes relevant to schizophrenia (<xref ref-type="bibr" rid="B235">235</xref>–<xref ref-type="bibr" rid="B237">237</xref>), including an elevated power of baseline gamma, theta, and beta oscillations and decrease of stimulus-evoked oscillations in these frequency bands (<xref ref-type="bibr" rid="B228">228</xref>). Interestingly, pyramidal cells were also more excitable in response to current injections. In contrast to the phenotype induced by pharmacological or PV-specific NMDAR hypofunction, in mice with NMDAR hypofunction in <italic>excitatory</italic> cells the expression of PV and Gad67 was not altered in the neocortex or hippocampus (<xref ref-type="bibr" rid="B228">228</xref>). This demonstrates that several behavioral and electrophysiological endophenotypes seen in schizophrenia could be caused by NMDAR hypofunction in excitatory pyramidal cells <italic>alone</italic> and do not require reduced Gad67 expression in PV cells. Notably, the level of cortical Gad67 expression also varies strongly among patients with schizophrenia (<xref ref-type="bibr" rid="B148">148</xref>), suggesting that its reduction might not be a necessary element of disease development.</p>
<p>In a similar approach, following ablation of GluN2B from excitatory cells across the forebrain (<italic>Grin2B<sup>ΔCamKIIα</sup></italic> mice), a broad range of profound memory deficits were found, including chance-level performance in novel-object recognition and alternation-based spatial working memory, but also in spatial long-term memory tasks, and in visual discrimination learning (<xref ref-type="bibr" rid="B234">234</xref>). In contrast, when GluN2B-ablation was restricted to CA1 and dentate gyrus excitatory cells, basic spatial associative learning was left intact, although deficits in spatial reversal learning and (to a lesser extent) alternation-based working memory remained (<xref ref-type="bibr" rid="B234">234</xref>).</p>
<p>However, there are two caveats to these observations: firstly, on the one hand, some deficits seen after ablation of <italic>Grin1</italic> or <italic>Grin2B</italic> in excitatory cells (<xref ref-type="table" rid="T2"><bold>Table 2</bold></xref>) may be difficult to reconcile with the symptom-profile of schizophrenia, including a wide range of deficits in basic long-term associative spatial memory tasks, fear extinction and cue-discrimination in fear-conditioning, as well as enhanced social memory (<xref ref-type="bibr" rid="B188">188</xref>, <xref ref-type="bibr" rid="B226">226</xref>, <xref ref-type="bibr" rid="B229">229</xref>, <xref ref-type="bibr" rid="B231">231</xref>). Note, however, that these learning abnormalities could reflect abnormal credit assignment with <italic>inappropriate</italic> associations between cues resulting from aberrant assignment of salience, which is suspected to be a core deficit in schizophrenia (<xref ref-type="bibr" rid="B238">238</xref>–<xref ref-type="bibr" rid="B240">240</xref>).</p>
<p>Secondly, a study using a different Cre line that expresses in a wide range of cortical excitatory cells (although lacking expression in deeper layers in some areas of neocortex and in all layers of some parts of neocortex, e.g. retrosplenial cortex, and in a considerable proportion of hippocampal pyramidal cells), found almost no schizophrenia-related deficits (<xref ref-type="bibr" rid="B230">230</xref>). Therefore, it is probably a rather specific subset of excitatory cells, which likely include—but are not limited to—hippocampal pyramidal neurons, in which NMDAR hypofunction may lead to schizophrenia-related deficits.</p>
</sec>
<sec id="s16">
<title>The Role Of NMDAR Hypofunction In Thalamic Neurons And The Importance Of GluN2C</title>
<p>A third potential location of NMDAR hypofunction promoting schizophrenia pathogenesis is the thalamus—especially its reticular nucleus (RTN), whose neurons are GABAergic, PV-positive, and rely largely on GluN2C-containing NMDARs for their excitatory drive (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B114">114</xref>). GluN2C-NMDARs are also expressed in the glutamatergic cells of the relay and unspecific nuclei of the thalamus (<xref ref-type="bibr" rid="B241">241</xref>).</p>
<p>Work by John Lisman’s group supports a model in which blockade of GluN2C-containing NMDARs in both the excitatory relay cells and the inhibitory PV-positive RTN cells of the thalamus might be the key mechanism by which NMDAR antagonists like ketamine produce increased delta oscillations. Ketamine—at a psychotomimetic dose in humans—strongly blocks GluN2C-containing receptors, but affects GluN2A/2B-containing NMDARs to a lesser degree, since the former are about three times more sensitive to this drug compared to the latter (<xref ref-type="bibr" rid="B114">114</xref>). Additionally, the channel is relatively insensitive to Mg<sup>2+</sup> ions, allowing it to provide a tonic excitatory drive at the resting potential of thalamic neurons (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B107">107</xref>). GluN2C-NMDAR blockade by ketamine would be expected to hyperpolarize both cell types, thereby activating T-type calcium channels Cav3.3 (slow) in PV-positive RTN cells and Cav3.1 channels (fast) in glutamatergic relay cells (<xref ref-type="bibr" rid="B242">242</xref>, <xref ref-type="bibr" rid="B243">243</xref>), inducing endogenous depolarization-cycles that translate into thalamocortical delta oscillations. This hypothesis is supported by the finding that prefrontal delta oscillations are induced by ketamine and are (abnormally) present in the wake state of patients with schizophrenia (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B114">114</xref>).</p>
<p>We also observed strong prefrontal delta oscillations after application of MK-801 in <italic>Grin1<sup>ΔPV</sup></italic> mice (<xref ref-type="bibr" rid="B175">175</xref>). A combination of reduced activation of inhibitory, PV-positive RTN cells due to NMDAR ablation in <italic>Grin1<sup>ΔPV</sup></italic> mice on one hand, and an additional blockade of remaining NMDARs in thalamic relay cells by MK-801 on the other, could lead to hyperpolarization and activation of Cav3.1 channels in relay cells, and hence the induction of delta oscillations [as observed in (<xref ref-type="bibr" rid="B175">175</xref>)]. Also note that Cav3.3 is a schizophrenia risk gene, and the risk-associated mutation renders this channel hypofunctional (<xref ref-type="bibr" rid="B244">244</xref>), thereby potentially producing weaker activation of inhibitory RTN cells. Notably, local infusion of MK-801 specifically into the mediodorsal nucleus of the thalamus (at high doses) and into the RTN (already at low doses) causes increased glutamate release in prefrontal cortex in rodents (<xref ref-type="bibr" rid="B118">118</xref>, <xref ref-type="bibr" rid="B119">119</xref>, <xref ref-type="bibr" rid="B121">121</xref>). It should also be noted that specific nuclei in the human (but not the rodent) thalamus also contain PV-positive interneurons and projection neurons, and a degeneration of the latter has been described in post-mortem tissue from schizophrenia patients (<xref ref-type="bibr" rid="B245">245</xref>, <xref ref-type="bibr" rid="B246">246</xref>).</p>
</sec>
<sec id="s17">
<title>NMDAR Hypofunction in Dopamine Cells, Striatal Neurons, and SST Interneurons</title>
<p>Other candidate cell types which have been implicated in schizophrenia and suggested as a locus of NMDAR hypofunction are SST-positive interneurons (<xref ref-type="bibr" rid="B247">247</xref>) and VTA dopamine neurons (<xref ref-type="bibr" rid="B78">78</xref>). In contrast to neocortical PV interneurons and pyramidal cells (<xref ref-type="bibr" rid="B117">117</xref>), both of these cell types contain GluN2D-NMDARs (<xref ref-type="bibr" rid="B78">78</xref>) which—like GluN2C-containing NMDARs—have a higher affinity for ketamine and are largely insensitive to the Mg<sup>2+</sup>-block at resting membrane potential (<xref ref-type="bibr" rid="B78">78</xref>); these properties imply that NMDAR antagonists would preferentially reduce excitatory drive in those cells, as opposed to neurons that contain mainly GluN2A/B-NMDARs. <italic>Grin1<sup>ΔSST</sup></italic> mice still need to be evaluated comprehensively regarding schizophrenia-related deficits, but a first analysis showed that they do not demonstrate the elevated accumbal and blunted prefrontal dopamine release after amphetamine application and elevated amphetamine-induced locomotion seen in <italic>Grin1<sup>ΔPpp1r2</sup></italic> and <italic>Grin1<sup>ΔPV</sup></italic> mice (<xref ref-type="bibr" rid="B40">40</xref>).</p>
<p>A further locus of NMDAR hypofunction might be VTA dopamine neurons. These cells are a putative hub of schizophrenia pathology and feature a surprising decrease in expression of NMDARs in a prominent schizophrenia mouse model with striatal D2R overexpression (<xref ref-type="bibr" rid="B248">248</xref>). Selective ablation of NMDARs from dopamine neurons does not induce core endophenotypes of schizophrenia such as deficits of working memory, short-term object memory, sociability, or pre-pulse inhibition, nor elevated novelty- or amphetamine-induced locomotor activity (<xref ref-type="bibr" rid="B249">249</xref>, <xref ref-type="bibr" rid="B250">250</xref>). However, NMDAR knockout from dopamine neurons causes inappropriate generalization in fear-learning across cues as well as impaired visual discrimination and spatial reference learning (<xref ref-type="bibr" rid="B250">250</xref>, <xref ref-type="bibr" rid="B251">251</xref>).</p>
<p>Finally, NMDAR ablation has been experimentally confined to medium spiny neurons (MSNs) of the basal ganglia using the RGS9-Cre driver line. Mice lacking all NMDARs (i.e. <italic>Grin1</italic>) in MSNs display deficits in motor learning [on the rotarod (<xref ref-type="bibr" rid="B187">187</xref>)], while mice lacking GluN2B-containing NMDARs in MSNs have difficulties with visual discrimination learning (i.e. long-term associative memory) and its reversal, while simple operant learning is intact (<xref ref-type="bibr" rid="B232">232</xref>). It is unclear to what extent these deficits are relevant to schizophrenia, and the overall behavioral profile suggests that striatal MSNs are not a major site of NMDAR hypofunction in the pathogenesis of this disease.</p>
<p>Deficits of accurate discrimination between sensory stimuli and resulting over-generalization during learning—seen with NMDAR ablation in the VTA and the MSNs—might, however, point to aberrations of learning processes that could contribute to aberrant salience (<xref ref-type="bibr" rid="B239">239</xref>) and the formation of inappropriate associations and delusions in humans (<xref ref-type="bibr" rid="B252">252</xref>).</p>
</sec>
<sec id="s18" sec-type="conclusions">
<title>Conclusions</title>
<p>In summary, NMDAR hypofunction in multiple <italic>specific</italic> neuron types may contribute to the causation of symptoms in schizophrenia. Indeed, given that genetically driven schizophrenia will potentially produce NMDAR hypofunction across all cells, it may be unrealistic to think that deficits in any one cell type may explain the disorder. It is possible that <italic>acute</italic> blockade of NMDARs by NMDAR antagonists such as ketamine causes schizophrenia-related symptoms by preferentially reducing the activity of neurons that express NMDARs containing GluN2D (SST interneurons, dopamine neurons) and GluN2C (thalamic relay cells, PV-positive cells of the thalamic RTN and cortex, and presynaptic terminals of PV interneurons). NMDAR hypofunction in the <italic>chronic</italic> disease state, in contrast, is probably localized somewhat differently, and GluN2A/B-containing NMDARs likely play a role as well. While there is little compelling evidence that NMDAR hypofunction in PV-positive interneurons causes schizophrenia <italic>directly</italic>, it is likely a key <italic>risk factor</italic> for this disease. It renders PV interneurons more prone to oxidative stress which may be exacerbated by inflammation, environmental stress, or interactions with other risk genes.</p>
<p>The consequences of NMDAR hypofunction in other interneurons, such as SST and CCK cells still remain to be comprehensively assessed. NMDAR ablation in dopamine or striatal MSNs, in contrast, does not seem to induce a schizophrenia-related spectrum of deficits, although the observed specific aberrations in valuation and over-generalization during learning might contribute to positive symptoms. Nevertheless, some of the symptoms of schizophrenia—especially in the cognitive domain—may be caused by NMDAR hypofunction in the thalamus and in specific subsets of cortical pyramidal cells. We speculate that treatments that increase NMDAR function, reduce oxidative stress, or directly boost the function of PV and other interneurons, could conceivably be beneficial in these cases, especially if applied in the prodrome or early in schizophrenia (<xref ref-type="bibr" rid="B253">253</xref>). Given the limited success of previous approaches to enhance NMDAR-function rather directly, it is likely that any future success will depend on a better understanding of the interacting role(s) of NMDARs in different cell types within multiple different neural circuits.</p>
</sec>
<sec id="s19">
<title>Author Contributions</title>
<p>AB, KK, and DK conducted literature research and prepared the manuscript, which was revised by all authors.</p>
</sec>
<sec id="s20" sec-type="funding-information">
<title>Funding</title>
<p>The research that was conducted by the authors and is discussed in this review was funded by a Sir Henry Wellcome Postdoctoral Fellowship (DK, DMK; grant number 098896), a predoctoral OXION fellowship from the Wellcome Trust (AMB), a predoctoral LGFG fellowship from the state of Baden-Württemberg (KK), the John Fell Fund of the Oxford University Press (DK, DMB), the DFG (DK), grants from the Medical Research Council (DMK, DMB), and an Investigator Award from the Wellcome Trust (DMK). The publication of this article is funded by a grant from the Deutsche Forschungsgemeinschaft (DFG, KA/4594/2-1) and Ulm University.</p>
</sec>
<sec id="s21">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We wish to thank Drs. Simon Butt (Oxford), Norbert Weiss (Prague), Johannes Hell (Davis), John Lisman (deceased), and Alexander Sartorius (Mannheim) for helpful advice, and Simonas Masiulis (Oxford) and Elizabeth Nicholson (London) for contributing essential data sets to our previous publications in this field.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mueser</surname><given-names>KT</given-names></name><name><surname>McGurk</surname><given-names>SR</given-names></name></person-group>
<article-title>Schizophrenia</article-title>. <source/>Lancet (<year>2004</year>) <volume>363</volume>:<page-range>2063–72</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16458-1</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Sawa</surname><given-names>A</given-names></name><name><surname>Mortensen</surname><given-names>PB</given-names></name></person-group>
<article-title>Schizophrenia</article-title>. <source/>Lancet (<year>2016</year>) <volume>388</volume>:<fpage>86</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)01121-6</pub-id>
<pub-id pub-id-type="pmid">26777917</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="editor"><name><surname>Hyman</surname><given-names>SE</given-names></name></person-group>
<article-title>Revolution Stalled</article-title>. <source/>Sci Transl Med (<year>2012</year>) <volume>4</volume>:<fpage>155cm11</fpage>–<lpage>155cm11</lpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3003142</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leucht</surname><given-names>S</given-names></name><name><surname>Cipriani</surname><given-names>A</given-names></name><name><surname>Spineli</surname><given-names>L</given-names></name><name><surname>Mavridis</surname><given-names>D</given-names></name><name><surname>Örey</surname><given-names>D</given-names></name><name><surname>Richter</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis</article-title>. <source/>Lancet (<year>2013</year>) <volume>382</volume>:<page-range>951–62</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60733-3</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Downing</surname><given-names>AM</given-names></name><name><surname>Kinon</surname><given-names>BJ</given-names></name><name><surname>Millen</surname><given-names>BA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Morozova</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia</article-title>. <source/>BMC Psychiatry (<year>2014</year>) <volume>14</volume>:<fpage>351</fpage>. <pub-id pub-id-type="doi">10.1186/s12888-014-0351-3</pub-id>
<pub-id pub-id-type="pmid">25539791</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Millen</surname><given-names>BA</given-names></name><name><surname>Kinon</surname><given-names>BJ</given-names></name><name><surname>Gomez</surname><given-names>J-C</given-names></name></person-group>
<article-title>Pomaglumetad methionil (LY2140023 Monohydrate) and Aripiprazole in patients with Schizophrenia: a Phase 3, Multicenter, double-blind comparison</article-title>. <source/>Schizophr Res Treat (<year>2014</year>) <elocation-id>758212</elocation-id>. <pub-id pub-id-type="doi">10.1155/2014/758212</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stauffer</surname><given-names>VL</given-names></name><name><surname>Millen</surname><given-names>BA</given-names></name><name><surname>Andersen</surname><given-names>S</given-names></name><name><surname>Kinon</surname><given-names>BJ</given-names></name><name><surname>LaGrandeur</surname><given-names>L</given-names></name><name><surname>Lindenmayer</surname><given-names>JP</given-names></name><etal></etal></person-group>
<article-title>Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo</article-title>. <source/>Schizophr Res (<year>2013</year>) <volume>150</volume>:<page-range>434–41</page-range>. <pub-id pub-id-type="doi">10.1016/j.schres.2013.08.020</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Kinon</surname><given-names>BJ</given-names></name><name><surname>Baygani</surname><given-names>S</given-names></name><name><surname>Millen</surname><given-names>BA</given-names></name><name><surname>Velona</surname><given-names>I</given-names></name><name><surname>Kollack-Walker</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia</article-title>. <source/>BMC Psychiatry (<year>2013</year>) <volume>13</volume>:<fpage>143</fpage>. <pub-id pub-id-type="doi">10.1186/1471-244X-13-143</pub-id>
<pub-id pub-id-type="pmid">23694720</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bugarski-Kirola</surname><given-names>D</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Sameljak</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>C</given-names></name><name><surname>Blaettler</surname><given-names>T</given-names></name><name><surname>Millar</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme</article-title>. <source/>Lancet Psychiatry (<year>2016</year>) <volume>3</volume>:<page-range>1115–28</page-range>. <pub-id pub-id-type="doi">10.1016/S2215-0366(16)30344-3</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lane</surname><given-names>H-Y</given-names></name><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Green</surname><given-names>MF</given-names></name><name><surname>Hellemann</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>C-C</given-names></name><name><surname>Chen</surname><given-names>P-W</given-names></name><etal></etal></person-group>
<article-title>Add-on Treatment of Benzoate for Schizophrenia: a randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor</article-title>. <source/>JAMA Psychiatry (<year>2013</year>) <volume>70</volume>:<page-range>1267–75</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.2159</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group>
<article-title>NMDA Receptor and Schizophrenia: a brief history</article-title>. <source/>Schizophr Bull (<year>2012</year>) <volume>38</volume>:<page-range>920–6</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/sbs076</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Zukin</surname><given-names>SR</given-names></name><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Umbricht</surname><given-names>D</given-names></name></person-group>
<article-title>Has an Angel Shown the Way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia</article-title>. <source/>Schizophr Bull (<year>2012</year>) <volume>38</volume>:<page-range>958–66</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/sbs069</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name></person-group>
<article-title>Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet</article-title>? <source/>Schizophr Bull (<year>2012</year>) <volume>38</volume>:<page-range>911–3</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/sbs100</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Forsyth</surname><given-names>JK</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name></person-group>
<article-title>Mapping the consequences of impaired synaptic plasticity in schizophrenia through development: an integrative model for diverse clinical features</article-title>. <source/>Trends Cognit Sci (<year>2017</year>) <volume>21</volume>:<page-range>760–78</page-range>. <pub-id pub-id-type="doi">10.1016/j.tics.2017.06.006</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Charney</surname><given-names>AW</given-names></name><name><surname>Readhead</surname><given-names>B</given-names></name><name><surname>Kidd</surname><given-names>BA</given-names></name><name><surname>Kähler</surname><given-names>AK</given-names></name><name><surname>Kenny</surname><given-names>PJ</given-names></name><etal></etal></person-group>
<article-title>Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach</article-title>. <source/>Lancet Psychiatry (<year>2016</year>) <volume>3</volume>:<page-range>350–7</page-range>. <pub-id pub-id-type="doi">10.1016/S2215-0366(15)00553-2</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab></person-group>
<article-title>Biological insights from 108 schizophrenia-associated genetic loci</article-title>. <source/>Nature (<year>2014</year>) <volume>511</volume>:<page-range>421–7</page-range>. <pub-id pub-id-type="doi">10.1038/nature13595</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>NC</given-names></name><name><surname>Bagade</surname><given-names>S</given-names></name><name><surname>McQueen</surname><given-names>MB</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name><name><surname>Kavvoura</surname><given-names>FK</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><etal></etal></person-group>
<article-title>Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database</article-title>. <source/>Nat Genet (<year>2008</year>) <volume>40</volume>:<page-range>827–34</page-range>. <pub-id pub-id-type="doi">10.1038/ng.171</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weickert</surname><given-names>CS</given-names></name><name><surname>Fung</surname><given-names>SJ</given-names></name><name><surname>Catts</surname><given-names>VS</given-names></name><name><surname>Schofield</surname><given-names>PR</given-names></name><name><surname>Allen</surname><given-names>KM</given-names></name><name><surname>Moore</surname><given-names>LT</given-names></name><etal></etal></person-group>
<article-title>Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2013</year>) <volume>18</volume>:<page-range>1185–92</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2012.137</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Catts</surname><given-names>VS</given-names></name><name><surname>Lai</surname><given-names>YL</given-names></name><name><surname>Weickert</surname><given-names>CS</given-names></name><name><surname>Weickert</surname><given-names>TW</given-names></name><name><surname>Catts</surname><given-names>SV</given-names></name></person-group>
<article-title>A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: how can we link molecular abnormalities to mismatch negativity deficits</article-title>?. <source/>Biol Psychol (<year>2016</year>) <volume>116</volume>:<fpage>57</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsycho.2015.10.013</pub-id>
<pub-id pub-id-type="pmid">26549579</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsavou</surname><given-names>A</given-names></name><name><surname>Curtis</surname><given-names>D</given-names></name></person-group>
<article-title>In-silico investigation of coding variants potentially affecting the functioning of the glutamatergic N-methyl-D-aspartate receptor in schizophrenia</article-title>. <source/>Psychiatr Genet (<year>2019</year>) <volume>29</volume>:<fpage>44</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1097/YPG.0000000000000216</pub-id>
<pub-id pub-id-type="pmid">30664045</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curtis</surname><given-names>D</given-names></name><name><surname>Coelewij</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S-H</given-names></name><name><surname>Humphrey</surname><given-names>J</given-names></name><name><surname>Mott</surname><given-names>R</given-names></name></person-group>
<article-title>Weighted burden analysis of exome-sequenced case-control sample implicates synaptic genes in Schizophrenia aetiology</article-title>. <source/>Behav Genet (<year>2018</year>) <volume>48</volume>:<fpage>198</fpage>–<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1007/s10519-018-9893-3</pub-id>
<pub-id pub-id-type="pmid">29564678</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bannerman</surname><given-names>DM</given-names></name><name><surname>Niewoehner</surname><given-names>B</given-names></name><name><surname>Lyon</surname><given-names>L</given-names></name><name><surname>Romberg</surname><given-names>C</given-names></name><name><surname>Schmitt</surname><given-names>WB</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>NMDA Receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory</article-title>. <source/>J Neurosci (<year>2008</year>) <volume>28</volume>:<page-range>3623–30</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3639-07.2008</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilmour</surname><given-names>G</given-names></name><name><surname>Pioli</surname><given-names>EY</given-names></name><name><surname>Dix</surname><given-names>SL</given-names></name><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Conway</surname><given-names>MW</given-names></name><name><surname>Jones</surname><given-names>WT</given-names></name><etal></etal></person-group>
<article-title>Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for “NMDA antagonist modelling” of schizophrenia</article-title>. <source/>Psychopharmacol (Berl) (<year>2009</year>) <volume>205</volume>:<page-range>203–16</page-range>. <pub-id pub-id-type="doi">10.1007/s00213-009-1530-7</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higgins</surname><given-names>GA</given-names></name><name><surname>Ballard</surname><given-names>TM</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Kemp</surname><given-names>JA</given-names></name><name><surname>Gill</surname><given-names>R</given-names></name></person-group>
<article-title>Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition</article-title>. <source/>Neuropharmacology (<year>2003</year>) <volume>44</volume>:<page-range>324–41</page-range>. <pub-id pub-id-type="doi">10.1016/s0028-3908(02)00402-1</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalton</surname><given-names>GL</given-names></name><name><surname>Ma</surname><given-names>LM</given-names></name><name><surname>Phillips</surname><given-names>AG</given-names></name><name><surname>Floresco</surname><given-names>SB</given-names></name></person-group>
<article-title>Blockade of NMDA GluN2B receptors selectively impairs behavioral flexibility but not initial discrimination learning</article-title>. <source/>Psychopharmacol (Berl) (<year>2011</year>) <volume>216</volume>:<page-range>525–35</page-range>. <pub-id pub-id-type="doi">10.1007/s00213-011-2246-z</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Gastambide</surname><given-names>F</given-names></name><name><surname>Gilmour</surname><given-names>G</given-names></name><name><surname>Dix</surname><given-names>S</given-names></name><name><surname>Foss</surname><given-names>J</given-names></name><name><surname>Lloyd</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory</article-title>. <source/>Psychopharmacol (Berl) (<year>2011</year>) <volume>217</volume>:<page-range>255–69</page-range>. <pub-id pub-id-type="doi">10.1007/s00213-011-2277-5</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiménez-Sánchez</surname><given-names>L</given-names></name><name><surname>Campa</surname><given-names>L</given-names></name><name><surname>Auberson</surname><given-names>YP</given-names></name><name><surname>Adell</surname><given-names>A</given-names></name></person-group>
<article-title>The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling Schizophrenia and treating refractory depression</article-title>. <source/>Neuropsychopharmacology (<year>2014</year>) <volume>39</volume>:<page-range>2673–80</page-range>. <pub-id pub-id-type="doi">10.1038/npp.2014.123</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higgins</surname><given-names>GA</given-names></name><name><surname>Silenieks</surname><given-names>LB</given-names></name><name><surname>MacMillan</surname><given-names>C</given-names></name><name><surname>Sevo</surname><given-names>J</given-names></name><name><surname>Zeeb</surname><given-names>FD</given-names></name><name><surname>Thevarkunnel</surname><given-names>S</given-names></name></person-group>
<article-title>Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment</article-title>. <source/>Behav Brain Res (<year>2016</year>) <volume>311</volume>:<fpage>1</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2016.05.025</pub-id>
<pub-id pub-id-type="pmid">27180168</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higgins</surname><given-names>GA</given-names></name><name><surname>Ballard</surname><given-names>TM</given-names></name><name><surname>Enderlin</surname><given-names>M</given-names></name><name><surname>Haman</surname><given-names>M</given-names></name><name><surname>Kemp</surname><given-names>JA</given-names></name></person-group>
<article-title>Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat</article-title>. <source/>Psychopharmacol (Berl) (<year>2005</year>) <volume>179</volume>:<fpage>85</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-005-2203-9</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Lai</surname><given-names>Y-L</given-names></name><name><surname>Huang</surname><given-names>C-H</given-names></name><name><surname>Huang</surname><given-names>Y-J</given-names></name><name><surname>Lane</surname><given-names>H-Y</given-names></name></person-group>
<article-title>Combination of G72 genetic variation and g72 protein level to detect Schizophrenia: machine learning approaches</article-title>. <source/>Front Psychiatry (<year>2018</year>) <volume>9</volume>:<fpage>566</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2018.00566</pub-id>
<pub-id pub-id-type="pmid">30459659</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karlsgodt</surname><given-names>KH</given-names></name><name><surname>Robleto</surname><given-names>K</given-names></name><name><surname>Trantham-Davidson</surname><given-names>H</given-names></name><name><surname>Jairl</surname><given-names>C</given-names></name><name><surname>Cannon</surname><given-names>TD</given-names></name><name><surname>Lavin</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Reduced dysbindin expression mediates N-Methyl-D-Aspartate receptor hypofunction and impaired working memory performance</article-title>. <source/>Biol Psychiatry (<year>2011</year>) <volume>69</volume>:<fpage>28</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.09.012</pub-id>
<pub-id pub-id-type="pmid">21035792</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weickert</surname><given-names>CS</given-names></name><name><surname>Rothmond</surname><given-names>DA</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Kleinman</surname><given-names>JE</given-names></name><name><surname>Straub</surname><given-names>RE</given-names></name></person-group>
<article-title>Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of Schizophrenia patients</article-title>. <source/>Schizophr Res (<year>2008</year>) <volume>98</volume>:<page-range>105–10</page-range>. <pub-id pub-id-type="doi">10.1016/j.schres.2007.05.041</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hahn</surname><given-names>C-G</given-names></name><name><surname>Wang</surname><given-names>H-Y</given-names></name><name><surname>Cho</surname><given-names>D-S</given-names></name><name><surname>Talbot</surname><given-names>K</given-names></name><name><surname>Gur</surname><given-names>RE</given-names></name><name><surname>Berrettini</surname><given-names>WH</given-names></name><etal></etal></person-group>
<article-title>Altered neuregulin 1–erbB4 signaling contributes to NMDA&lt; receptor hypofunction in schizophrenia</article-title>. <source/>Nat Med (<year>2006</year>) <volume>12</volume>:<page-range>824–8</page-range>. <pub-id pub-id-type="doi">10.1038/nm1418</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Woo</surname><given-names>R-S</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name></person-group>
<article-title>The neuregulin-1 receptor ErbB4 controls glutamatergic synapse maturation and plasticity</article-title>. <source/>Neuron (<year>2007</year>) <volume>54</volume>:<page-range>583–97</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.03.028</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bjarnadottir</surname><given-names>M</given-names></name><name><surname>Misner</surname><given-names>DL</given-names></name><name><surname>Haverfield-Gross</surname><given-names>S</given-names></name><name><surname>Bruun</surname><given-names>S</given-names></name><name><surname>Helgason</surname><given-names>VG</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Neuregulin1 (NRG1) signaling through fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/– Knock-Outs compared with wild-type mice</article-title>. <source/>J Neurosci (<year>2007</year>) <volume>27</volume>:<page-range>4519–29</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4314-06.2007</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>R</given-names></name><name><surname>Straub</surname><given-names>RE</given-names></name><name><surname>Weickert</surname><given-names>CS</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Kleinman</surname><given-names>JE</given-names></name><name><surname>Weinberger</surname><given-names>DR</given-names></name></person-group>
<article-title>Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2004</year>) <volume>9</volume>:<fpage>299</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001434</pub-id>
<pub-id pub-id-type="pmid">14569272</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>AJ</given-names></name><name><surname>Lipska</surname><given-names>BK</given-names></name><name><surname>Weickert</surname><given-names>CS</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Straub</surname><given-names>RE</given-names></name><name><surname>Hashimoto</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease</article-title>. <source/>Proc Natl Acad Sci (<year>2006</year>) <volume>103</volume>:<page-range>6747–52</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.0602002103</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vullhorst</surname><given-names>D</given-names></name><name><surname>Mitchell</surname><given-names>RM</given-names></name><name><surname>Keating</surname><given-names>C</given-names></name><name><surname>Roychowdhury</surname><given-names>S</given-names></name><name><surname>Karavanova</surname><given-names>I</given-names></name><name><surname>Tao-Cheng</surname><given-names>J-H</given-names></name><etal></etal></person-group>
<article-title>A negative feedback loop controls NMDA receptor function in cortical interneurons <italic>via</italic> neuregulin 2/ErbB4 signalling</article-title>. <source/>Nat Commun (<year>2015</year>) <volume>6</volume>:<fpage>7222</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8222</pub-id>
<pub-id pub-id-type="pmid">26027736</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Shamir</surname><given-names>A</given-names></name><name><surname>Skirzewski</surname><given-names>M</given-names></name><name><surname>Leiva-Salcedo</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>OB</given-names></name><name><surname>Karavanova</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders</article-title>. <source/>Mol Psychiatry (<year>2018</year>) <volume>23</volume>:<page-range>1233–43</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2017.22</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakao</surname><given-names>K</given-names></name><name><surname>Jeevakumar</surname><given-names>V</given-names></name><name><surname>Jiang</surname><given-names>SZ</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Diaz</surname><given-names>NB</given-names></name><name><surname>Pretell Annan</surname><given-names>CA</given-names></name><etal></etal></person-group>
<article-title>Schizophrenia-like dopamine release abnormalities in a mouse model of NMDA receptor hypofunction</article-title>. <source/>Schizophr Bull (<year>2019</year>) <volume>45</volume>:<page-range>138–47</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/sby003</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lisman</surname><given-names>JE</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name><name><surname>Green</surname><given-names>RW</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Benes</surname><given-names>FM</given-names></name><name><surname>Heckers</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia</article-title>. <source/>Trends Neurosci (<year>2008</year>) <volume>31</volume>:<page-range>234–42</page-range>. <pub-id pub-id-type="doi">10.1016/j.tins.2008.02.005</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kapur</surname><given-names>S</given-names></name><name><surname>Seeman</surname><given-names>P</given-names></name></person-group>
<article-title>NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D 2 and serotonin 5-HT 2 receptors—implications for models of schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2002</year>) <volume>7</volume>:<page-range>837–44</page-range>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001093</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seeman</surname><given-names>P</given-names></name><name><surname>Ko</surname><given-names>F</given-names></name><name><surname>Tallerico</surname><given-names>T</given-names></name></person-group>
<article-title>Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics</article-title>. <source/>Mol Psychiatry (<year>2005</year>) <volume>10</volume>:<page-range>877–83</page-range>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001682</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seeman</surname><given-names>P</given-names></name><name><surname>Guan</surname><given-names>H-C</given-names></name></person-group>
<article-title>Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia</article-title>. <source/>Synap N Y N (<year>2008</year>) <volume>62</volume>:<page-range>819–28</page-range>. <pub-id pub-id-type="doi">10.1002/syn.20561</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seeman</surname><given-names>P</given-names></name><name><surname>Guan</surname><given-names>H-C</given-names></name><name><surname>Hirbec</surname><given-names>H</given-names></name></person-group>
<article-title>Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil</article-title>. <source/>Synap N Y N (<year>2009</year>) <volume>63</volume>:<fpage>698</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1002/syn.20647</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabin</surname><given-names>RA</given-names></name><name><surname>Doat</surname><given-names>M</given-names></name><name><surname>Winter</surname><given-names>JC</given-names></name></person-group>
<article-title>Role of serotonergic 5-HT2A receptors in the psychotomimetic actions of phencyclidine</article-title>. <source/>Int J Neuropsychopharmacol (<year>2000</year>) <volume>3</volume>:<page-range>333–8</page-range>. <pub-id pub-id-type="doi">10.1017/S1461145700002091</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goodman</surname><given-names>CB</given-names></name><name><surname>Thomas</surname><given-names>DN</given-names></name><name><surname>Pert</surname><given-names>A</given-names></name><name><surname>Emilien</surname><given-names>B</given-names></name><name><surname>Cadet</surname><given-names>JL</given-names></name><name><surname>Carroll</surname><given-names>FI</given-names></name><etal></etal></person-group>
<article-title>RTI-4793-14, a new ligand with high affinity and selectivity for the (+)-MK801-insensitive [3H]1-]1-(2-thienyl)cyclohexyl]piperidine binding site (PCP site 2) of guinea pig brain</article-title>. <source/>Synap N Y N (<year>1994</year>) <volume>16</volume>:<fpage>59</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1002/syn.890160107</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Gibbons</surname><given-names>S</given-names></name><name><surname>Arunotayanun</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X-P</given-names></name><name><surname>Setola</surname><given-names>V</given-names></name><name><surname>Treble</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>The ketamine analogue methoxetamine and 3- and 4-Methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor</article-title>. <source/>PloS One (<year>2013</year>) <volume>8</volume>:<elocation-id>e59334</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0059334</pub-id>
<pub-id pub-id-type="pmid">23527166</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanos</surname><given-names>P</given-names></name><name><surname>Moaddel</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>PJ</given-names></name><name><surname>Georgiou</surname><given-names>P</given-names></name><name><surname>Fischell</surname><given-names>J</given-names></name><name><surname>Elmer</surname><given-names>GI</given-names></name><etal></etal></person-group>
<article-title>NMDAR inhibition-independent antidepressant actions of ketamine metabolites</article-title>. <source/>Nature (<year>2016</year>) <volume>533</volume>:<page-range>481–6</page-range>. <pub-id pub-id-type="doi">10.1038/nature17998</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Wray</surname><given-names>NH</given-names></name><name><surname>Schappi</surname><given-names>JM</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Senese</surname><given-names>NB</given-names></name><name><surname>Rasenick</surname><given-names>MM</given-names></name></person-group>
<article-title>NMDAR-independent, cAMP-dependent antidepressant actions of ketamine</article-title>. <source/>Mol Psychiatry (<year>2018</year>). <pub-id pub-id-type="doi">10.1038/s41380-018-0083-8</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Zukin</surname><given-names>SR</given-names></name></person-group>
<article-title>Recent advances in the phencyclidine model of schizophrenia</article-title>. <source/>Am J Psychiatry (<year>1991</year>) <volume>148</volume>:<page-range>1301–8</page-range>. <pub-id pub-id-type="doi">10.1176/ajp.148.10.1301</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Karper</surname><given-names>LP</given-names></name><name><surname>Seibyl</surname><given-names>JP</given-names></name><name><surname>Freeman</surname><given-names>GK</given-names></name><name><surname>Delaney</surname><given-names>R</given-names></name><name><surname>Bremner</surname><given-names>JD</given-names></name><etal></etal></person-group>
<article-title>Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses</article-title>. <source/>Arch Gen Psychiatry (<year>1994</year>) <volume>51</volume>:<fpage>199</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950030035004</pub-id>
<pub-id pub-id-type="pmid">8122957</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Newcomer</surname><given-names>JW</given-names></name><name><surname>Farber</surname><given-names>NB</given-names></name><name><surname>Jevtovic-Todorovic</surname><given-names>V</given-names></name><name><surname>Selke</surname><given-names>G</given-names></name><name><surname>Melson</surname><given-names>AK</given-names></name><name><surname>Hershey</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Ketamine-Induced NMDA receptor hypofunction as a model of memory impairment and psychosis</article-title>. <source/>Neuropsychopharmacology (<year>1999</year>) <volume>20</volume>:<page-range>106–18</page-range>. <pub-id pub-id-type="doi">10.1016/S0893-133X(98)00067-0</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kegeles</surname><given-names>LS</given-names></name><name><surname>Abi-Dargham</surname><given-names>A</given-names></name><name><surname>Zea-Ponce</surname><given-names>Y</given-names></name><name><surname>Rodenhiser-Hill</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>JJ</given-names></name><name><surname>Van Heertum</surname><given-names>RL</given-names></name><etal></etal></person-group>
<article-title>Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2000</year>) <volume>48</volume>:<page-range>627–40</page-range>. <pub-id pub-id-type="doi">10.1016/S0006-3223(00)00976-8</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lahti</surname><given-names>AC</given-names></name><name><surname>Koffel</surname><given-names>B</given-names></name><name><surname>LaPorte</surname><given-names>D</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name></person-group>
<article-title>Subanesthetic doses of ketamine stimulate psychosis in Schizophrenia</article-title>. <source/>Neuropsychopharmacology (<year>1995</year>) <volume>13</volume>:<fpage>9</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/0893-133X(94)00131-I</pub-id>
<pub-id pub-id-type="pmid">8526975</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ban</surname><given-names>TA</given-names></name><name><surname>Lohrenz</surname><given-names>JJ</given-names></name><name><surname>Lehmann</surname><given-names>HE</given-names></name></person-group>
<article-title>Observations on the action of Sernyl-a new psychotropic drug</article-title>. <source/>Can Psychiatr Assoc J (<year>1961</year>) <volume>6</volume>:<page-range>150–7</page-range>. <pub-id pub-id-type="doi">10.1177/070674376100600307</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Domino</surname><given-names>EF</given-names></name><name><surname>Luby</surname><given-names>ED</given-names></name></person-group>
<article-title>Phencyclidine/Schizophrenia: one view toward the past, the other to the future</article-title>. <source/>Schizophr Bull (<year>2012</year>) <volume>38</volume>:<page-range>914–9</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/sbs011</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luby</surname><given-names>ED</given-names></name><name><surname>Cohen</surname><given-names>BD</given-names></name><name><surname>Rosenbaum</surname><given-names>G</given-names></name><name><surname>Gottlieb</surname><given-names>JS</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name></person-group>
<article-title>Study of a new schizophrenomimetic drug; sernyl</article-title>. <source/>AMA Arch Neurol Psychiatry (<year>1959</year>) <volume>81</volume>:<page-range>363–9</page-range>. <pub-id pub-id-type="doi">10.1001/archneurpsyc.1959.02340150095011</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anticevic</surname><given-names>A</given-names></name><name><surname>Corlett</surname><given-names>PR</given-names></name><name><surname>Cole</surname><given-names>MW</given-names></name><name><surname>Savic</surname><given-names>A</given-names></name><name><surname>Gancsos</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>N-Methyl-D-Aspartate Receptor antagonist effects on prefrontal cortical connectivity better model early than chronic Schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2015</year>) <volume>77</volume>:<page-range>569–80</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.07.022</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deutsch</surname><given-names>SI</given-names></name><name><surname>Mastropaolo</surname><given-names>J</given-names></name><name><surname>Rosse</surname><given-names>RB</given-names></name></person-group>
<article-title>Neurodevelopmental consequences of early exposure to phencyclidine and related drugs</article-title>. <source/>Clin Neuropharmacol (<year>1998</year>) <volume>21</volume>:<page-range>320–32</page-range>.</mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>du Bois</surname><given-names>TM</given-names></name><name><surname>Huang</surname><given-names>X-F</given-names></name></person-group>
<article-title>Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia</article-title>. <source/>Brain Res Rev (<year>2007</year>) <volume>53</volume>:<page-range>260–70</page-range>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2006.09.001</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Contestabile</surname><given-names>A</given-names></name></person-group>
<article-title>Roles of NMDA receptor activity and nitric oxide production in brain development</article-title>. <source/>Brain Res Rev (<year>2000</year>) <volume>32</volume>:<fpage>476</fpage>–<lpage>509</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-0173(00)00018-7</pub-id>
<pub-id pub-id-type="pmid">10760552</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kjaerby</surname><given-names>C</given-names></name><name><surname>Hovelsø</surname><given-names>N</given-names></name><name><surname>Dalby</surname><given-names>NO</given-names></name><name><surname>Sotty</surname><given-names>F</given-names></name></person-group>
<article-title>Phencyclidine administration during neurodevelopment alters network activity in prefrontal cortex and hippocampus in adult rats</article-title>. <source/>J Neurophysiol (<year>2017</year>) <volume>118</volume>:<page-range>1002–11</page-range>. <pub-id pub-id-type="doi">10.1152/jn.00081.2017</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>AL</given-names></name><name><surname>Taylor</surname><given-names>DA</given-names></name><name><surname>Malone</surname><given-names>DT</given-names></name></person-group>
<article-title>Consequences of early life MK-801 administration: long-term behavioural effects and relevance to schizophrenia research</article-title>. <source/>Behav Brain Res (<year>2012</year>) <volume>227</volume>:<page-range>276–86</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbr.2011.10.052</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Brugger</surname><given-names>S</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Stone</surname><given-names>JM</given-names></name></person-group>
<article-title>Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders</article-title>. <source/>J Psychopharmacol (Oxf) (<year>2013</year>) <volume>27</volume>:<page-range>771–8</page-range>. <pub-id pub-id-type="doi">10.1177/0269881113494107</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greifenstein</surname><given-names>F</given-names></name><name><surname>DeVAULT</surname><given-names>M</given-names></name><name><surname>Yoshitake</surname><given-names>J</given-names></name><name><surname>Gajewski</surname><given-names>J</given-names></name></person-group>
<article-title>A study of a 1-aryl cyclo hexyl amine for anesthesia*</article-title>. <source/>Anesth Analg (<year>1958</year>) <volume>37</volume>:<page-range>283–94</page-range>.</mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name></person-group>
<article-title>The neurobiology of psychedelic drugs: implications for the treatment of mood disorders</article-title>. <source/>Nat Rev Neurosci (<year>2010</year>) <volume>11</volume>:<page-range>642–51</page-range>. <pub-id pub-id-type="doi">10.1038/nrn2884</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janke</surname><given-names>C</given-names></name><name><surname>Bumb</surname><given-names>JM</given-names></name><name><surname>Aksay</surname><given-names>SS</given-names></name><name><surname>Thiel</surname><given-names>M</given-names></name><name><surname>Kranaster</surname><given-names>L</given-names></name><name><surname>Sartorius</surname><given-names>A</given-names></name></person-group>
<article-title>Ketamin als Anästhetikum bei der Elektrokrampftherapie</article-title>. <source/>Anaesthesist (<year>2015</year>) <volume>64</volume>:<page-range>357–64</page-range>. <pub-id pub-id-type="doi">10.1007/s00101-015-0027-5</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gandal</surname><given-names>MJ</given-names></name><name><surname>Sisti</surname><given-names>J</given-names></name><name><surname>Klook</surname><given-names>K</given-names></name><name><surname>Ortinski</surname><given-names>PI</given-names></name><name><surname>Leitman</surname><given-names>V</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction</article-title>. <source/>Transl Psychiatry (<year>2012</year>) <volume>2</volume>:<fpage>e142</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2012.69</pub-id>
<pub-id pub-id-type="pmid">22806213</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barkus</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>LA</given-names></name><name><surname>Sharp</surname><given-names>T</given-names></name><name><surname>Bannerman</surname><given-names>DM</given-names></name></person-group>
<article-title>GluN1 hypomorph mice exhibit wide-ranging behavioral alterations</article-title>. <source/>Genes Brain Behav (<year>2012</year>) <volume>11</volume>:<page-range>342–51</page-range>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00767.x</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohn</surname><given-names>AR</given-names></name><name><surname>Gainetdinov</surname><given-names>RR</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name></person-group>
<article-title>Mice with reduced NMDA receptor expression display behaviors related to Schizophrenia</article-title>. <source/>Cell (<year>1999</year>) <volume>98</volume>:<page-range>427–36</page-range>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)81972-8</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moy</surname><given-names>SS</given-names></name><name><surname>Nikolova</surname><given-names>VD</given-names></name><name><surname>Riddick</surname><given-names>NV</given-names></name><name><surname>Baker</surname><given-names>LK</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name></person-group>
<article-title>Preweaning sensorimotor deficits and adolescent hypersociability in grin1 knockdown mice</article-title>. <source/>Dev Neurosci (<year>2012</year>) <volume>34</volume>:<page-range>159–73</page-range>. <pub-id pub-id-type="doi">10.1159/000337984</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bodarky</surname><given-names>CL</given-names></name><name><surname>Halene</surname><given-names>TB</given-names></name><name><surname>Ehrlichman</surname><given-names>RS</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Hahn</surname><given-names>C-G</given-names></name><etal></etal></person-group>
<article-title>Novel environment and GABA agonists alter event-related potentials in N-Methyl-d-aspartate NR1 hypomorphic and wild-type mice</article-title>. <source/>J Pharmacol Exp Ther (<year>2009</year>) <volume>331</volume>:<page-range>308–18</page-range>. <pub-id pub-id-type="doi">10.1124/jpet.109.150938</pub-id>
</mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halene</surname><given-names>TB</given-names></name><name><surname>Ehrlichman</surname><given-names>RS</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Christian</surname><given-names>EP</given-names></name><name><surname>Jonak</surname><given-names>GJ</given-names></name><name><surname>Gur</surname><given-names>TL</given-names></name><etal></etal></person-group>
<article-title>Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for Schizophrenia</article-title>. <source/>Genes Brain Behav (<year>2009</year>) <volume>8</volume>:<page-range>661–75</page-range>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2009.00504.x</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gandal</surname><given-names>MJ</given-names></name><name><surname>Anderson</surname><given-names>RL</given-names></name><name><surname>Billingslea</surname><given-names>EN</given-names></name><name><surname>Carlson</surname><given-names>GC</given-names></name><name><surname>Roberts</surname><given-names>TPL</given-names></name><name><surname>Siegel</surname><given-names>SJ</given-names></name></person-group>
<article-title>Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia</article-title>?. <source/>Genes Brain Behav (<year>2012</year>) <volume>11</volume>:<page-range>740–50</page-range>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00816.x</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Tüzün</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Masjuan</surname><given-names>J</given-names></name><name><surname>Rossi</surname><given-names>JE</given-names></name><name><surname>Voloschin</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Paraneoplastic Anti–N-methyl-D-aspartate receptor encephalitis associated with Ovarian teratoma</article-title>. <source/>Ann Neurol (<year>2007</year>) <volume>61</volume>:<fpage>25</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21050</pub-id>
<pub-id pub-id-type="pmid">17262855</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kayser</surname><given-names>MS</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name></person-group>
<article-title>Anti-NMDA Receptor encephalitis in psychiatry</article-title>. <source/>Curr Psychiatry Rev (<year>2011</year>) <volume>7</volume>:<page-range>189–93</page-range>. <pub-id pub-id-type="doi">10.2174/157340011797183184</pub-id>
</mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Jeevakumar</surname><given-names>V</given-names></name><name><surname>Nakao</surname><given-names>K</given-names></name></person-group>
<article-title>Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia</article-title>. <source/>NPJ Schizophr (<year>2017</year>) <volume>3</volume>:<fpage>7</fpage>. <pub-id pub-id-type="doi">10.1038/s41537-016-0003-3</pub-id>
<pub-id pub-id-type="pmid">28560253</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Gleichman</surname><given-names>AJ</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tsou</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Cellular and synaptic mechanisms of Anti-NMDA receptor encephalitis</article-title>. <source/>J Neurosci (<year>2010</year>) <volume>30</volume>:<page-range>5866–75</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0167-10.2010</pub-id>
</mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moscato</surname><given-names>EH</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Parsons</surname><given-names>TD</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Balice-Gordon</surname><given-names>RJ</given-names></name></person-group>
<article-title>Acute mechanisms underlying antibody effects in anti–N-Methyl-D-Aspartate Receptor encephalitis</article-title>. <source/>Ann Neurol (<year>2014</year>) <volume>76</volume>:<page-range>108–19</page-range>. <pub-id pub-id-type="doi">10.1002/ana.24195</pub-id>
</mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finke</surname><given-names>C</given-names></name><name><surname>Kopp</surname><given-names>UA</given-names></name><name><surname>Prüss</surname><given-names>H</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Wandinger</surname><given-names>K-P</given-names></name><name><surname>Ploner</surname><given-names>CJ</given-names></name></person-group>
<article-title>Cognitive deficits following anti-NMDA receptor encephalitis</article-title>. <source/>J Neurol Neurosurg Psychiatry (<year>2012</year>) <volume>83</volume>:<page-range>195–8</page-range>. <pub-id pub-id-type="doi">10.1136/jnnp-2011-300411</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wandinger</surname><given-names>K-P</given-names></name><name><surname>Saschenbrecker</surname><given-names>S</given-names></name><name><surname>Stoecker</surname><given-names>W</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name></person-group>
<article-title>Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis</article-title>. <source/>J Neuroimmunol (<year>2011</year>) <volume>231</volume>:<fpage>86</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.09.012</pub-id>
<pub-id pub-id-type="pmid">20951441</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Lancaster</surname><given-names>E</given-names></name><name><surname>Martinez-Hernandez</surname><given-names>E</given-names></name><name><surname>Rosenfeld</surname><given-names>MR</given-names></name><name><surname>Balice-Gordon</surname><given-names>R</given-names></name></person-group>
<article-title>Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis</article-title>. <source/>Lancet Neurol (<year>2011</year>) <volume>10</volume>:<fpage>63</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(10)70253-2</pub-id>
<pub-id pub-id-type="pmid">21163445</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>SE</given-names></name><name><surname>Pargeon</surname><given-names>K</given-names></name><name><surname>Frechette</surname><given-names>ES</given-names></name><name><surname>Hirsch</surname><given-names>LJ</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name></person-group>
<article-title>Extreme delta brush</article-title>. <source/>Neurology (<year>2012</year>) <volume>79</volume>:<page-range>1094–100</page-range>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3182698cd8</pub-id>
</mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schulman</surname><given-names>JJ</given-names></name><name><surname>Cancro</surname><given-names>R</given-names></name><name><surname>Lowe</surname><given-names>SI</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Walton</surname><given-names>KD</given-names></name><name><surname>Llinás</surname><given-names>RR</given-names></name></person-group>
<article-title>Imaging of thalamocortical dysrhythmia in neuropsychiatry</article-title>. <source/>Front Hum Neurosci (<year>2011</year>) <volume>5</volume>:<fpage>69</fpage>. <pub-id pub-id-type="doi">10.3389/fnhum.2011.00069</pub-id>
<pub-id pub-id-type="pmid">21863138</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Diwani</surname><given-names>A</given-names></name><name><surname>Handel</surname><given-names>A</given-names></name><name><surname>Townsend</surname><given-names>L</given-names></name><name><surname>Pollak</surname><given-names>T</given-names></name><name><surname>Leite</surname><given-names>MI</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name><etal></etal></person-group>
<article-title>The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data</article-title>. <source/>Lancet Psychiatry (<year>2019</year>) <volume>6</volume>:<page-range>235–46</page-range>. <pub-id pub-id-type="doi">10.1016/S2215-0366(19)30001-X</pub-id>
</mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Insel</surname><given-names>TR</given-names></name></person-group>
<article-title>Rethinking schizophrenia</article-title>. <source/>Nature (<year>2010</year>) <volume>468</volume>:<page-range>187–93</page-range>. <pub-id pub-id-type="doi">10.1038/nature09552</pub-id>
</mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bugarski-Kirola</surname><given-names>D</given-names></name><name><surname>Blaettler</surname><given-names>T</given-names></name><name><surname>Arango</surname><given-names>C</given-names></name><name><surname>Fleischhacker</surname><given-names>WW</given-names></name><name><surname>Garibaldi</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Bitopertin in negative symptoms of Schizophrenia—Results from the phase III FlashLyte and DayLyte studies</article-title>. <source/>Biol Psychiatry (<year>2017</year>) <volume>82</volume>:<fpage>8</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2016.11.014</pub-id>
<pub-id pub-id-type="pmid">28117049</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name></person-group>
<article-title>Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia</article-title>. <source/>CNS Drugs (<year>2011</year>) <volume>25</volume>:<page-range>859–85</page-range>. <pub-id pub-id-type="doi">10.2165/11586650-000000000-00000</pub-id>
</mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacKay</surname><given-names>M-AB</given-names></name><name><surname>Paylor</surname><given-names>JW</given-names></name><name><surname>Wong</surname><given-names>JTF</given-names></name><name><surname>Winship</surname><given-names>IR</given-names></name><name><surname>Baker</surname><given-names>GB</given-names></name><name><surname>Dursun</surname><given-names>SM</given-names></name></person-group>
<article-title>Multidimensional connectomics and treatment-resistant Schizophrenia: linking phenotypic circuits to targeted therapeutics</article-title>. <source/>Front Psychiatry (<year>2018</year>) <volume>9</volume>:<fpage>537</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2018.00537</pub-id>
<pub-id pub-id-type="pmid">30425662</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeVito</surname><given-names>LM</given-names></name><name><surname>Balu</surname><given-names>DT</given-names></name><name><surname>Kanter</surname><given-names>BR</given-names></name><name><surname>Lykken</surname><given-names>C</given-names></name><name><surname>Basu</surname><given-names>AC</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name><etal></etal></person-group>
<article-title>Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology</article-title>. <source/>Genes Brain Behav (<year>2011</year>) <volume>10</volume>:<page-range>210–22</page-range>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2010.00656.x</pub-id>
</mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mothet</surname><given-names>J-P</given-names></name><name><surname>Parent</surname><given-names>AT</given-names></name><name><surname>Wolosker</surname><given-names>H</given-names></name><name><surname>Brady</surname><given-names>RO</given-names></name><name><surname>Linden</surname><given-names>DJ</given-names></name><name><surname>Ferris</surname><given-names>CD</given-names></name><etal></etal></person-group>
<article-title>d-Serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor</article-title>. <source/>Proc Natl Acad Sci (<year>2000</year>) <volume>97</volume>:<page-range>4926–31</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.97.9.4926</pub-id>
</mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Czepita</surname><given-names>D</given-names></name><name><surname>Daw</surname><given-names>NW</given-names></name><name><surname>Reid</surname><given-names>SN</given-names></name></person-group>
<article-title>Glycine at the NMDA receptor in cat visual cortex: saturation and changes with age</article-title>. <source/>J Neurophysiol (<year>1996</year>) <volume>75</volume>:<page-range>311–7</page-range>. <pub-id pub-id-type="doi">10.1152/jn.1996.75.1.311</pub-id>
</mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pritchett</surname><given-names>D</given-names></name><name><surname>Hasan</surname><given-names>S</given-names></name><name><surname>Tam</surname><given-names>SKE</given-names></name><name><surname>Engle</surname><given-names>SJ</given-names></name><name><surname>Brandon</surname><given-names>NJ</given-names></name><name><surname>Sharp</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>d-amino acid oxidase knockout (Dao –/–) mice show enhanced short-term memory performance and heightened anxiety, but no sleep or circadian rhythm disruption</article-title>. <source/>Eur J Neurosci (<year>2015</year>) <volume>41</volume>:<page-range>1167–79</page-range>. <pub-id pub-id-type="doi">10.1111/ejn.12880</pub-id>
</mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pritchett</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>AM</given-names></name><name><surname>Barkus</surname><given-names>C</given-names></name><name><surname>Engle</surname><given-names>SJ</given-names></name><name><surname>Brandon</surname><given-names>NJ</given-names></name><name><surname>Sharp</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Searching for cognitive enhancement in the Morris water maze: better and worse performance in D-amino acid oxidase knockout (Dao –/–) mice</article-title>. <source/>Eur J Neurosci (<year>2016</year>) <volume>43</volume>:<page-range>979–89</page-range>. <pub-id pub-id-type="doi">10.1111/ejn.13192</pub-id>
</mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stone</surname><given-names>JM</given-names></name><name><surname>Dietrich</surname><given-names>C</given-names></name><name><surname>Edden</surname><given-names>R</given-names></name><name><surname>Mehta</surname><given-names>MA</given-names></name><name><surname>De Simoni</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>LJ</given-names></name><etal></etal></person-group>
<article-title>Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology</article-title>. <source/>Mol Psychiatry (<year>2012</year>) <volume>17</volume>:<page-range>664–5</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2011.171</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merritt</surname><given-names>K</given-names></name><name><surname>Egerton</surname><given-names>A</given-names></name><name><surname>Kempton</surname><given-names>MJ</given-names></name><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>McGuire</surname><given-names>PK</given-names></name></person-group>
<article-title>Nature of glutamate alterations in Schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies</article-title>. <source/>JAMA Psychiatry (<year>2016</year>) <volume>73</volume>:<page-range>665–74</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.0442</pub-id>
</mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schobel</surname><given-names>SA</given-names></name><name><surname>Chaudhury</surname><given-names>NH</given-names></name><name><surname>Khan</surname><given-names>UA</given-names></name><name><surname>Paniagua</surname><given-names>B</given-names></name><name><surname>Styner</surname><given-names>MA</given-names></name><name><surname>Asllani</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver</article-title>. <source/>Neuron (<year>2013</year>) <volume>78</volume>:<fpage>81</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.02.011</pub-id>
<pub-id pub-id-type="pmid">23583108</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Homayoun</surname><given-names>H</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name></person-group>
<article-title>NMDA Receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</article-title>. <source/>J Neurosci (<year>2007</year>) <volume>27</volume>:<page-range>11496–500</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2213-07.2007</pub-id>
</mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>ME</given-names></name><name><surname>Homayoun</surname><given-names>H</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name></person-group>
<article-title>NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex</article-title>. <source/>Proc Natl Acad Sci U.S.A. (<year>2004</year>) <volume>101</volume>:<page-range>8467–72</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.0308455101</pub-id>
</mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jodo</surname><given-names>E</given-names></name></person-group>
<article-title>The role of the hippocampo-prefrontal cortex system in phencyclidine-induced psychosis: a model for schizophrenia</article-title>. <source/>J Physiol-Paris (<year>2013</year>) <volume>107</volume>:<page-range>434–40</page-range>. <pub-id pub-id-type="doi">10.1016/j.jphysparis.2013.06.002</pub-id>
</mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furlanis</surname><given-names>E</given-names></name><name><surname>Traunmüller</surname><given-names>L</given-names></name><name><surname>Fucile</surname><given-names>G</given-names></name><name><surname>Scheiffele</surname><given-names>P</given-names></name></person-group>
<article-title>Landscape of ribosome-engaged transcript isoforms reveals extensive neuronal-cell-class-specific alternative splicing programs</article-title>. <source/>Nat Neurosci (<year>2019</year>) <volume>22</volume>:<page-range>1709–17</page-range>. <pub-id pub-id-type="doi">10.1038/s41593-019-0465-5</pub-id>
</mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Scheiffele</surname><given-names>P</given-names></name></person-group> (<year>2019</year>). <source/>SPLICECODE DATABASE.</mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perszyk</surname><given-names>RE</given-names></name><name><surname>DiRaddo</surname><given-names>JO</given-names></name><name><surname>Strong</surname><given-names>KL</given-names></name><name><surname>Low</surname><given-names>C-M</given-names></name><name><surname>Ogden</surname><given-names>KK</given-names></name><name><surname>Khatri</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>GluN2D-Containing N-methyl-d-Aspartate Receptors mediate synaptic transmission in hippocampal interneurons and regulate interneuron activity</article-title>. <source/>Mol Pharmacol (<year>2016</year>) <volume>90</volume>:<fpage>689</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1124/mol.116.105130</pub-id>
<pub-id pub-id-type="pmid">27625038</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swanger</surname><given-names>SA</given-names></name><name><surname>Vance</surname><given-names>KM</given-names></name><name><surname>Acker</surname><given-names>TM</given-names></name><name><surname>Zimmerman</surname><given-names>SS</given-names></name><name><surname>DiRaddo</surname><given-names>JO</given-names></name><name><surname>Myers</surname><given-names>SJ</given-names></name><etal></etal></person-group>
<article-title>A novel negative allosteric modulator selective for GluN2C/2D-containing NMDA receptors inhibits synaptic transmission in hippocampal interneurons</article-title>. <source/>ACS Chem Neurosci (<year>2018</year>) <volume>9</volume>:<page-range>306–19</page-range>. <pub-id pub-id-type="doi">10.1021/acschemneuro.7b00329</pub-id>
</mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>von Engelhardt</surname><given-names>J</given-names></name><name><surname>Bocklisch</surname><given-names>C</given-names></name><name><surname>Tönges</surname><given-names>L</given-names></name><name><surname>Herb</surname><given-names>A</given-names></name><name><surname>Mishina</surname><given-names>M</given-names></name><name><surname>Monyer</surname><given-names>H</given-names></name></person-group>
<article-title>GluN2D-containing NMDA receptors-mediate synaptic currents in hippocampal interneurons and pyramidal cells in juvenile mice</article-title>. <source/>Front Cell Neurosci (<year>2015</year>) <fpage>9</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2015.00095</pub-id>
<pub-id pub-id-type="pmid">25698924</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotermanski</surname><given-names>SE</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group>
<article-title>Mg2+ imparts NMDA receptor subtype selectivity to the alzheimer’s drug memantine</article-title>. <source/>J Neurosci (<year>2009</year>) <volume>29</volume>:<page-range>2774–9</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3703-08.2009</pub-id>
</mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paoletti</surname><given-names>P</given-names></name><name><surname>Neyton</surname><given-names>J</given-names></name></person-group>
<article-title>NMDA receptor subunits: function and pharmacology</article-title>. <source/>Curr Opin Pharmacol (<year>2007</year>) <volume>7</volume>:<fpage>39</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2006.08.011</pub-id>
<pub-id pub-id-type="pmid">17088105</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuner</surname><given-names>T</given-names></name><name><surname>Schoepfer</surname><given-names>R</given-names></name></person-group>
<article-title>Multiple structural elements determine subunit specificity of Mg2+ Block in NMDA Receptor channels</article-title>. <source/>J Neurosci (<year>1996</year>) <volume>16</volume>:<page-range>3549–58</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.16-11-03549.1996</pub-id>
</mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tasic</surname><given-names>B</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Graybuck</surname><given-names>LT</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Nguyen</surname><given-names>TN</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Shared and distinct transcriptomic cell types across neocortical areas</article-title>. <source/>Nature (<year>2018</year>) <volume>563</volume>:<page-range>72–8</page-range>. <pub-id pub-id-type="doi">10.1038/s41586-018-0654-5</pub-id>
</mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Allen Institute</collab></person-group>
<article-title>RNA-Seq Mouse Data Navigator:: Allen Brain Atlas: Cell Types</article-title>. (<year>2018</year>). <uri xlink:href="http://celltypes.brain-map.org/rnaseq/mouse/v1-alm" xlink:type="simple">http://celltypes.brain-map.org/rnaseq/mouse/v1-alm</uri>.</mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monaghan</surname><given-names>DT</given-names></name><name><surname>Larsen</surname><given-names>H</given-names></name></person-group>
<article-title>NR1 and NR2 Subunit Contributions to N-Methyl-d-aspartate Receptor channel blocker pharmacology</article-title>. <source/>J Pharmacol Exp Ther (<year>1997</year>) <volume>280</volume>:<page-range>614–20</page-range>.</mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamakura</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Masaki</surname><given-names>H</given-names></name><name><surname>Shimoji</surname><given-names>K</given-names></name><name><surname>Mishina</surname><given-names>M</given-names></name></person-group>
<article-title>Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists</article-title>. <source/>Neuroreport (<year>1993</year>) <volume>4</volume>:<page-range>687–90</page-range>. <pub-id pub-id-type="doi">10.1097/00001756-199306000-00021</pub-id>
</mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khlestova</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Lisman</surname><given-names>J</given-names></name></person-group>
<article-title>The role of GluN2C-containing NMDA receptors in ketamine’s psychotogenic action and in Schizophrenia models</article-title>. <source/>J Neurosci (<year>2016</year>) <volume>36</volume>:<page-range>11151–7</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1203-16.2016</pub-id>
</mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hagino</surname><given-names>Y</given-names></name><name><surname>Kasai</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Nabeshima</surname><given-names>T</given-names></name><name><surname>Mishina</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Essential role of NMDA receptor channel ε4 subunit (GluN2D) in the effects of phencyclidine, but not methamphetamine</article-title>. <source/>PloS One (<year>2010</year>) <volume>5</volume>:<elocation-id>e13722</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0013722</pub-id>
<pub-id pub-id-type="pmid">21060893</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sapkota</surname><given-names>K</given-names></name><name><surname>Mao</surname><given-names>Z</given-names></name><name><surname>Synowicki</surname><given-names>P</given-names></name><name><surname>Lieber</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Ikezu</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>GluN2D N-Methyl-d-Aspartate Receptor subunit contribution to the stimulation of brain activity and gamma oscillations by Ketamine: implications for Schizophrenia</article-title>. <source/>J Pharmacol Exp Ther (<year>2016</year>) <volume>356</volume>:<page-range>702–11</page-range>. <pub-id pub-id-type="doi">10.1124/jpet.115.230391</pub-id>
</mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xi</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>HX</given-names></name><name><surname>Stradtman</surname><given-names>GG</given-names></name><name><surname>Gao</surname><given-names>WJ</given-names></name></person-group>
<article-title>Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex</article-title>. <source/>Int J Neuropsychopharmacol (<year>2009</year>) <volume>12</volume>:<page-range>1395–408</page-range>. <pub-id pub-id-type="doi">10.1017/S146114570900042X</pub-id>
</mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fukuyama</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name></person-group>
<article-title>Cystine/Glutamate antiporter and aripiprazole compensate NMDA antagonist-induced dysfunction of thalamocortical L-Glutamatergic transmission</article-title>. <source/>Int J Mol Sci (<year>2018</year>) <volume>19</volume>:<elocation-id>3645</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijms19113645</pub-id>
</mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fukuyama</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>R</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Shiroyama</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name></person-group>
<article-title>Clozapine Normalizes a Glutamatergic transmission abnormality induced by an impaired NMDA Receptor in the thalamocortical pathway <italic>via the</italic> Activation of a Group III Metabotropic Glutamate Receptor</article-title>. <source/>Biomolecules (<year>2019</year>) <volume>9</volume>:<fpage>234</fpage>. <pub-id pub-id-type="doi">10.3390/biom9060234</pub-id>
</mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jodo</surname><given-names>E</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Katayama</surname><given-names>T</given-names></name><name><surname>Hoshino</surname><given-names>K-Y</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Niwa</surname><given-names>S-I</given-names></name><etal></etal></person-group>
<article-title>Activation of medial prefrontal cortex by phencyclidine is mediated <italic>via a</italic> Hippocampo-prefrontal pathway</article-title>. <source/>Cereb Cortex (<year>2005</year>) <volume>15</volume>:<page-range>663–9</page-range>. <pub-id pub-id-type="doi">10.1093/cercor/bhh168</pub-id>
</mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Fukuyama</surname><given-names>K</given-names></name><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Shiroyama</surname><given-names>T</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name></person-group>
<article-title>Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism <italic>via</italic> activation of system xc–</article-title>. <source/>Pharmacol Res Perspect (<year>2019</year>) <volume>7</volume>:<fpage>e00457</fpage>. <pub-id pub-id-type="doi">10.1002/prp2.457</pub-id>
</mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jentsch</surname><given-names>JD</given-names></name><name><surname>Redmond</surname><given-names>DE</given-names></name><name><surname>Elsworth</surname><given-names>JD</given-names></name><name><surname>Taylor</surname><given-names>JR</given-names></name><name><surname>Youngren</surname><given-names>KD</given-names></name><name><surname>Roth</surname><given-names>RH</given-names></name></person-group>
<article-title>Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of Phencyclidine</article-title>. <source/>Science (<year>1997</year>) <volume>277</volume>:<page-range>953–5</page-range>. <pub-id pub-id-type="doi">10.1126/science.277.5328.953</pub-id>
</mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jentsch</surname><given-names>JD</given-names></name><name><surname>Tran</surname><given-names>A</given-names></name><name><surname>Le</surname><given-names>D</given-names></name><name><surname>Youngren</surname><given-names>KD</given-names></name><name><surname>Roth</surname><given-names>RH</given-names></name></person-group>
<article-title>Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat</article-title>. <source/>Neuropsychopharmacology (<year>1997</year>) <volume>17</volume>:<page-range>92–9</page-range>. <pub-id pub-id-type="doi">10.1016/S0893-133X(97)00034-1</pub-id>
</mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahnaou</surname><given-names>A</given-names></name><name><surname>Huysmans</surname><given-names>H</given-names></name><name><surname>Biermans</surname><given-names>R</given-names></name><name><surname>Manyakov</surname><given-names>NV</given-names></name><name><surname>Drinkenburg</surname><given-names>WHIM</given-names></name></person-group>
<article-title>Ketamine: differential neurophysiological dynamics in functional networks in the rat brain</article-title>. <source/>Transl Psychiatry (<year>2017</year>) <volume>7</volume>:<fpage>e1237</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2017.198</pub-id>
<pub-id pub-id-type="pmid">28926001</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Slifstein</surname><given-names>M</given-names></name><name><surname>de Giessen</surname><given-names>E</given-names></name><name><surname>Snellenberg</surname><given-names>JV</given-names></name><name><surname>Thompson</surname><given-names>JL</given-names></name><name><surname>Narendran</surname><given-names>R</given-names></name><name><surname>Gil</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Deficits in prefrontal cortical and extrastriatal dopamine release in Schizophrenia: a positron emission tomographic functional magnetic resonance imaging study</article-title>. <source/>JAMA Psychiatry (<year>2015</year>) <volume>72</volume>:<page-range>316–24</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2414</pub-id>
</mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Honeycutt</surname><given-names>JA</given-names></name><name><surname>Chrobak</surname><given-names>JJ</given-names></name></person-group>
<article-title>Parvalbumin loss following chronic sub-anesthetic NMDA antagonist treatment is age-dependent in the hippocampus: Implications for modeling NMDA hypofunction</article-title>. <source/>bioRxiv (<year>2018</year>). <pub-id pub-id-type="doi">10.1101/399188.399188</pub-id>.
</mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Bender</surname><given-names>A</given-names></name><name><surname>Keck</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>AM</given-names></name><name><surname>Ohl</surname><given-names>F</given-names></name><name><surname>Raeder</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>A pharmacological model for psychosis based on N-methyl-D-aspartate Receptor hypofunction: molecular, cellular, functional and behavioral abnormalities</article-title>. <source/>Biol Psychiatry (<year>2006</year>) <volume>59</volume>:<page-range>721–9</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.08.029</pub-id>
</mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braun</surname><given-names>I</given-names></name><name><surname>Genius</surname><given-names>J</given-names></name><name><surname>Grunze</surname><given-names>H</given-names></name><name><surname>Bender</surname><given-names>A</given-names></name><name><surname>Möller</surname><given-names>H-J</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name></person-group>
<article-title>Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism</article-title>. <source/>Schizophr Res (<year>2007</year>) <volume>97</volume>:<page-range>254–63</page-range>. <pub-id pub-id-type="doi">10.1016/j.schres.2007.05.005</pub-id>
</mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdul-Monim</surname><given-names>Z</given-names></name><name><surname>Neill</surname><given-names>JC</given-names></name><name><surname>Reynolds</surname><given-names>GP</given-names></name></person-group>
<article-title>Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat</article-title>. <source/>J Psychopharmacol (Oxf) (<year>2007</year>) <volume>21</volume>:<fpage>198</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1177/0269881107067097</pub-id>
</mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behrens</surname><given-names>MM</given-names></name><name><surname>Ali</surname><given-names>SS</given-names></name><name><surname>Dao</surname><given-names>DN</given-names></name><name><surname>Lucero</surname><given-names>J</given-names></name><name><surname>Shekhtman</surname><given-names>G</given-names></name><name><surname>Quick</surname><given-names>KL</given-names></name><etal></etal></person-group>
<article-title>Ketamine-induced loss of phenotype of fast-spiking interneurons Is mediated by NADPH-Oxidase</article-title>. <source/>Science (<year>2007</year>) <volume>318</volume>:<page-range>1645–7</page-range>. <pub-id pub-id-type="doi">10.1126/science.1148045</pub-id>
</mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keilhoff</surname><given-names>G</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Grecksch</surname><given-names>G</given-names></name><name><surname>Wolf</surname><given-names>G</given-names></name><name><surname>Bernstein</surname><given-names>HG</given-names></name></person-group>
<article-title>Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia</article-title>. <source/>Neuroscience (<year>2004</year>) <volume>126</volume>:<page-range>591–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.03.039</pub-id>
</mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benneyworth</surname><given-names>MA</given-names></name><name><surname>Roseman</surname><given-names>AS</given-names></name><name><surname>Basu</surname><given-names>AC</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group>
<article-title>Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers</article-title>. <source/>Neurosci Lett (<year>2011</year>) <volume>488</volume>:<page-range>267–71</page-range>. <pub-id pub-id-type="doi">10.1016/j.neulet.2010.11.043</pub-id>
</mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fachim</surname><given-names>HA</given-names></name><name><surname>Srisawat</surname><given-names>U</given-names></name><name><surname>Dalton</surname><given-names>CF</given-names></name><name><surname>Harte</surname><given-names>MK</given-names></name><name><surname>Marsh</surname><given-names>S</given-names></name><name><surname>Neill</surname><given-names>JC</given-names></name><etal></etal></person-group>
<article-title>Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain</article-title>. <source/>Epigenomics (<year>2016</year>) <volume>8</volume>:<page-range>1179–83</page-range>. <pub-id pub-id-type="doi">10.2217/epi-2016-0050</pub-id>
</mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Volk</surname><given-names>DW</given-names></name></person-group>
<article-title>Cortical inhibitory neurons and schizophrenia</article-title>. <source/>Nat Rev Neurosci (<year>2005</year>) <volume>6</volume>:<page-range>312–24</page-range>. <pub-id pub-id-type="doi">10.1038/nrn1648</pub-id>
</mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Volk</surname><given-names>DW</given-names></name><name><surname>Eggan</surname><given-names>SM</given-names></name><name><surname>Mirnics</surname><given-names>K</given-names></name><name><surname>Pierri</surname><given-names>JN</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>gene expression deficits in a subclass of gaba neurons in the prefrontal cortex of subjects with Schizophrenia</article-title>. <source/>J Neurosci (<year>2003</year>) <volume>23</volume>:<page-range>6315–26</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-15-06315.2003</pub-id>
</mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collin</surname><given-names>T</given-names></name><name><surname>Chat</surname><given-names>M</given-names></name><name><surname>Lucas</surname><given-names>MG</given-names></name><name><surname>Moreno</surname><given-names>H</given-names></name><name><surname>Racay</surname><given-names>P</given-names></name><name><surname>Schwaller</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Developmental changes in parvalbumin regulate presynaptic Ca2+ Signaling</article-title>. <source/>J Neurosci (<year>2005</year>) <volume>25</volume>:<fpage>96</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3748-04.2005</pub-id>
<pub-id pub-id-type="pmid">15634771</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vreugdenhil</surname><given-names>M</given-names></name><name><surname>Jefferys</surname><given-names>JGR</given-names></name><name><surname>Celio</surname><given-names>MR</given-names></name><name><surname>Schwaller</surname><given-names>B</given-names></name></person-group>
<article-title>Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus</article-title>. <source/>J Neurophysiol (<year>2003</year>) <volume>89</volume>:<page-range>1414–22</page-range>. <pub-id pub-id-type="doi">10.1152/jn.00576.2002</pub-id>
</mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Kotzadimitriou</surname><given-names>D</given-names></name><name><surname>Nissen</surname><given-names>W</given-names></name><name><surname>Paizs</surname><given-names>M</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name><name><surname>Paulsen</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Neuregulin 1 Type I overexpression is associated with reduced NMDA Receptor–Mediated synaptic signaling in hippocampal interneurons expressing PV or CCK</article-title>. <source/>eNeuro (<year>2018</year>) <fpage>5</fpage>. <pub-id pub-id-type="doi">10.1523/ENEURO.0418-17.2018</pub-id>
</mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fazzari</surname><given-names>P</given-names></name><name><surname>Paternain</surname><given-names>AV</given-names></name><name><surname>Valiente</surname><given-names>M</given-names></name><name><surname>Pla</surname><given-names>R</given-names></name><name><surname>Luján</surname><given-names>R</given-names></name><name><surname>Lloyd</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling</article-title>. <source/>Nature (<year>2010</year>) <volume>464</volume>:<page-range>1376–80</page-range>. <pub-id pub-id-type="doi">10.1038/nature08928</pub-id>
</mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>NyÍri</surname><given-names>G</given-names></name><name><surname>Stephenson</surname><given-names>FA</given-names></name><name><surname>Freund</surname><given-names>TF</given-names></name><name><surname>Somogyi</surname><given-names>P</given-names></name></person-group>
<article-title>Large variability in synaptic n-methyl-d-aspartate receptor density on interneurons and a comparison with pyramidal-cell spines in the rat hippocampus</article-title>. <source/>Neuroscience (<year>2003</year>) <volume>119</volume>:<page-range>347–63</page-range>. <pub-id pub-id-type="doi">10.1016/S0306-4522(03)00157-X</pub-id>
</mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matta</surname><given-names>JA</given-names></name><name><surname>Pelkey</surname><given-names>KA</given-names></name><name><surname>Craig</surname><given-names>MT</given-names></name><name><surname>Chittajallu</surname><given-names>R</given-names></name><name><surname>Jeffries</surname><given-names>BW</given-names></name><name><surname>McBain</surname><given-names>CJ</given-names></name></person-group>
<article-title>Developmental origin dictates interneuron AMPA and NMDA receptor subunit composition and plasticity</article-title>. <source/>Nat Neurosci (<year>2013</year>) <volume>16</volume>:<page-range>1032–41</page-range>. <pub-id pub-id-type="doi">10.1038/nn.3459</pub-id>
</mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roux</surname><given-names>NL</given-names></name><name><surname>Cabezas</surname><given-names>C</given-names></name><name><surname>Böhm</surname><given-names>UL</given-names></name><name><surname>Poncer</surname><given-names>JC</given-names></name></person-group>
<article-title>Input-specific learning rules at excitatory synapses onto hippocampal parvalbumin-expressing interneurons</article-title>. <source/>J Physiol (<year>2013</year>) <volume>591</volume>:<page-range>1809–22</page-range>. <pub-id pub-id-type="doi">10.1113/jphysiol.2012.245852</pub-id>
</mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cornford</surname><given-names>JH</given-names></name><name><surname>Mercier</surname><given-names>MS</given-names></name><name><surname>Leite</surname><given-names>M</given-names></name><name><surname>Magloire</surname><given-names>V</given-names></name><name><surname>Häusser</surname><given-names>M</given-names></name><name><surname>Kullmann</surname><given-names>DM</given-names></name></person-group>
<article-title>Dendritic NMDA receptors in parvalbumin neurons enable strong and stable neuronal assemblies</article-title>. <source/>Elife (<year>2019</year>) <volume>8</volume>: <elocation-id>e49872</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.49872</pub-id>
<pub-id pub-id-type="pmid">31657720</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>HM</given-names></name></person-group>
<article-title>Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia</article-title>. <source/>Neurotox Res (<year>2008</year>) <volume>14</volume>:<page-range>237–48</page-range>. <pub-id pub-id-type="doi">10.1007/BF03033813</pub-id>
</mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Dienel</surname><given-names>SJ</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name></person-group>
<article-title>Alterations in cortical interneurons and cognitive function in schizophrenia</article-title>. <source/>Neurobiol Dis (<year>2018</year>). <pub-id pub-id-type="doi">10.1016/j.nbd.2018.06.020</pub-id>
</mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woo</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>J</given-names></name><name><surname>Benes</surname><given-names>F</given-names></name></person-group>
<article-title>Density of glutamic acid decarboxylase 67 messenger rna–containing neurons that express the n-methyl-d-aspartate receptor subunit nr2a in the anterior cingulate cortex in schizophrenia and bipolar disorder</article-title>. <source/>Arch Gen Psychiatry (<year>2004</year>) <volume>61</volume>:<page-range>649–57</page-range>. <pub-id pub-id-type="doi">10.1001/archpsyc.61.7.649</pub-id>
</mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curley</surname><given-names>AA</given-names></name><name><surname>Arion</surname><given-names>D</given-names></name><name><surname>Volk</surname><given-names>DW</given-names></name><name><surname>Asafu-Adjei</surname><given-names>JK</given-names></name><name><surname>Sampson</surname><given-names>AR</given-names></name><name><surname>Fish</surname><given-names>KN</given-names></name><etal></etal></person-group>
<article-title>Cortical deficits of glutamic acid decarboxylase 67 expression in Schizophrenia: clinical, protein, and cell type-specific features</article-title>. <source/>Am J Psychiatry (<year>2011</year>) <volume>168</volume>:<page-range>921–9</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2011.11010052</pub-id>
</mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Curley</surname><given-names>AA</given-names></name><name><surname>Glausier</surname><given-names>J</given-names></name><name><surname>Volk</surname><given-names>DW</given-names></name></person-group>
<article-title>Cortical parvalbumin interneurons and cognitive dysfunction in Schizophrenia</article-title>. <source/>Trends Neurosci (<year>2012</year>) <volume>35</volume>:<fpage>57</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2011.10.004</pub-id>
<pub-id pub-id-type="pmid">22154068</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frankle</surname><given-names>WG</given-names></name><name><surname>Cho</surname><given-names>RY</given-names></name><name><surname>Prasad</surname><given-names>KM</given-names></name><name><surname>Mason</surname><given-names>NS</given-names></name><name><surname>Paris</surname><given-names>J</given-names></name><name><surname>Himes</surname><given-names>ML</given-names></name><etal></etal></person-group>
<article-title>In vivo measurement of GABA transmission in healthy subjects and Schizophrenia patients</article-title>. <source/>Am J Psychiatry (<year>2015</year>) <volume>172</volume>:<page-range>1148–59</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2015.14081031</pub-id>
</mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donato</surname><given-names>F</given-names></name><name><surname>Rompani</surname><given-names>SB</given-names></name><name><surname>Caroni</surname><given-names>P</given-names></name></person-group>
<article-title>Parvalbumin-expressing basket-cell network plasticity induced by experience regulates adult learning</article-title>. <source/>Nature (<year>2013</year>) <volume>504</volume>:<page-range>272–6</page-range>. <pub-id pub-id-type="doi">10.1038/nature12866</pub-id>
</mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bitanihirwe</surname><given-names>BKY</given-names></name><name><surname>Lim</surname><given-names>MP</given-names></name><name><surname>Kelley</surname><given-names>JF</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Woo</surname><given-names>TUW</given-names></name></person-group>
<article-title>Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia</article-title>. <source/>BMC Psychiatry (<year>2009</year>) <volume>9</volume>:<fpage>71</fpage>. <pub-id pub-id-type="doi">10.1186/1471-244X-9-71</pub-id>
<pub-id pub-id-type="pmid">19917116</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woo</surname><given-names>T-UW</given-names></name><name><surname>Shrestha</surname><given-names>K</given-names></name><name><surname>Lamb</surname><given-names>D</given-names></name><name><surname>Minns</surname><given-names>MM</given-names></name><name><surname>Benes</surname><given-names>FM</given-names></name></person-group>
<article-title>N-Methyl-D-Aspartate Receptor and calbindin-containing neurons in the anterior cingulate cortex in Schizophrenia and bipolar disorder</article-title>. <source/>Biol Psychiatry (<year>2008</year>) <volume>64</volume>:<page-range>803–9</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.04.034</pub-id>
</mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>R</given-names></name><name><surname>Rassoulpour</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>H-Q</given-names></name><name><surname>Medoff</surname><given-names>D</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name><name><surname>Roberts</surname><given-names>RC</given-names></name></person-group>
<article-title>Increased cortical kynurenate content in schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2001</year>) <volume>50</volume>:<page-range>521–30</page-range>. <pub-id pub-id-type="doi">10.1016/S0006-3223(01)01078-2</pub-id>
</mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erhardt</surname><given-names>S</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Nordin</surname><given-names>C</given-names></name><name><surname>Skogh</surname><given-names>E</given-names></name><name><surname>Lindström</surname><given-names>LH</given-names></name><name><surname>Engberg</surname><given-names>G</given-names></name></person-group>
<article-title>Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia</article-title>. <source/>Neurosci Lett (<year>2001</year>) <volume>313</volume>:<page-range>96–8</page-range>. <pub-id pub-id-type="doi">10.1016/S0304-3940(01)02242-X</pub-id>
</mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chess</surname><given-names>AC</given-names></name><name><surname>Simoni</surname><given-names>MK</given-names></name><name><surname>Alling</surname><given-names>TE</given-names></name><name><surname>Bucci</surname><given-names>DJ</given-names></name></person-group>
<article-title>Elevations of endogenous kynurenic acid produce spatial working memory deficits</article-title>. <source/>Schizophr Bull (<year>2007</year>) <volume>33</volume>:<fpage>797</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbl033</pub-id>
<pub-id pub-id-type="pmid">16920787</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Potter</surname><given-names>MC</given-names></name><name><surname>Elmer</surname><given-names>GI</given-names></name><name><surname>Bergeron</surname><given-names>R</given-names></name><name><surname>Albuquerque</surname><given-names>EX</given-names></name><name><surname>Guidetti</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>H-Q</given-names></name><etal></etal></person-group>
<article-title>Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior</article-title>. <source/>Neuropsychopharmacology (<year>2010</year>) <volume>35</volume>:<page-range>1734–42</page-range>. <pub-id pub-id-type="doi">10.1038/npp.2010.39</pub-id>
</mixed-citation>
</ref>
<ref id="B157">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kegel</surname><given-names>ME</given-names></name><name><surname>Johansson</surname><given-names>V</given-names></name><name><surname>Wetterberg</surname><given-names>L</given-names></name><name><surname>Bhat</surname><given-names>M</given-names></name><name><surname>Schwieler</surname><given-names>L</given-names></name><name><surname>Cannon</surname><given-names>TD</given-names></name><etal></etal></person-group>
<article-title>Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity</article-title>. <source/>Psychiatry Res (<year>2017</year>) <volume>247</volume>:<page-range>105–12</page-range>. <pub-id pub-id-type="doi">10.1016/j.psychres.2016.11.017</pub-id>
</mixed-citation>
</ref>
<ref id="B158">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grace</surname><given-names>AA</given-names></name></person-group>
<article-title>Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of Schizophrenia</article-title>. <source/>Neuropharmacology (<year>2012</year>) <volume>62</volume>:<page-range>1342–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.05.011</pub-id>
</mixed-citation>
</ref>
<ref id="B159">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lodge</surname><given-names>DJ</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name></person-group>
<article-title>Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia</article-title>. <source/>J Neurosci (<year>2007</year>) <volume>27</volume>:<page-range>11424–30</page-range>. <pub-id pub-id-type="doi">10.1523/jneurosci.2847-07.2007</pub-id>
</mixed-citation>
</ref>
<ref id="B160">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>R</given-names></name><name><surname>Morrissey</surname><given-names>MD</given-names></name><name><surname>Mahadevan</surname><given-names>V</given-names></name><name><surname>Cajanding</surname><given-names>JD</given-names></name><name><surname>Woodin</surname><given-names>MA</given-names></name><name><surname>Yeomans</surname><given-names>JS</given-names></name><etal></etal></person-group>
<article-title>Parvalbumin and GAD65 interneuron inhibition in the ventral hippocampus induces distinct behavioral deficits relevant to schizophrenia</article-title>. <source/>J Neurosci (<year>2014</year>) <volume>34</volume>:<page-range>14948–60</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2204-14.2014</pub-id>
</mixed-citation>
</ref>
<ref id="B161">
<label>161</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Picard</surname><given-names>N</given-names></name><name><surname>Takesian</surname><given-names>AE</given-names></name><name><surname>Fagiolini</surname><given-names>M</given-names></name><name><surname>Hensch</surname><given-names>TK</given-names></name></person-group>
<article-title>NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity</article-title>. <source/>Mol Psychiatry (<year>2019</year>). <pub-id pub-id-type="doi">10.1038/s41380-018-0341-9</pub-id>
</mixed-citation>
</ref>
<ref id="B162">
<label>162</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilani</surname><given-names>AI</given-names></name><name><surname>Chohan</surname><given-names>MO</given-names></name><name><surname>Inan</surname><given-names>M</given-names></name><name><surname>Schobel</surname><given-names>SA</given-names></name><name><surname>Chaudhury</surname><given-names>NH</given-names></name><name><surname>Paskewitz</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Interneuron precursor transplants in adult hippocampus reverse psychosis-relevant features in a mouse model of hippocampal disinhibition</article-title>. <source/>Proc Natl Acad Sci (<year>2014</year>) <volume>111</volume>:<page-range>7450–5</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.1316488111</pub-id>
</mixed-citation>
</ref>
<ref id="B163">
<label>163</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grimm</surname><given-names>CM</given-names></name><name><surname>Aksamaz</surname><given-names>S</given-names></name><name><surname>Schulz</surname><given-names>S</given-names></name><name><surname>Teutsch</surname><given-names>J</given-names></name><name><surname>Sicinski</surname><given-names>P</given-names></name><name><surname>Liss</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity</article-title>. <source/>Transl Psychiatry (<year>2018</year>) <volume>8</volume>:<fpage>212</fpage>. <pub-id pub-id-type="doi">10.1038/s41398-018-0268-6</pub-id>
<pub-id pub-id-type="pmid">30301879</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chartoff</surname><given-names>EH</given-names></name><name><surname>Heusner</surname><given-names>CL</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name></person-group>
<article-title>Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists</article-title>. <source/>Neuropsychopharmacology (<year>2005</year>) <volume>30</volume>:<page-range>1324–33</page-range>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300678</pub-id>
</mixed-citation>
</ref>
<ref id="B165">
<label>165</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>M</given-names></name><name><surname>Carlsson</surname><given-names>A</given-names></name></person-group>
<article-title>The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice</article-title>. <source/>J Neural Transm (<year>1989</year>) <volume>75</volume>:<page-range>221–6</page-range>. <pub-id pub-id-type="doi">10.1007/bf01258633</pub-id>
</mixed-citation>
</ref>
<ref id="B166">
<label>166</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swanson</surname><given-names>CJ</given-names></name><name><surname>Schoepp</surname><given-names>DD</given-names></name></person-group>
<article-title>The Group II metabotropic glutamate receptor agonist (–)-2-Oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats</article-title>. <source/>J Pharmacol Exp Ther (<year>2002</year>) <volume>303</volume>:<page-range>919–27</page-range>. <pub-id pub-id-type="doi">10.1124/jpet.102.038422</pub-id>
</mixed-citation>
</ref>
<ref id="B167">
<label>167</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinpreis</surname><given-names>RE</given-names></name><name><surname>Salamone</surname><given-names>JD</given-names></name></person-group>
<article-title>The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study</article-title>. <source/>Brain Res (<year>1993</year>) <volume>612</volume>:<page-range>263–70</page-range>. <pub-id pub-id-type="doi">10.1016/0006-8993(93)91671-E</pub-id>
</mixed-citation>
</ref>
<ref id="B168">
<label>168</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Zsiros</surname><given-names>V</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Nakao</surname><given-names>K</given-names></name><name><surname>Kolata</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>GABAergic interneuron origin of schizophrenia pathophysiology</article-title>. <source/>Neuropharmacology (<year>2012</year>) <volume>62</volume>:<page-range>1574–83</page-range>.</mixed-citation>
</ref>
<ref id="B169">
<label>169</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jadi</surname><given-names>MP</given-names></name><name><surname>Behrens</surname><given-names>MM</given-names></name><name><surname>Sejnowski</surname><given-names>TJ</given-names></name></person-group>
<article-title>Abnormal gamma oscillations in N-Methyl-D-Aspartate receptor hypofunction models of Schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2016</year>) <volume>79</volume>:<page-range>716–26</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.07.005</pub-id>
</mixed-citation>
</ref>
<ref id="B170">
<label>170</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>SM</given-names></name><name><surname>Tsien</surname><given-names>RW</given-names></name><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Halassa</surname><given-names>MM</given-names></name></person-group>
<article-title>The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia</article-title>. <source/>Schizophr Res (<year>2015</year>) <volume>167</volume>:<fpage>98</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.12.026</pub-id>
<pub-id pub-id-type="pmid">25583246</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlén</surname><given-names>M</given-names></name><name><surname>Meletis</surname><given-names>K</given-names></name><name><surname>Siegle</surname><given-names>JH</given-names></name><name><surname>Cardin</surname><given-names>JA</given-names></name><name><surname>Futai</surname><given-names>K</given-names></name><name><surname>Vierling-Claassen</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior</article-title>. <source/>Mol Psychiatry (<year>2012</year>) <volume>17</volume>:<page-range>537–48</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2011.31</pub-id>
</mixed-citation>
</ref>
<ref id="B172">
<label>172</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pafundo</surname><given-names>DE</given-names></name><name><surname>Miyamae</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Gonzalez-Burgos</surname><given-names>G</given-names></name></person-group>
<article-title>Presynaptic Effects of N-Methyl-D-Aspartate Receptors enhance parvalbumin cell–mediated inhibition of pyramidal cells in mouse prefrontal cortex</article-title>. <source/>Biol Psychiatry (<year>2018</year>) <volume>84</volume>:<page-range>460–70</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2018.01.018</pub-id>
</mixed-citation>
</ref>
<ref id="B173">
<label>173</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belforte</surname><given-names>JE</given-names></name><name><surname>Zsiros</surname><given-names>V</given-names></name><name><surname>Sklar</surname><given-names>ER</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes</article-title>. <source/>Nat Neurosci (<year>2010</year>) <volume>13</volume>:<fpage>76</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2447</pub-id>
<pub-id pub-id-type="pmid">19915563</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butt</surname><given-names>SJB</given-names></name><name><surname>Sousa</surname><given-names>VH</given-names></name><name><surname>Fuccillo</surname><given-names>MV</given-names></name><name><surname>Hjerling-Leffler</surname><given-names>J</given-names></name><name><surname>Miyoshi</surname><given-names>G</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>The requirement of Nkx2-1 in the temporal specification of cortical interneuron subtypes</article-title>. <source/>Neuron (<year>2008</year>) <volume>59</volume>:<page-range>722–32</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.07.031</pub-id>
</mixed-citation>
</ref>
<ref id="B175">
<label>175</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bygrave</surname><given-names>AM</given-names></name><name><surname>Masiulis</surname><given-names>S</given-names></name><name><surname>Nicholson</surname><given-names>E</given-names></name><name><surname>Berkemann</surname><given-names>M</given-names></name><name><surname>Sprengel</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801</article-title>. <source/>Transl Psychiatry (<year>2016</year>) <volume>6</volume>:<fpage>e778</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2016.44</pub-id>
<pub-id pub-id-type="pmid">27070406</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Bygrave</surname><given-names>AM</given-names></name><name><surname>Masiulis</surname><given-names>S</given-names></name><name><surname>Kullmann</surname><given-names>DM</given-names></name><name><surname>Bannerman</surname><given-names>DM</given-names></name><name><surname>Kätzel</surname><given-names>D</given-names></name></person-group>
<article-title>Gene-environment interaction in a conditional NMDAR-Knockout model of Schizophrenia</article-title>. <source/>Front Behav Neurosci (<year>2019</year>) <fpage>12</fpage>. <pub-id pub-id-type="doi">10.3389/fnbeh.2018.00332</pub-id>
<pub-id pub-id-type="pmid">30787871</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saunders</surname><given-names>JA</given-names></name><name><surname>Tatard-Leitman</surname><given-names>VM</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Billingslea</surname><given-names>EN</given-names></name><name><surname>Roberts</surname><given-names>TP</given-names></name><name><surname>Siegel</surname><given-names>SJ</given-names></name></person-group>
<article-title>Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes</article-title>. <source/>Autism Res Off J Int Soc Autism Res (<year>2013</year>) <volume>6</volume>:<fpage>69</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1264</pub-id>
</mixed-citation>
</ref>
<ref id="B178">
<label>178</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Billingslea</surname><given-names>EN</given-names></name><name><surname>Tatard-Leitman</surname><given-names>VM</given-names></name><name><surname>Anguiano</surname><given-names>J</given-names></name><name><surname>Jutzeler</surname><given-names>CR</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Saunders</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits</article-title>. <source/>Neuropsychopharmacology (<year>2014</year>) <volume>39</volume>:<page-range>1603–13</page-range>. <pub-id pub-id-type="doi">10.1038/npp.2014.7</pub-id>
</mixed-citation>
</ref>
<ref id="B179">
<label>179</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pozzi</surname><given-names>L</given-names></name><name><surname>Dorocic</surname><given-names>IP</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Carlén</surname><given-names>M</given-names></name><name><surname>Meletis</surname><given-names>K</given-names></name></person-group>
<article-title>Mice Lacking NMDA Receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists</article-title>. <source/>PloS One (<year>2014</year>) <volume>9</volume>:<elocation-id>e83879</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0083879</pub-id>
<pub-id pub-id-type="pmid">24454710</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korotkova</surname><given-names>T</given-names></name><name><surname>Fuchs</surname><given-names>EC</given-names></name><name><surname>Ponomarenko</surname><given-names>A</given-names></name><name><surname>von Engelhardt</surname><given-names>J</given-names></name><name><surname>Monyer</surname><given-names>H</given-names></name></person-group>
<article-title>NMDA Receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory</article-title>. <source/>Neuron (<year>2010</year>) <volume>68</volume>:<page-range>557–69</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.017</pub-id>
</mixed-citation>
</ref>
<ref id="B181">
<label>181</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Rompala</surname><given-names>GR</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Cowell</surname><given-names>RM</given-names></name><name><surname>Nakazawa</surname><given-names>K</given-names></name></person-group>
<article-title>Social isolation exacerbates Schizophrenia-like phenotypes <italic>via</italic> Oxidative Stress in Cortical Interneurons</article-title>. <source/>Biol Psychiatry (<year>2013</year>) <volume>73</volume>:<page-range>1024–34</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2012.12.004</pub-id>
</mixed-citation>
</ref>
<ref id="B182">
<label>182</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>EC</given-names></name><name><surname>Zivkovic</surname><given-names>AR</given-names></name><name><surname>Cunningham</surname><given-names>MO</given-names></name><name><surname>Middleton</surname><given-names>S</given-names></name><name><surname>Lebeau</surname><given-names>FE</given-names></name><name><surname>Bannerman</surname><given-names>DM</given-names></name><etal></etal></person-group>
<article-title>Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior</article-title>. <source/>Neuron (<year>2007</year>) <volume>53</volume>:<fpage>591</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.031</pub-id>
<pub-id pub-id-type="pmid">17296559</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>AJ</given-names></name><name><surname>Sauer</surname><given-names>J-F</given-names></name><name><surname>Riedel</surname><given-names>G</given-names></name><name><surname>McClure</surname><given-names>C</given-names></name><name><surname>Ansel</surname><given-names>L</given-names></name><name><surname>Cheyne</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Parvalbumin-positive CA1 interneurons are required for spatial working but not for reference memory</article-title>. <source/>Nat Neurosci (<year>2011</year>) <volume>14</volume>:<page-range>297–9</page-range>. <pub-id pub-id-type="doi">10.1038/nn.2751</pub-id>
</mixed-citation>
</ref>
<ref id="B184">
<label>184</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hippenmeyer</surname><given-names>S</given-names></name><name><surname>Vrieseling</surname><given-names>E</given-names></name><name><surname>Sigrist</surname><given-names>M</given-names></name><name><surname>Portmann</surname><given-names>T</given-names></name><name><surname>Laengle</surname><given-names>C</given-names></name><name><surname>Ladle</surname><given-names>DR</given-names></name><name><surname>Arber</surname><given-names>S</given-names></name></person-group>
<article-title>A Developmental switch in the response of DRG neurons to ETS transcription factor signaling</article-title>. <source/>PloS Biol (<year>2005</year>) <volume>3</volume>:<fpage>e159</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0030159</pub-id>
<pub-id pub-id-type="pmid">15836427</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sohal</surname><given-names>VS</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yizhar</surname><given-names>O</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name></person-group>
<article-title>Parvalbumin neurons and gamma rhythms enhance cortical circuit performance</article-title>. <source/>Nature (<year>2009</year>) <volume>459</volume>:<fpage>698</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1038/nature07991</pub-id>
<pub-id pub-id-type="pmid">19396159</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Niewoehner</surname><given-names>B</given-names></name><name><surname>Single</surname><given-names>FN</given-names></name><name><surname>Hvalby</surname></name><name><surname>Jensen</surname><given-names>V</given-names></name><name><surname>Meyer zum Alten Borgloh</surname><given-names>S</given-names></name><name><surname>Seeburg</surname><given-names>PH</given-names></name><etal></etal></person-group>
<article-title>Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus</article-title>. <source/>Eur J Neurosci (<year>2007</year>) <volume>25</volume>:<page-range>837–46</page-range>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05312.x</pub-id>
</mixed-citation>
</ref>
<ref id="B187">
<label>187</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dang</surname><given-names>MT</given-names></name><name><surname>Yokoi</surname><given-names>F</given-names></name><name><surname>Yin</surname><given-names>HH</given-names></name><name><surname>Lovinger</surname><given-names>DM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group>
<article-title>Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum</article-title>. <source/>Proc Natl Acad Sci (<year>2006</year>) <volume>103</volume>:<page-range>15254–9</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.0601758103</pub-id>
</mixed-citation>
</ref>
<ref id="B188">
<label>188</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsien</surname><given-names>JZ</given-names></name><name><surname>Huerta</surname><given-names>PT</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name></person-group>
<article-title>The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory</article-title>. <source/>Cell (<year>1996</year>) <volume>87</volume>:<page-range>1327–38</page-range>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)81827-9</pub-id>
</mixed-citation>
</ref>
<ref id="B189">
<label>189</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corcoran</surname><given-names>C</given-names></name><name><surname>Mujica-Parodi</surname><given-names>L</given-names></name><name><surname>Yale</surname><given-names>S</given-names></name><name><surname>Leitman</surname><given-names>D</given-names></name><name><surname>Malaspina</surname><given-names>D</given-names></name></person-group>
<article-title>Could stress cause psychosis in individuals vulnerable to Schizophrenia</article-title>?. <source/>CNS Spectr (<year>2002</year>) <volume>7</volume>:<fpage>33</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1017/s1092852900022240</pub-id>
<pub-id pub-id-type="pmid">15254447</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Os</surname><given-names>J</given-names></name><name><surname>Kenis</surname><given-names>G</given-names></name><name><surname>Rutten</surname><given-names>BPF</given-names></name></person-group>
<article-title>The environment and schizophrenia</article-title>. <source/>Nature (<year>2010</year>) <volume>468</volume>:<page-range>203–12</page-range>. <pub-id pub-id-type="doi">10.1038/nature09563</pub-id>
</mixed-citation>
</ref>
<ref id="B191">
<label>191</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Réthelyi</surname><given-names>JM</given-names></name><name><surname>Benkovits</surname><given-names>J</given-names></name><name><surname>Bitter</surname><given-names>I</given-names></name></person-group>
<article-title>Genes and environments in schizophrenia: the different pieces of a manifold puzzle</article-title>. <source/>Neurosci Biobehav Rev (<year>2013</year>) <volume>37</volume>:<page-range>2424–37</page-range>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.04.010</pub-id>
</mixed-citation>
</ref>
<ref id="B192">
<label>192</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Linszen</surname><given-names>DH</given-names></name><name><surname>Dingemans</surname><given-names>PM</given-names></name><name><surname>Nugter</surname><given-names>MA</given-names></name><name><surname>van der Does</surname><given-names>AJW</given-names></name><name><surname>Scholte</surname><given-names>WF</given-names></name><name><surname>Lenior</surname><given-names>MA</given-names></name></person-group>
<article-title>Patient attributes and expressed emotion as risk factors for psychotic relapse</article-title>. <source/>Schizophr Bull (<year>1997</year>) <volume>23</volume>:<page-range>119–30</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/23.1.119</pub-id>
</mixed-citation>
</ref>
<ref id="B193">
<label>193</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parker</surname><given-names>G</given-names></name><name><surname>Hadzi-Pavlovic</surname><given-names>D</given-names></name></person-group>
<article-title>Expressed emotion as a predictor of schizophrenic relapse: an analysis of aggregated data</article-title>. <source/>Psychol Med (<year>1990</year>) <volume>20</volume>:<page-range>961–5</page-range>. <pub-id pub-id-type="doi">10.1017/s0033291700036655</pub-id>
</mixed-citation>
</ref>
<ref id="B194">
<label>194</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peterson</surname><given-names>EC</given-names></name><name><surname>Docherty</surname><given-names>NM</given-names></name></person-group>
<article-title>Expressed emotion, attribution, and control in parents of Schizophrenic patients</article-title>. <source/>Psychiatry Interpers Biol Process (<year>2004</year>) <volume>67</volume>:<fpage>197</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1521/psyc.67.2.197.35959</pub-id>
</mixed-citation>
</ref>
<ref id="B195">
<label>195</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Cowell</surname><given-names>RM</given-names></name><name><surname>Nakazawa</surname><given-names>K</given-names></name></person-group>
<article-title>Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia</article-title>. <source/>Front Behav Neurosci (<year>2013</year>) <volume>7</volume>:<fpage>116</fpage>. <pub-id pub-id-type="doi">10.3389/fnbeh.2013.00116</pub-id>
<pub-id pub-id-type="pmid">24027504</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Do</surname><given-names>KQ</given-names></name><name><surname>Cabungcal</surname><given-names>JH</given-names></name><name><surname>Frank</surname><given-names>A</given-names></name><name><surname>Steullet</surname><given-names>P</given-names></name><name><surname>Cuenod</surname><given-names>M</given-names></name></person-group>
<article-title>Redox dysregulation, neurodevelopment, and schizophrenia</article-title>. <source/>Curr Opin Neurobiol (<year>2009</year>) <volume>19</volume>:<page-range>220–30</page-range>. <pub-id pub-id-type="doi">10.1016/j.conb.2009.05.001</pub-id>
</mixed-citation>
</ref>
<ref id="B197">
<label>197</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herken</surname><given-names>H</given-names></name><name><surname>Uz</surname><given-names>E</given-names></name><name><surname>Özyurt</surname><given-names>H</given-names></name><name><surname>Söğüt</surname><given-names>S</given-names></name><name><surname>Virit</surname><given-names>O</given-names></name><name><surname>Akyol</surname><given-names>Ö</given-names></name></person-group>
<article-title>Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2001</year>) <volume>6</volume>:<fpage>66</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4000789</pub-id>
<pub-id pub-id-type="pmid">11244487</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hardingham</surname><given-names>GE</given-names></name><name><surname>Do</surname><given-names>KQ</given-names></name></person-group>
<article-title>Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis</article-title>. <source/>Nat Rev Neurosci (<year>2016</year>) <volume>17</volume>:<page-range>125–34</page-range>. <pub-id pub-id-type="doi">10.1038/nrn.2015.19</pub-id>
</mixed-citation>
</ref>
<ref id="B199">
<label>199</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Do</surname><given-names>KQ</given-names></name><name><surname>Trabesinger</surname><given-names>AH</given-names></name><name><surname>Kirsten-Krüger</surname><given-names>M</given-names></name><name><surname>Lauer</surname><given-names>CJ</given-names></name><name><surname>Dydak</surname><given-names>U</given-names></name><name><surname>Hell</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex <italic>in vivo</italic></article-title>. <source/>Eur J Neurosci (<year>2000</year>) <volume>12</volume>:<page-range>3721–8</page-range>. <pub-id pub-id-type="doi">10.1046/j.1460-9568.2000.00229.x</pub-id>
</mixed-citation>
</ref>
<ref id="B200">
<label>200</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>D</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name></person-group>
<article-title>Magnetic resonance spectroscopy study of the antioxidant defense system in Schizophrenia</article-title>. <source/>Antioxid Redox Signal (<year>2010</year>) <volume>15</volume>:<page-range>2057–65</page-range>. <pub-id pub-id-type="doi">10.1089/ars.2010.3453</pub-id>
</mixed-citation>
</ref>
<ref id="B201">
<label>201</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cabungcal</surname><given-names>JH</given-names></name><name><surname>Counotte</surname><given-names>DS</given-names></name><name><surname>Lewis</surname><given-names>E</given-names></name><name><surname>Tejeda</surname><given-names>HA</given-names></name><name><surname>Piantadosi</surname><given-names>P</given-names></name><name><surname>Pollock</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia</article-title>. <source/>Neuron (<year>2014</year>) <volume>83</volume>:<page-range>1073–84</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.07.028</pub-id>
</mixed-citation>
</ref>
<ref id="B202">
<label>202</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behrens</surname><given-names>MM</given-names></name><name><surname>Sejnowski</surname><given-names>TJ</given-names></name></person-group>
<article-title>Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex</article-title>?. <source/>Neuropharmacology (<year>2009</year>) <volume>57</volume>:<fpage>193</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.06.002</pub-id>
<pub-id pub-id-type="pmid">19523965</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Choi</surname><given-names>Y-B</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation</article-title>. <source/>Trends Neurosci (<year>2002</year>) <volume>25</volume>:<page-range>474–80</page-range>. <pub-id pub-id-type="doi">10.1016/S0166-2236(02)02245-2</pub-id>
</mixed-citation>
</ref>
<ref id="B204">
<label>204</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papadia</surname><given-names>S</given-names></name><name><surname>Soriano</surname><given-names>FX</given-names></name><name><surname>Léveillé</surname><given-names>F</given-names></name><name><surname>Martel</surname><given-names>M-A</given-names></name><name><surname>Dakin</surname><given-names>KA</given-names></name><name><surname>Hansen</surname><given-names>HH</given-names></name><etal></etal></person-group>
<article-title>Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses</article-title>. <source/>Nat Neurosci (<year>2008</year>) <volume>11</volume>:<page-range>476–87</page-range>. <pub-id pub-id-type="doi">10.1038/nn2071</pub-id>
</mixed-citation>
</ref>
<ref id="B205">
<label>205</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baxter</surname><given-names>PS</given-names></name><name><surname>Bell</surname><given-names>KFS</given-names></name><name><surname>Hasel</surname><given-names>P</given-names></name><name><surname>Kaindl</surname><given-names>AM</given-names></name><name><surname>Fricker</surname><given-names>M</given-names></name><name><surname>Thomson</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system</article-title>. <source/>Nat Commun (<year>2015</year>) <volume>6</volume>:<fpage>6761</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7761</pub-id>
<pub-id pub-id-type="pmid">25854456</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cabungcal</surname><given-names>J-H</given-names></name><name><surname>Steullet</surname><given-names>P</given-names></name><name><surname>Morishita</surname><given-names>H</given-names></name><name><surname>Kraftsik</surname><given-names>R</given-names></name><name><surname>Cuenod</surname><given-names>M</given-names></name><name><surname>Hensch</surname><given-names>TK</given-names></name><etal></etal></person-group>
<article-title>Perineuronal nets protect fast-spiking interneurons against oxidative stress</article-title>. <source/>Proc Natl Acad Sci (<year>2013</year>) <volume>110</volume>:<page-range>9130–5</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.1300454110</pub-id>
</mixed-citation>
</ref>
<ref id="B207">
<label>207</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steullet</surname><given-names>P</given-names></name><name><surname>Cabungcal</surname><given-names>J-H</given-names></name><name><surname>Coyle</surname><given-names>J</given-names></name><name><surname>Didriksen</surname><given-names>M</given-names></name><name><surname>Gill</surname><given-names>K</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name><etal></etal></person-group>
<article-title>Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2017</year>) <volume>22</volume>:<page-range>936–43</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2017.47</pub-id>
</mixed-citation>
</ref>
<ref id="B208">
<label>208</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paylor</surname><given-names>JW</given-names></name><name><surname>Lins</surname><given-names>BR</given-names></name><name><surname>Greba</surname><given-names>Q</given-names></name><name><surname>Moen</surname><given-names>N</given-names></name><name><surname>de Moraes</surname><given-names>RS</given-names></name><name><surname>Howland</surname><given-names>JG</given-names></name><etal></etal></person-group>
<article-title>Developmental disruption of perineuronal nets in the medial prefrontal cortex after maternal immune activation</article-title>. <source/>Sci Rep (<year>2016</year>) <volume>6</volume>:<elocation-id>37580</elocation-id>. <pub-id pub-id-type="doi">10.1038/srep37580</pub-id>
<pub-id pub-id-type="pmid">27876866</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Pinto-Duarte</surname><given-names>A</given-names></name><name><surname>Sejnowski</surname><given-names>TJ</given-names></name><name><surname>Behrens</surname><given-names>MM</given-names></name></person-group>
<article-title>How Nox2-Containing NADPH oxidase affects cortical Circuits in the NMDA receptor antagonist model of Schizophrenia</article-title>. <source/>Antioxid Redox Signal (<year>2013</year>) <volume>18</volume>:<page-range>1444–62</page-range>. <pub-id pub-id-type="doi">10.1089/ars.2012.4907</pub-id>
</mixed-citation>
</ref>
<ref id="B210">
<label>210</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Steullet</surname><given-names>P</given-names></name><name><surname>Cabungcal</surname><given-names>JH</given-names></name><name><surname>Monin</surname><given-names>A</given-names></name><name><surname>Dwir</surname><given-names>D</given-names></name><name><surname>O’Donnell</surname><given-names>P</given-names></name><name><surname>Cuenod</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology</article-title>?. <source/>Schizophr Res (<year>2014</year>). <pub-id pub-id-type="doi">10.1016/j.schres.2014.06.021</pub-id>
</mixed-citation>
</ref>
<ref id="B211">
<label>211</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behrens</surname><given-names>MM</given-names></name><name><surname>Ali</surname><given-names>SS</given-names></name><name><surname>Dugan</surname><given-names>LL</given-names></name></person-group>
<article-title>Interleukin-6 mediates the increase in NADPH-Oxidase in the ketamine model of Schizophrenia</article-title>. <source/>J Neurosci (<year>2008</year>) <volume>28</volume>:<page-range>13957–66</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4457-08.2008</pub-id>
</mixed-citation>
</ref>
<ref id="B212">
<label>212</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meyer</surname><given-names>U</given-names></name></person-group>
<article-title>Developmental neuroinflammation and schizophrenia</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2013</year>) <volume>42</volume>:<fpage>20</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2011.11.003</pub-id>
<pub-id pub-id-type="pmid">22122877</pub-id></mixed-citation>
</ref>
<ref id="B213">
<label>213</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Monaghan</surname><given-names>DT</given-names></name><name><surname>Jane</surname><given-names>DE</given-names></name></person-group>
<article-title>Pharmacology of NMDA Receptors</article-title>. In: <person-group person-group-type="editor"><name><surname>Van Dongen</surname><given-names>AM</given-names></name></person-group> (Editor). <source/>Biology of the NMDA Receptor. Front in Neurosci. (<publisher-loc>Boca Raton (FL)</publisher-loc>: <publisher-name>CRC Press/Taylor &amp; Francis</publisher-name>).</mixed-citation>
</ref>
<ref id="B214">
<label>214</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Moshaver</surname><given-names>A</given-names></name><name><surname>Raymond</surname><given-names>LA</given-names></name></person-group>
<article-title>Differential sensitivity of RecombinantN-Methyl-d-Aspartate Receptor subtypes to zinc inhibition</article-title>. <source/>Mol Pharmacol (<year>1997</year>) <volume>51</volume>:<page-range>1015–23</page-range>. <pub-id pub-id-type="doi">10.1124/mol.51.6.1015</pub-id>
</mixed-citation>
</ref>
<ref id="B215">
<label>215</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paoletti</surname><given-names>P</given-names></name><name><surname>Ascher</surname><given-names>P</given-names></name><name><surname>Neyton</surname><given-names>J</given-names></name></person-group>
<article-title>High-affinity zinc inhibition of NMDA NR1–NR2A Receptors</article-title>. <source/>J Neurosci (<year>1997</year>) <volume>17</volume>:<page-range>5711–25</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.17-15-05711.1997</pub-id>
</mixed-citation>
</ref>
<ref id="B216">
<label>216</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pelkey</surname><given-names>KA</given-names></name><name><surname>Chittajallu</surname><given-names>R</given-names></name><name><surname>Craig</surname><given-names>MT</given-names></name><name><surname>Tricoire</surname><given-names>L</given-names></name><name><surname>Wester</surname><given-names>JC</given-names></name><name><surname>McBain</surname><given-names>CJ</given-names></name></person-group>
<article-title>Hippocampal GABAergic inhibitory interneurons</article-title>. <source/>Physiol Rev (<year>2017</year>) <volume>97</volume>:<page-range>1619–747</page-range>. <pub-id pub-id-type="doi">10.1152/physrev.00007.2017</pub-id>
</mixed-citation>
</ref>
<ref id="B217">
<label>217</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>SA</given-names></name><name><surname>Mazurek</surname><given-names>MF</given-names></name><name><surname>Rosebush</surname><given-names>PI</given-names></name></person-group>
<article-title>Catatonia: our current understanding of its diagnosis, treatment and pathophysiology</article-title>. <source/>World J Psychiatry (<year>2016</year>) <volume>6</volume>:<page-range>391–8</page-range>. <pub-id pub-id-type="doi">10.5498/wjp.v6.i4.391</pub-id>
</mixed-citation>
</ref>
<ref id="B218">
<label>218</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morris</surname><given-names>RGM</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Lynch</surname><given-names>GS</given-names></name><name><surname>Baudry</surname><given-names>M</given-names></name></person-group>
<article-title>Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5</article-title>. <source/>Nature (<year>1986</year>) <volume>319</volume>:<page-range>774–6</page-range>. <pub-id pub-id-type="doi">10.1038/319774a0</pub-id>
</mixed-citation>
</ref>
<ref id="B219">
<label>219</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bannerman</surname><given-names>DM</given-names></name><name><surname>Good</surname><given-names>MA</given-names></name><name><surname>Butcher</surname><given-names>SP</given-names></name><name><surname>Ramsay</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>RGM</given-names></name></person-group>
<article-title>Distinct components of spatial learning revealed by prior training and NMDA receptor blockade</article-title>. <source/>Nature (<year>1995</year>) <volume>378</volume>:<page-range>182–6</page-range>. <pub-id pub-id-type="doi">10.1038/378182a0</pub-id>
</mixed-citation>
</ref>
<ref id="B220">
<label>220</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bannerman</surname><given-names>DM</given-names></name><name><surname>Sprengel</surname><given-names>R</given-names></name><name><surname>Sanderson</surname><given-names>DJ</given-names></name><name><surname>McHugh</surname><given-names>SB</given-names></name><name><surname>Rawlins</surname><given-names>JNP</given-names></name><name><surname>Monyer</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Hippocampal synaptic plasticity, spatial memory and anxiety</article-title>. <source/>Nat Rev Neurosci (<year>2014</year>) <volume>15</volume>:<page-range>181–92</page-range>. <pub-id pub-id-type="doi">10.1038/nrn3677</pub-id>
</mixed-citation>
</ref>
<ref id="B221">
<label>221</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saucier</surname><given-names>D</given-names></name><name><surname>Cain</surname><given-names>DP</given-names></name></person-group>
<article-title>Spatial learning without NMDA receptor-dependent long-term potentiation</article-title>. <source/>Nature (<year>1995</year>) <volume>378</volume>:<page-range>186–9</page-range>. <pub-id pub-id-type="doi">10.1038/378186a0</pub-id>
</mixed-citation>
</ref>
<ref id="B222">
<label>222</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Quirk</surname><given-names>MC</given-names></name><name><surname>Chitwood</surname><given-names>RA</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Yeckel</surname><given-names>MF</given-names></name><name><surname>Sun</surname><given-names>LD</given-names></name><etal></etal></person-group>
<article-title>Requirement for Hippocampal CA3 NMDA Receptors in associative memory recall</article-title>. <source/>Science (<year>2002</year>) <volume>297</volume>:<page-range>211–8</page-range>. <pub-id pub-id-type="doi">10.1126/science.1071795</pub-id>
</mixed-citation>
</ref>
<ref id="B223">
<label>223</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>LD</given-names></name><name><surname>Quirk</surname><given-names>MC</given-names></name><name><surname>Rondi-Reig</surname><given-names>L</given-names></name><name><surname>Wilson</surname><given-names>MA</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name></person-group>
<article-title>Hippocampal CA3 NMDA Receptors are crucial for memory acquisition of one-time experience</article-title>. <source/>Neuron (<year>2003</year>) <volume>38</volume>:<page-range>305–15</page-range>. <pub-id pub-id-type="doi">10.1016/S0896-6273(03)00165-X</pub-id>
</mixed-citation>
</ref>
<ref id="B224">
<label>224</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brigman</surname><given-names>JL</given-names></name><name><surname>Wright</surname><given-names>T</given-names></name><name><surname>Talani</surname><given-names>G</given-names></name><name><surname>Prasad-Mulcare</surname><given-names>S</given-names></name><name><surname>Jinde</surname><given-names>S</given-names></name><name><surname>Seabold</surname><given-names>GK</given-names></name><etal></etal></person-group>
<article-title>Loss of GluN2B-Containing NMDA Receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning</article-title>. <source/>J Neurosci (<year>2010</year>) <volume>30</volume>:<page-range>4590–600</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0640-10.2010</pub-id>
</mixed-citation>
</ref>
<ref id="B225">
<label>225</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rondi-Reig</surname><given-names>L</given-names></name><name><surname>Petit</surname><given-names>GH</given-names></name><name><surname>Tobin</surname><given-names>C</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Berthoz</surname><given-names>A</given-names></name></person-group>
<article-title>Impaired sequential egocentric and allocentric memories in forebrain-Specific–NMDA receptor knock-out mice during a new task dissociating strategies of navigation</article-title>. <source/>J Neurosci (<year>2006</year>) <volume>26</volume>:<page-range>4071–81</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3408-05.2006</pub-id>
</mixed-citation>
</ref>
<ref id="B226">
<label>226</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bannerman</surname><given-names>DM</given-names></name><name><surname>Bus</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Sanderson</surname><given-names>DJ</given-names></name><name><surname>Schwarz</surname><given-names>I</given-names></name><name><surname>Jensen</surname><given-names>V</given-names></name><etal></etal></person-group>
<article-title>Dissecting spatial knowledge from spatial choice by hippocampal NMDA receptor deletion</article-title>. <source/>Nat Neurosci (<year>2012</year>) <volume>15</volume>:<page-range>1153–9</page-range>. <pub-id pub-id-type="doi">10.1038/nn.3166</pub-id>
</mixed-citation>
</ref>
<ref id="B227">
<label>227</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McHugh</surname><given-names>TJ</given-names></name><name><surname>Blum</surname><given-names>KI</given-names></name><name><surname>Tsien</surname><given-names>JZ</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>MA</given-names></name></person-group>
<article-title>Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice</article-title>. <source/>Cell (<year>1996</year>) <volume>87</volume>:<page-range>1339–49</page-range>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)81828-0</pub-id>
</mixed-citation>
</ref>
<ref id="B228">
<label>228</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tatard-Leitman</surname><given-names>VM</given-names></name><name><surname>Jutzeler</surname><given-names>CR</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Saunders</surname><given-names>JA</given-names></name><name><surname>Billingslea</surname><given-names>EN</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Pyramidal cell selective ablation of N-Methyl-D-Aspartate Receptor 1 causes increase in cellular and network excitability</article-title>. <source/>Biol Psychiatry (<year>2015</year>) <volume>77</volume>:<page-range>556–68</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.06.026</pub-id>
</mixed-citation>
</ref>
<ref id="B229">
<label>229</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finlay</surname><given-names>JM</given-names></name><name><surname>Dunham</surname><given-names>GA</given-names></name><name><surname>Isherwood</surname><given-names>AM</given-names></name><name><surname>Newton</surname><given-names>CJ</given-names></name><name><surname>Nguyen</surname><given-names>TV</given-names></name><name><surname>Reppar</surname><given-names>PC</given-names></name><etal></etal></person-group>
<article-title>Effects of prefrontal cortex and hippocampal NMDA NR1-subunit deletion on complex cognitive and social behaviors</article-title>. <source/>Brain Res (<year>2015</year>) <volume>1600</volume>:<fpage>70</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2014.10.037</pub-id>
<pub-id pub-id-type="pmid">25452020</pub-id></mixed-citation>
</ref>
<ref id="B230">
<label>230</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rompala</surname><given-names>GR</given-names></name><name><surname>Zsiros</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Kolata</surname><given-names>SM</given-names></name><name><surname>Nakazawa</surname><given-names>K</given-names></name></person-group>
<article-title>Contribution of NMDA Receptor hypofunction in prefrontal and cortical excitatory neurons to Schizophrenia-like phenotypes</article-title>. <source/>PloS One (<year>2013</year>) <volume>8</volume>:<elocation-id>e61278</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0061278</pub-id>
<pub-id pub-id-type="pmid">23613827</pub-id></mixed-citation>
</ref>
<ref id="B231">
<label>231</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vieira</surname><given-names>PA</given-names></name><name><surname>Corches</surname><given-names>A</given-names></name><name><surname>Lovelace</surname><given-names>JW</given-names></name><name><surname>Westbrook</surname><given-names>KB</given-names></name><name><surname>Mendoza</surname><given-names>M</given-names></name><name><surname>Korzus</surname><given-names>E</given-names></name></person-group>
<article-title>Prefrontal NMDA receptors expressed in excitatory neurons control fear discrimination and fear extinction</article-title>. <source/>Neurobiol Learn Mem (<year>2015</year>) <volume>119</volume>:<fpage>52</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2014.12.012</pub-id>
<pub-id pub-id-type="pmid">25615540</pub-id></mixed-citation>
</ref>
<ref id="B232">
<label>232</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brigman</surname><given-names>JL</given-names></name><name><surname>Daut</surname><given-names>RA</given-names></name><name><surname>Wright</surname><given-names>T</given-names></name><name><surname>Gunduz-Cinar</surname><given-names>O</given-names></name><name><surname>Graybeal</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>MI</given-names></name><etal></etal></person-group>
<article-title>GluN2B in corticostriatal circuits governs choice learning and choice shifting</article-title>. <source/>Nat Neurosci (<year>2013</year>) <volume>16</volume>:<page-range>1101–10</page-range>. <pub-id pub-id-type="doi">10.1038/nn.3457</pub-id>
</mixed-citation>
</ref>
<ref id="B233">
<label>233</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mantamadiotis</surname><given-names>T</given-names></name><name><surname>Lemberger</surname><given-names>T</given-names></name><name><surname>Bleckmann</surname><given-names>SC</given-names></name><name><surname>Kern</surname><given-names>H</given-names></name><name><surname>Kretz</surname><given-names>O</given-names></name><name><surname>Villalba</surname><given-names>AM</given-names></name><etal></etal></person-group>
<article-title>Disruption of CREB function in brain leads to neurodegeneration</article-title>. <source/>Nat Genet (<year>2002</year>) <volume>31</volume>:<fpage>47</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/ng882</pub-id>
<pub-id pub-id-type="pmid">11967539</pub-id></mixed-citation>
</ref>
<ref id="B234">
<label>234</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Engelhardt</surname><given-names>J</given-names></name><name><surname>Doganci</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>V</given-names></name><name><surname>Hvalby</surname><given-names>Ø</given-names></name><name><surname>Göngrich</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Contribution of hippocampal and extra-hippocampal NR2B-Containing NMDA Receptors to performance on spatial learning tasks</article-title>. <source/>Neuron (<year>2008</year>) <volume>60</volume>:<page-range>846–60</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.09.039</pub-id>
</mixed-citation>
</ref>
<ref id="B235">
<label>235</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uhlhaas</surname><given-names>PJ</given-names></name><name><surname>Singer</surname><given-names>W</given-names></name></person-group>
<article-title>Abnormal neural oscillations and synchrony in schizophrenia</article-title>. <source/>Nat Rev Neurosci (<year>2010</year>) <volume>11</volume>:<page-range>100–13</page-range>. <pub-id pub-id-type="doi">10.1038/nrn2774</pub-id>
</mixed-citation>
</ref>
<ref id="B236">
<label>236</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bachiller</surname><given-names>A</given-names></name><name><surname>Poza</surname><given-names>J</given-names></name><name><surname>Gómez</surname><given-names>C</given-names></name><name><surname>Molina</surname><given-names>V</given-names></name><name><surname>Suazo</surname><given-names>V</given-names></name><name><surname>Hornero</surname><given-names>R</given-names></name></person-group>
<article-title>A comparative study of event-related coupling patterns during an auditory oddball task in schizophrenia</article-title>. <source/>J Neural Eng (<year>2015</year>) <volume>12</volume>:<elocation-id>016007</elocation-id>. <pub-id pub-id-type="doi">10.1088/1741-2560/12/1/016007</pub-id>
<pub-id pub-id-type="pmid">25474418</pub-id></mixed-citation>
</ref>
<ref id="B237">
<label>237</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreou</surname><given-names>C</given-names></name><name><surname>Leicht</surname><given-names>G</given-names></name><name><surname>Nolte</surname><given-names>G</given-names></name><name><surname>Polomac</surname><given-names>N</given-names></name><name><surname>Moritz</surname><given-names>S</given-names></name><name><surname>Karow</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Resting-state theta-band connectivity and verbal memory in schizophrenia and in the high-risk state</article-title>. <source/>Schizophr Res (<year>2015</year>) <volume>161</volume>:<fpage>299</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.12.018</pub-id>
<pub-id pub-id-type="pmid">25553979</pub-id></mixed-citation>
</ref>
<ref id="B238">
<label>238</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>M</given-names></name></person-group>
<article-title>A neurocomputational approach to delusions</article-title>. <source/>Compr Psychiatry (<year>1995</year>) <volume>36</volume>:<fpage>83</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/S0010-440X(95)90103-5</pub-id>
<pub-id pub-id-type="pmid">7758303</pub-id></mixed-citation>
</ref>
<ref id="B239">
<label>239</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kapur</surname><given-names>S</given-names></name></person-group>
<article-title>Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia</article-title>. <source/>Am J Psychiatry (<year>2003</year>) <volume>160</volume>:<fpage>13</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.160.1.13</pub-id>
<pub-id pub-id-type="pmid">12505794</pub-id></mixed-citation>
</ref>
<ref id="B240">
<label>240</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barkus</surname><given-names>C</given-names></name><name><surname>Sanderson</surname><given-names>DJ</given-names></name><name><surname>Rawlins</surname><given-names>JNP</given-names></name><name><surname>Walton</surname><given-names>ME</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name><name><surname>Bannerman</surname><given-names>DM</given-names></name></person-group>
<article-title>What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit</article-title>. <source/>Mol Psychiatry (<year>2014</year>) <volume>19</volume>:<page-range>1060–70</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2014.91</pub-id>
</mixed-citation>
</ref>
<ref id="B241">
<label>241</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vukadinovic</surname><given-names>Z</given-names></name></person-group>
<article-title>NMDA receptor hypofunction and the thalamus in schizophrenia</article-title>. <source/>Physiol Behav (<year>2014</year>) <volume>131</volume>:<page-range>156–9</page-range>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2014.04.038</pub-id>
</mixed-citation>
</ref>
<ref id="B242">
<label>242</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiss</surname><given-names>N</given-names></name><name><surname>Zamponi</surname><given-names>GW</given-names></name></person-group>
<article-title>T-type calcium channels: From molecule to therapeutic opportunities</article-title>. <source/>Int J Biochem Cell Biol (<year>2019</year>) <volume>108</volume>:<page-range>34–9</page-range>. <pub-id pub-id-type="doi">10.1016/j.biocel.2019.01.008</pub-id>
</mixed-citation>
</ref>
<ref id="B243">
<label>243</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>X-B</given-names></name><name><surname>Murray</surname><given-names>KD</given-names></name><name><surname>Jones</surname><given-names>EG</given-names></name></person-group>
<article-title>Low-threshold calcium channel subunit Ca(v) 3.3 is specifically localized in GABAergic neurons of rodent thalamus and cerebral cortex</article-title>. <source/>J Comp Neurol (<year>2011</year>) <volume>519</volume>:<page-range>1181–95</page-range>. <pub-id pub-id-type="doi">10.1002/cne.22567</pub-id>
</mixed-citation>
</ref>
<ref id="B244">
<label>244</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrade</surname><given-names>A</given-names></name><name><surname>Hope</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>A</given-names></name><name><surname>Yorgan</surname><given-names>V</given-names></name><name><surname>Lipscombe</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>JQ</given-names></name></person-group>
<article-title>A rare schizophrenia risk variant of CACNA1I disrupts Cav3.3 channel activity</article-title>. <source/>Sci Rep (<year>2016</year>) <volume>6</volume>:<elocation-id>34233</elocation-id>. <pub-id pub-id-type="doi">10.1038/srep34233</pub-id>
<pub-id pub-id-type="pmid">27756899</pub-id></mixed-citation>
</ref>
<ref id="B245">
<label>245</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Danos</surname><given-names>P</given-names></name><name><surname>Baumann</surname><given-names>B</given-names></name><name><surname>Bernstein</surname><given-names>HG</given-names></name><name><surname>Franz</surname><given-names>M</given-names></name><name><surname>Stauch</surname><given-names>R</given-names></name><name><surname>Northoff</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons</article-title>. <source/>Psychiatry Res (<year>1998</year>) <volume>82</volume>:<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/s0925-4927(97)00071-1</pub-id>
<pub-id pub-id-type="pmid">9645546</pub-id></mixed-citation>
</ref>
<ref id="B246">
<label>246</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dixon</surname><given-names>G</given-names></name><name><surname>Dissanaike</surname><given-names>S</given-names></name><name><surname>Harper</surname><given-names>CG</given-names></name></person-group>
<article-title>Parvalbumin-immunoreactive neurons in the human anteroventral thalamic nucleus</article-title>. <source/>Neuroreport (<year>2000</year>) <volume>11</volume>:<fpage>97</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1097/00001756-200001170-00020</pub-id>
<pub-id pub-id-type="pmid">10683838</pub-id></mixed-citation>
</ref>
<ref id="B247">
<label>247</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alherz</surname><given-names>F</given-names></name><name><surname>Alherz</surname><given-names>M</given-names></name><name><surname>Almusawi</surname><given-names>H</given-names></name></person-group>
<article-title>NMDAR hypofunction and somatostatin-expressing GABAergic interneurons and receptors: a newly identified correlation and its effects in schizophrenia</article-title>. <source/>Schizophr Res Cognit (<year>2017</year>) <volume>8</volume>:<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.scog.2017.02.001</pub-id>
<pub-id pub-id-type="pmid">28740825</pub-id></mixed-citation>
</ref>
<ref id="B248">
<label>248</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krabbe</surname><given-names>S</given-names></name><name><surname>Duda</surname><given-names>J</given-names></name><name><surname>Schiemann</surname><given-names>J</given-names></name><name><surname>Poetschke</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>G</given-names></name><name><surname>Kandel</surname><given-names>ER</given-names></name><etal></etal></person-group>
<article-title>Increased dopamine D2 receptor activity in the striatum alters the firing pattern of dopamine neurons in the ventral tegmental area</article-title>. <source/>Proc Natl Acad Sci (<year>2015</year>) <volume>112</volume>:<page-range>E1498–506</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.1500450112</pub-id>
</mixed-citation>
</ref>
<ref id="B249">
<label>249</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zweifel</surname><given-names>LS</given-names></name><name><surname>Argilli</surname><given-names>E</given-names></name><name><surname>Bonci</surname><given-names>A</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name></person-group>
<article-title>Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors</article-title>. <source/>Neuron (<year>2008</year>) <volume>59</volume>:<page-range>486–96</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.05.028</pub-id>
</mixed-citation>
</ref>
<ref id="B250">
<label>250</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zweifel</surname><given-names>LS</given-names></name><name><surname>Parker</surname><given-names>JG</given-names></name><name><surname>Lobb</surname><given-names>CJ</given-names></name><name><surname>Rainwater</surname><given-names>A</given-names></name><name><surname>Wall</surname><given-names>VZ</given-names></name><name><surname>Fadok</surname><given-names>JP</given-names></name><etal></etal></person-group>
<article-title>Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior</article-title>. <source/>Proc Natl Acad Sci (<year>2009</year>) <volume>106</volume>:<page-range>7281–8</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.0813415106</pub-id>
</mixed-citation>
</ref>
<ref id="B251">
<label>251</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zweifel</surname><given-names>LS</given-names></name><name><surname>Fadok</surname><given-names>JP</given-names></name><name><surname>Argilli</surname><given-names>E</given-names></name><name><surname>Garelick</surname><given-names>MG</given-names></name><name><surname>Jones</surname><given-names>GL</given-names></name><name><surname>Dickerson</surname><given-names>TMK</given-names></name><etal></etal></person-group>
<article-title>Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety</article-title>. <source/>Nat Neurosci (<year>2011</year>) <volume>14</volume>:<page-range>620–6</page-range>. <pub-id pub-id-type="doi">10.1038/nn.2808</pub-id>
</mixed-citation>
</ref>
<ref id="B252">
<label>252</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>PC</given-names></name><name><surname>Frith</surname><given-names>CD</given-names></name></person-group>
<article-title>Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia</article-title>. <source/>Nat Rev Neurosci (<year>2009</year>) <volume>10</volume>:<fpage>48</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2536</pub-id>
<pub-id pub-id-type="pmid">19050712</pub-id></mixed-citation>
</ref>
<ref id="B253">
<label>253</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sommer</surname><given-names>IE</given-names></name><name><surname>Bearden</surname><given-names>CE</given-names></name><name><surname>van Dellen</surname><given-names>E</given-names></name><name><surname>Breetvelt</surname><given-names>EJ</given-names></name><name><surname>Duijff</surname><given-names>SN</given-names></name><name><surname>Maijer</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Early interventions in risk groups for schizophrenia: what are we waiting for</article-title>? <source/>NPJ Schizophr (<year>2016</year>) <volume>2</volume>:<fpage>16003</fpage>. <pub-id pub-id-type="doi">10.1038/npjschz.2016.3</pub-id>
<pub-id pub-id-type="pmid">27336054</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>